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SUMMARY 
The research in this thesis involved four studies of the variability in 
plasma concentrations and effects of a selection of drugs used in 
schizophrenia, cardiac surgery and palliative care. 
1. Fluphenazine study 
ii 
Steady-state pre-dose plasma concentrations of fluphenazine were 
measured using a gas chromatography I mass spectrometry assay in 24 
patients with schizophrenia who were receiving continuous treatment 
with depot intramuscular fluphenazine decanoate. Clinical response was 
measured using the Andreasen Scale for positive and negative 
symptoms. Poorer clinical control was related to higher log transformed 
plasma concentrations of fluphenazine and higher fluphenazine 
decanoate dosage. The log transformed plasma concentrations of 
fluphenazine and the fluphenazine decanoate dosages were weakly 
related. These results indicated the useful role that plasma level 
monitoring can fulfil in identifying patients who are therapy-resistant 
despite optimal or high plasma levels. 
2. CPB study 
This study examined the effect of cardiopulmonary bypass (CPB) surgery 
on the total and unbound plasma concentrations of fentanyl and the total 
plasma concentrations of alcuronium in sixteen patients. Due to the 
large number of factors which may affect pharmacokinetics during CPB, 
the results were difficult to deal with mathematically. Despite marked 
declines in the plasma concentrations of both drugs on initiation of CPB, 
suitable plasma concentrations for anaesthesia were maintained 
throughout the procedure. 
iii 
3. Subcutaneous fentanyl 
This study investigated the steady-state total and unbound plasma 
concentrations of fentanyl during continuous subcutaneous 
administration in 20 palliative care patients. Infusion rates and both 
total and unbound plasma concentrations of fentanyl were correlated. 
Even with standardisation for dosage, there was an 8-fold variation in 
total plasma concentrations and a 3.5-fold variation in unbound plasma 
concentrations of fentanyl. There was considerable inter-patient 
variability in the pharmacokinetics of fentanyl with subcutaneous 
infusion in the palliative care setting, which necessitated careful titration 
of dosage according to individual clinical response. 
4. Nebulised morphine trial 
The final study involved a trial of nebulised morphine for dyspnoea in 
eleven palliative care patients. Due to patient attrition and the resulting 
small sample size, a significant improvement in respiratory function and 
assessment of dyspnoea could not be found overall. Individual patients, 
however, reported an improvement in their symptoms. More studies 
with increased numbers are needed to statistically prove the benefit of 
nebulised morphine over saline alone for the relief of dyspnoea. 
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GENERAL INTRODUCTION 
The enormous interindividual variability in plasma concentrations of 
drugs in patients receiving identical doses and the great diversity of 
responses to a particular plasma concentration has led to a growing 
interest in the need to individualise dosage and indeed therapy itself 
(Henry et al, 1994). 
Pharmacokinetic variables are a major source of the above-mentioned 
non-uniformity and may include alterations to absorption, distribution, 
metabolism and excretion. Distribution, metabolism and excretion can 
all be affected by such things as age, sex, body weight and composition, 
tissue perfusion, degree of plasma protein binding, genetic factors, 
hepatic blood flow, renal function, drug interactions and the presence of 
chronic disease (Rowland & Tozer, 1989). 
The clinical response to a drug even given the same plasma level will 
also vary with age, health, presence of chronic disease, genetic factors, 
interactions with other drugs and social habits such as alcohol and 
smoking (Grasela, 1994). 
Different sections of the population may be problematic to treat 
optimally resulting from both the chronic natur~ of the condition they 
suffer and the interindividual variability of drug handling and response 
among the patients (Grasela, 1994). 
Schizophrenia affects 1 % of the population worldwide (Ryan, 1991) and 
after over thirty years of neuroleptic treatment, the objective is still not 
to provide a cure but to restore basic functions to an adequate level and 
seek relief from symptoms so as to ensure a satisfying and productive 
life. Schizophrenic patients often do not have concomitant organic 
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diseases such as renal or hepatic insufficiency but variations in metabolic 
activity are present due to hereditary and other factors, eg cigarette 
smoking, alcoholism and brain damage, which can all alter required 
dosages (Sramek et al, 1988). Antipsychotics typically have a narrow 
therapeutic window, an absence of an easily titratable clinical response, 
poor response rates and troublesome side effects all of which complicate 
treatment and add to the enormous difficulties of working with the 
mentally ill. 
Palliative care patients can prove difficult to study scientifically due to 
the fact that quality of life is the overriding concern in the clinical 
management of these patients (Davis & Hardy, 1994). The aim is to 
provide treatment that enables these patients to experience the highest 
quality of life possible given their condition with attention focussed on 
the relief of suffering and alleviation of symptoms without providing a 
cure. The patients are commonly suffering from a multitude of disease 
states and as a result there is a high prevalence of polypharmacy in 
palliative care. In addition, elderly and cachectic patients may have 
abnormal pharmacokinetics due to an altered clearance, 
hypoalbuminaemia, poor fat stores or muscle wasting (Regnard, 1992). 
In both populations the desired treatments should minimise toxicity and 
maximise acceptability, especially when these patients are very likely to 
be taking these medications every day for the rest of their lives. 
Furthermore, therapeutic failures are most likely to arise if the drug in 
question has a low therapeutic index or large pharmacokinetic 
variability, or if the patient is at particular risk due to concurrent disease 
or multiple drug therapy. 
A third group of patients, those undergoing cardiopulmonary bypass, 
may not be taking drugs of interest long-term, but in the perioperative 
period may receive up to 20 drugs concurrently (Buylaert, 1989) making 
interactions and additive side effects particularly important. In addition, 
the extreme changes during bypass to perfusion, protein binding and 
hepatic blood flow lead to many potential alterations to drug disposition 
and tend to make pharmacokinetic studies complicated (Hall, 1991). 
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Given the magnitude of the alterations to many factors in the study 
populations, the intention to control therapy on a dosage basis alone 
would prove difficult. To achieve therapeutic success, the dosage must 
be tailored in each case to meet individual needs. This can substantially 
decrease the likelihood and magnitude of both the over- and 
underdosage which are often causes of treatment failures. Tailoring of a 
dosage regimen for each individual and evaluating patients with 
possible toxicological problems is sometimes more easily achieved with 
knowledge of the plasma drug concentration in the patient (Brown et al, 
1993). However, despite the knowledge of plasma drug concentration 
and average pharmacokinetic and pharmacodynamic data being valuable 
aids in the individualisation of dosage, they should not be used as 
substitutes for careful monitoring of clinical response. This is important 
as the concentration-effect relationship is often variable between 
individuals and for each patient there may exist a specific threshold 
concentration (Brown et al, 1993). Ultimately, information relating to 
the individual patient is most important. 
If one dosage form proves unsuitable (eg because a patient is unable to 
take oral medication) or if side effects become undesirable ( eg because of a 
high oral dose needed for therapeutic effect), a different dosage form of 
the same or similar drug with an altered dosage requirement may be the 
answer to treat the symptoms. Examples of this practice are: 
i) ·intramuscular fluphenazine decanoate given when oral dosages are 
subject to non-compliance, incomplete absorption, first-pass effect and 
drug interactions (e.g., antacids); ii) subcutaneous fentanyl given when 
the palliative care patient is no longer able to take oral medication for 
pain control and when morphine causes unpleasant side effects such as 
confusion; iii) nebulised morphine given for dyspnoea in preference to 
oral or subcutaneous morphine thus avoiding some of the central side 
effects due to a lower dosage. The need for such changes in therapy will 
be determined on an individual basis according to the extent of any 
problems with the current drug therapy. 
In this thesis, four studies involving plasma level monitoring and/ or 
therapy individualisation were undertaken as outlined below. 
1. A study of schizophrenic patients receiving chronic fluphenazine 
therapy aiming to examine the interpatient variability in steady-state 
plasma levels. 
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A group of twelve patients were collected as part of the author's Honours 
thesis (1991), but because insufficient data did not allow any definite 
conclusions to be made regarding plasma fluphenazine concentrations 
and either side effects or clinical state, a further twelve patients were 
recruited and their plasma analysed. This enabled a more detailed 
statistical treatment of the data and conclusions to be drawn. 
Using proposed therapeutic ranges for fluphenazine from other studies, 
the proportion of study patients within this range was determined and 
related to clinical control in order to examine if there is any value 
monitoring in this situation or whether it is just an additional piece of 
information to guide and assess drug therapy. 
2. A study of patients undergoing cardiopulmonary bypass (CPB) surgery 
designed to determine the extent to which fentanyl and alcuronium 
pharmacokinetics are altered in these patients including investigations 
of the change in plasma protein binding of fentanyl and the extent of 
alcuronium and fentanyl binding to the extracorporeal circuit. 
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The effect of CPB on concentration of drugs has been studied (Hug et al, 
1994; Hall et al, 1993; Koska et al, 1981) but with very different dosage 
regimens and in different clinical settings which produce variations in 
the surgical procedure itself. This made it relevant to investigate the 
change in plasma concentrations of two of the drugs used commonly in 
CPB operations at the Cardiac Unit (Royal Hobart Hospital) - fentanyl and 
alcuronium; the major issue being whether suitable plasma 
concentrations are maintained given the extreme physiological changes 
occurring over the bypass period. 
3. A study of palliative care patients receiving subcutaneous fentanyl 
intended to examine the interpatient variability in steady-state plasma 
concentrations and relate these concentrations to dosage, pain control 
and other variables. 
No studies measuring the concentration of fentanyl after subcutaneous 
administration have been reported so this will allow a comparison 
between these concentrations and those found after transdermal and 
intravenous administration. Previous studies involve measurements in 
both palliative care and postoperative pain, where minimum effective 
analgesic concentrations have been documented (Zech et al, 1992; 
Gourlay et al, 1989). The occurrence of tolerance in palliative care 
patients may diminish the potential for target plasma concentrations. 
4. A trial in palliative care patients to evaluate the benefits of nebulised 
morphine administered for the treatment of dyspnoea. 
There is currently no indication that nebulised morphine is any better 
than saline for dyspnoea in palliative care so these patients may 
generally be receiving extra drugs unnecessarily. As they were already 
receiving many medications it would seem better to try and minimise 
therapy so as to reduce the potential for drug interactions and additive 
side effects. 
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Trials involving palliative care patients tend to encounter problems with 
patient accrual, attrition and selection of adequate outcome measures 
and the resulting small sample size and great intersubject variability did 
not allow for much statistical analysis in this study (Rinck et al, 1995). 
PART I 
MONITORING PLASMA LEVELS OF FLUPHENAZINE 
DURING CHRONIC TREATMENT 
CHAPTER 1 : INTRODUCTION 
1.1 Antipsychotics 
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Fluphenazine is a phenothiazine antipsychotic used in the treatment of 
schizophrenia. The long-acting depot formulation of fluphenazine 
decanoate is widely used to promote patient compliance, minimise the 
fluctuations in plasma concentrations of the drug, and possibly reduce 
the incidence of adverse effects (Davis et al, 1994; Hale, 1993; Burnett et al, 
1993). 
The use of fluphenazine may give rise to a number of adverse effects, 
including sedation, anticholinergic effects (such as dry mouth, blurred 
vision, urinary retention and constipation) and extrapyramidal effects. 
Tardive dyskinesia, which occurs in 20-30% of all patients on long term 
treatment (Gunne, 1990; McCreadie et al, 1992), is the major problem 
limiting the use of antipsychotics in the maintenance treatment of 
schizophrenia. Tardive dyskinesia has been considered to be related to 
the overall duration of exposure to antipsychotics and/ or to the total 
amount absorbed (Balant-Gorgia & Balant, 1987). Similarly, it has often 
been suggested that high plasma levels of the antipsychotics are 
associated with the development of tardive dyskinesia, although the 
evidence remains conflicting (McCreadie et al, 1992; Yesavage et al, 1987). 
It seems sensible to ensure that patients do not receive greater dosages, 
and have higher plasma concentrations, of antipsychotics than clinically 
necessary (Marder, 1994; Bollini et al, 1994). 
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There is a large inter-patient variability in the dosage requirements of 
antipsychotic drugs. Typical dosages of fluphenazine decanoate in clinical 
practice are 12.S to 75 mg intramuscularly every two to six weeks. Part of 
this variability is attributable to individual differences in the 
pharmacokinetics of these drugs; it has been well documented that 
steady-state plasma levels of the antipsychotics vary substantially 
between patients receiving the same dosage (Balant-Gorgia & Balant, 
1987; Verghese et al, 1987; Martensson, 1990; Balant-Gorgia et al, 1993). 
The inter-patient variability in pharmacokinetics, the relatively high rate 
of exacerbation of symptoms amongst patients with schizophrenia and 
the possible association between plasma levels and extrapyramidal 
adverse effects have led to considerable research over the last 10 years 
examining relationships between plasma levels of antipsychotics and 
clinical efficacy or adverse effects. This research has resulted in the 
tentative identification of therapeutic plasma concentration ranges for 
chlorpromazine, haloperidol, fluphenazine, perphenazine, thioridazine 
and thiothixene (Balant-Gorgia et al, 1993; Van Putten et al, 1991; 
Axelsson, 1990; Dahl, 1986; Table 1.1). 
Table 1.1: Tentative therapeutic range of plasma concentrations for antipsychotics 
Drug 
Chlorpromazine 
Haloperidol 
Fluphenazine 
Perphenazine 
Thiothixene 
Tentative therapeutic range of plasma concentrations 
(n /mL) 
30-100 
5-15 
0.2 - 2.0 
0.8 - 2.4 
2-15 
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Consequently, the determination of plasma levels of the antipsychotics is 
becoming more common in clinical practice as a potential means of 
assessing and improving patient compliance, reducing adverse effects, 
and improving the antipsychotic effect. It has been suggested that plasma 
level monitoring should be performed at least once a year in the 
maintenance treatment of chronic psychotic disorders (Axelsson, 1990), to 
shorten the duration of patients' disability and hospital stay, lessen the 
relapse rate, and reduce the incidence of adverse effects (Marder, 1994; 
Axelsson, 1990; Simpson & Kashinath, 1985). Several studies have 
examined the relationship between plasma concentrations of 
fluphenazine and clinical response, and a therapeutic range of 
approximately 0.2 to 2 ng/mL has been proposed (Balant-Gorgia et al, 
1993; Van Putten et al, 1991; Axelsson, 1990; Dahl, 1986; Simpson & 
Kashinath, 1985; Jann et al, 1985; Dysken et al, 1981; Mavroidis et al, 1984; 
Midha et al, 1993). Others, however, believe that there have been 
insufficient well-designed studies with large numbers of patients to 
establish a therapeutic range Gavaid et al, 1991; Baldessarini et al, 1988). 
1.2 Objectives of this Study 
The objectives of this study were to determine the steady-state plasma 
concentrations of fluphenazine in patients receiving the drug by repeat 
depot intramuscular injection and not previously exposed to plasma 
level monitoring of antipsychotic drugs, and to examine any 
relationships between the plasma concentrations and clinical response. 
Because patients were not followed prospectively from the 
commencement of therapy, the study was not able to assist in defining a 
therapeutic range, but rather provides a snapshot of depot fluphenazine 
therapy during chronic treatment of schizophrenia. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
The materials used were: pure fluphenazine hydrochloride (Bristol-
Myers Squibb Pharmaceuticals, Noble Park, Australia) and 
trifluoperazine (SmithKline Beecham, Sydney, Australia); heptane (AR; 
Mallinkrodt, Kentucky, USA); isopropanol (AR; Ajax Chemicals, 
Auburn, Australia); hydrochloric acid (AR; May and Baker Ltd, West 
Footscray, Australia); and sodium hydroxide (AnalaR, BDH Chemicals, 
Kilsyth, Australia). All of the other reagents were also of analytical 
grade. All glassware had been chromic acid washed. Outdated plasma 
from The Red Cross Society, Hobart was used for preparing standards. 
The instrument used was a Hewlett-Packard model 5890 gas 
chromatograph coupled to a Hewlett-Packard 5970 mass selective 
detector. The column was a 13 m x 0.32 mm internal diameter Hewlett-
Packard crosslinked fused-silica ultraperformance capillary column 
coated with methyl silicone gum (0.52 µm film thickness; HP-1). 
2.2 Analytical Methods 
Depot injections give low concentrations of fluphenazine in plasma 
which present considerable problems in the development of an assay 
with sufficient sensitivity and specificity. An assay utilising gas 
chromatography /mass spectrometry (GC/MS) with selective ion 
monitoring was adapted from several previously published procedures 
(Javaid et al, 1981; Franklin et al, 1978; Rivera-Calimlim & Siracusa, 
1977). 
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2.2.1 Extraction from Plasma 
Plasma standards were spiked to give fluphenazine concentrations of 0.1, 
0.5, 1.0, 2.0, 3.0, 4.0 and S.O ng/mL from methanol solutions; 0.5 µg/mL 
and SO ng/mL. Aliquots (S mL) of plasma (patient samples, drug-free 
plasma, and plasma standards as above) were pipetted into 10 mL glass, 
conical-tipped, stoppered, centrifuge tubes. The internal standard, 80 ng 
trifluoperazine in methanol (10 µL), was added; 0.5 mL of SM NaOH was 
added and the mixture extracted by shaking for 20 min on a horizontal 
shaker with 10 mL of heptane/isopropanol (9:1 v /v). Each tube was spun 
for lS min in a refrigerated centrifuge (10°C) at 2,000 rpm to separate the 
phases and the upper organic layer was transferred to another 10 mL 
glass centrifuge tube and 1 mL of 0.lM HCl was added before vortexing 
for 2 min, centrifuging for 10 min at 2,000 rpm and discarding the organic 
phase. The acid phase was alkalinized with 0.2S mL SM NaOH and 
extracted with O.S mL heptane/isopropanol (9:1 v /v) by vortexing for 1 
min. After centrifugation for 10 min at 2,000 rpm, the organic phase was 
transferred to a 1 mL Reacti-Vial® (Pierce Chemical Company, Rockford, 
USA) and dried under a gentle stream of nitrogen at room temperature. 
2.2.2 Derivatisation 
To each vial containing the residue of the extract from plasma, 10 µL of 
N,0-bis(trimethylsilyl)trifluoroacetamide (BSTFA; Pierce Chemical 
Company) was added and mixed. It was capped and heated to 70°C in an 
oven and 30 min was all9wed for the reaction to go to completion. This 
derivatisation is said to increase the sensitivity ten-fold (Whelpton & 
Curry, 1976) because the TMS derivative is less polar and therefore 
chromatographs better. 
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2.2.3 Quantification by Gas Chromatography/Mass Spectrometry 
The injector temperature was ambient, the detector temperature was 
290°C and the oven temperature program was 35°C for 0.5 minutes then 
increasing at a rate of 30°C/minute to 250°C and 10°C/minute to 310°C. 
Ultrahigh-purity helium (Commonwealth Industial Gases Ltd, Hobart, 
Australia) was used as a carrier gas with a head pressure of 10 psi. The 
ions monitored for fluphenazine were m/z 280 and m/z 406 and for 
trifluoperazine were m/z 266 and m/z 407. The mass spectrometer was 
tuned to m/z 264 to optimise the sensitivity of the assay. 
About 1 to 2 µL of derivatised mixture was injected using a direct on-
column technique into the gas chromatograph and the ratio of the peak 
area of fluphenazine to the peak area of the internal standard 
(trifluoperazine) was calculated. The concentration of fluphenazine in 
the plasma sample was calculated directly from the equation of the 
fluphenazine/trifluoperazine standard curve prepared from a series of 
such ratios obtained for standards. 
The reproducibility of the method was ascertained by adding a known 
concentration of fluphenazine (2 ng/mL) and trifluoperazine (16 ng/mL) 
to five aliquots of drug-free plasma (5 mL) and analysing with the 
described procedure on the same day. The coefficient of variation of the 
peak area ratio of fluphenazine/trifluoperazine was calculated from the 
following formula: 
Coefficient of variation(%)= (standard deviation/mean) x 100 
The recovery of the extraction procedure was determined by comparing 
the peak areas of a known fluphenazine concentration (2 ng/mL) from 
(i) 5 mL of plasma and (ii) heptane/isopropanol (9:1 v /v). A full 
standard curve was run each time samples were analysed. 
2.3 Human Procedures 
Ethical approval to perform the research had been obtained from both 
the University of Tasmania and the Tasmanian State Mental Health 
Ethics Committees. 
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Twenty four patients with schizophrenia, as specified in the DSM-III-R 
criteria of the American Psychiatric Association (1987), were studied. The 
first twelve patients were part of the author's Honours thesis entitled 
"Monitoring plasma levels of fluphenazine during chronic treatment-
relationship to efficacy and adverse effects" submitted November 1991 at 
the University of Tasmania. All had given informed consent (Appendix 
1). They were regular attenders at a community-based rehabilitation, 
support and treatment centre (Peacock Centre, Hobart, Tasmania, 
Australia) who were receiving long term (i.e., greater than 3 years) 
treatment with depot fluphenazine decanoate (Modecate®). Relevant 
patient data were extracted from medical records (Appendix 2). Standard 
biochemical tests of liver and renal function were performed by the 
Clinical Chemistry Department of the Royal Hobart Hospital. After at 
least three injections with an identical dose of depot fluphenazine 
decanoate, a venous blood sample of 5 to 10 mL was drawn just prior to 
dosing and placed into tubes containing lithium heparin as an 
anticoagulant. In most cases, patients had been receiving constant 
dosages for the past 12 months. Plasma was separated by centrifugation 
and frozen at -18°C until determination of the fluphenazine 
concentration. 
The Andreasen Scale for negative and positive symptoms was used to 
assess the presence and relative quantity of symptoms of schizophrenia 
(Andreasen, 1985; Koreen et al, 1994; Appendix 3). The assessments were 
independently performed by a psychiatrist and psychiatric nurse within 
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two weeks of blood collection. At the end of the client interview, the 
scores were reviewed by the assessors. Where there was concurrence 
with the two scores, a single score between zero and five was recorded. In 
cases of nonconcurrence, a single score was agreed upon after discussion. 
A negative symptom score was computed from the sum of the five 
"Scale for Assessment of Negative Symptoms" (SANS) items (alogia, 
avolition, anhedonia, associality and inattention). Similarly, a positive 
symptom score was calculated from the sum of the four "Scale for 
Assessment of Positive Symptoms" (SAPS) items (hallucinations, 
delusions, bizarre behaviour and positive formal thought disorder). A 
scale of 0 to 5 was used for each item; the higher the number obtained, 
the more severe the schizophrenic symptoms. The global indicator of 
clinical control was defined as the sum of the positive and negative 
symptom scores. The presence of any adverse effeCts, specifically 
extrapyramidal movement disorders, was also noted. 
2.4 Statistical Analysis 
The data were entered into a Statview® SE+ Graphics (Abacus Concepts, 
Palo Alto, California, USA) file on a Macintosh® computer to facilitate 
statistical analysis. The Spearman Rank correlation coefficient was 
employed to determine whether there were any statistically significant 
relationships between plasma concentrations of fluphenazine and 
variables such as fluphenazine decanoate dosage and assessment of 
clinical control. Mann-Whitney U-tests were used to assess relationships 
between the plasma concentrations and categorical variables (e.g., sex and 
concomitant treatment with anti-Parkinsonian agents). Plasma 
concentrations of fluphenazine below the sensitivity of the assay 
procedure (0.1 ng/mL) were treated as being zero. A 'p' value below 0.05 
was considered statistically significant. The patient data file can be seen 
in Appendix 4. 
CHAPTER 3: RESULTS 
3.1 Analytical Variables 
3.1.1 Retention Times of Relevant Peaks 
The approximate retention times for trifluoperazine and fluphenazine 
were 11.4 and 14 min respectively (Figure 3.2). Using selected ion 
monitoring GC/MS, there were no interfering peaks at these retention 
times. 
3.1.2 Standard Curve 
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The relationship between the plasma concentration of fluphenazine and 
the peak area ratio (fluphenazine/trifluoperazine) was essentially linear 
(ratio = 0.269 x concentration + 0.0068; r2 = 0.998) over the concentration 
range of 0.1 to 5.0 ng/mL (Figure 3.1). 
3.1.3 Recovery and Reproducibility 
The analytical recovery of fluphenazine was found to be 56% (n = 5) and 
the within-day coefficient of variation for the determination of 
fluphenazine was 5.0%. 
3.1.4 Sensitivity 
The sensitivity limit of the assay for measuring fluphenazine in plasma 
was 0.1 ng/mL when 5 mL of plasma was used. 
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3.2 Study Results 
3.2.1 Patient Characteristics 
The sample of 24 patients consisted of 18 males and 6 females, ranging in 
age from 26 to 67 years, with a median age of 49 years. Their clinical 
characteristics are summarised in Table 3.1. Most patients were 
prescribed a number of other drugs (including other antipsychotic agents) 
on a long term basis, none of which have been documented as affecting 
the pharmacokinetics of fluphenazine (Table 3.2). None of the patients 
had biochemical evidence of hepatic or renal disease. One patient 
(number 20) had Parkinsonian signs and another (number 5) had tardive 
d yskinesia. 
Table 3.1: Summary of the Clinical Characteristics of the Sample of Patients (n=24) 
Range Mean Median 
Weight (kg) 50-113 79.2 80 
Duration of condition (years) 3-40 21 18 
Duration of FPZ therapy (years) 2-21 8.4 7 
Current FPZ dose (mg/month) 12.5 -150 53.6 43.8 
Cumulative FPZ dose (mg/year) 213-2175 719.2 450 
The median monthly dosage of fluphenazine decanoate was 43.8 mg, 
with a range of 12.5 to 150 mg (Figure 3.3). 
3.2.2 Fluphenazine Concentrations in Plasma 
The steady-state plasma concentrations of fluphenazine showed a 
marked inter-patient variability (Figure 3.4). The median concentration 
was 0.5 ng/mL (range< 0.1to27.9 ng/mL). 
Table 3.2: Other drugs prescribed for the study sample (DA-antagonists highlighted) 
Subject number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
Other drugs 
haloperidol, benztropine 
benztropine 
haloperidol, benztropine, propranolol 
propantheline, thioridazine 
benzhexol, clonazepam 
nil 
haloperidol, benztropine 
nil 
imipramine, alprazolam, carbernazepine 
thioridazine 
haloperidol, benztropine, diazeparn 
lithium 
nil 
haloperidol, benztropine, clonazeparn, ketoprofen, propranolol, 
indapamide 
rnianserin, thioridazine, ranitidine 
thioridazine, propantheline 
clonazeparn 
haloperidol, benztropine 
nil 
orphenadrine 
metformin, gliblenclamide 
chlorpromazine 
chloral hydrate, theophylline, doxycycline 
hydrochlorothiazide I amiloride, rnetforrnin, glibenclamide 
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Figure 3.3: Frequency distribution of current 
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3.2.3 Plasma Fluphenazine Concentration m Relation to Fluphenazine 
Decanoate Dose 
There were no significant correlations between either the fluphenazine 
decanoate dosage (mg/month) or fluphenazine decanoate dosage 
corrected for bodyweight (mg/kg/month) and the steady-state plasma 
concentration of fluphenazine (Spearman p = 0.26, p > 0.20 and 
Spearman p = 0.33, p > 0.10, respectively). 
3.2.4 Relationship Between Plasma Fluphenazine Concentration and 
Clinical State 
21 
There was also considerable variability in clinical control, with a median 
value of 12 for the sum of the SANS items (range: 4 to 20), 6 for the sum 
of the SAPS items (range: 0 to 19), and 16 for the sum of the positive and 
negative symptom scores (range: 8 to 28) (Figure 3.5). The steady-state 
plasma concentrations of fluphenazine were not related to clinical 
control, expressed as the sum of the SANS items (Spearman p = 0.23, p > 
0.20), the sum of the SAPS items (Spearman p = 0.19, p > 0.20), or the sum 
of the positive and negative symptom scores (Spearman p = 0.31, p > 
0.10). Also, clinical control was not significantly different in patients 
with steady-state plasma concentrations of fluphenazine between 0.2 and 
2 ng/mL compared to patients with levels above or below this tentative 
therapeutic range (SANS: Mann-Whitney U = 41.5, z = 0.97, p > 0.20; 
SAPS: Mann-Whitney U = 39, z = 1.14, p > 0.20; global: Mann-Whitney U 
= 32.5, z = 1.57, p > 0.10). 
Table 3.3: Clinical Control in relation to plasma levels of fluphenazine 
Plasma fluphenazine level 
Between 0.2 - 2.0 ng/mL (n=17) 
< 0.2 or> 2.0 ng/mL (n=7) 
Global clinical control 
median 15; range 8 - 26 
median 20; range 14- 28 
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In order to improve the normality of the distribution of plasma 
concentrations of fluphenazine, the values were log transformed as has 
been done in previous studies (Midha et al, 1993; Marder et al, 1991; Van 
Putten et al, 1991). The resulting values were significantly related to 
clinical control, expressed as the sum of the negative symptom scores 
(Spearman p = 0.45, p < 0.05) or the sum of the positive and negative 
symptom scores (Spearman p = 0.47, p < 0.05), but not to the sum of the 
positive symptoms (Spearman p = 0.24, p > 0.20). Hence, poorer control 
was related to higher log transformed plasma concentrations of 
fluphenazine; poorer control also tended to be associated with a higher 
fluphenazine decanoate dosage (e.g., Spearman p = 0.38, p = 0.07 for 
global control and monthly dosage). The log transformed plasma 
concentrations of fluphenazine were related to the fluphenazine 
decanoate dosage (mg/month; Figure 3.6) and fluphenazine decanoate 
dosage corrected for bodyweight (mg/kg/month; Spearman p = 0.42, p = 
0.05 and Spearman p = 0.44, p = 0.06, respectively). 
The patients receiving another antipsychotic drug in addition to 
fluphenazine decanoate tended to have poorer clinical control, expressed 
as the sum of the negative symptom scores (Mann-Whitney U = 34, z = 
1.93, p = 0.05) or the sum of the positive and negative symptom scores 
(Mann-Whitney U = 30.5, z = 2.15, p < 0.05), but not as the sum of the 
positive symptoms (Mann-Whitney U = 49.5, z = 0.97, p > 0.20). 
Table 3.4: Effect of another antipsychotic on clinical controll 
Receiving another Global clinical SANS SAPS 
anti psychotic control 
Yes (n=ll) 20 (14-28) 13 (5-20) 6 (1-19) 
No (n=l3) 13 (8-23) 9 (4-14) 5 (0-11) 
significance p<0.05 p::::0.05 p>0.20 
1. Results expressed as median (range) 
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Figure 3.6: Plasma fluphenazine concentration (log) 
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These patients were also being administered higher dosages of 
fluphenazine decanoate (Mann-Whitney U = 38, z = 1.94, p = 0.05), but 
did not have significantly higher plasma concentrations (or log 
transformed plasma concentrations) of fluphenazine. 
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3.2.5 Relationship Between Plasma Fluphenazine Level and Presence of 
Extrapyramidal Side Effects 
The steady-state plasma concentrations of fluphenazine in patients 
taking an anti-Parkinsonian medication were significantly higher than 
in patients not taking such medication (Mann-Whitney U = 34.5, z = 1.97, 
p < 0.05; '.fable 3.5). The fluphenazine decanoate dosage (mg/month) or 
fluphenazine decanoate dosage corrected for bodyweight (mg/kg/month) 
were not significantly different between the two groups (Mann-Whitney 
U = 45, z = 1.34, p > 0.10 and Mann-Whitney U = 39.5, z = 1.03, p > 0.20, 
respectively). 
Table 3.5: Relationshif between taking a concurrent anticholinergic and FPZ dosage and 
plasma concentration 
Concurrent anticholinergic 
Yes (n=9) 
No (n=15) 
significance 
FPZ dosage (mg/month) 
75 (12.5-100) 
37.5 (16.6-150) 
p>0.10 
1. Results expressed as median (range). 
3.2.6 Effect of Age on Plasma Fluphenazine Levels 
FPZ plasma concentration 
(n /mL) 
1.0 (0-13.7) 
0.3 (0-27.9) 
p<0.05 
There were no significant associations between the age or sex of the 
patient or the duration of fluphenazine decanoate therapy and the 
dosage or steady-state plasma concentration of fluphenazine. 
CHAPTER 4: DISCUSSION 
Previously reported fluphenazine assay methods proved unsuitable for 
plasma concentration monitoring in this study due to problems with 
interfering peaks and limited sensitivity and reproducibility. The 
GC/MS procedure described here is specific for the measurement of 
fluphenazine and sensitive enough to measure the low plasma 
concentrations observed after intramuscular depot treatment with 
fluphenazine decanoate. The limit of detection was found to be 0.1 
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ng/ mL when 5 mL of plasma was extracted for fluphenazine 
determination. This is an improvement on the sensitivity of previously 
published assays Gavaid et al, 1981 (0.5 ng/mL); Franklin et al, 1978 (1.0 
ng/mL); Rivera-Calimlim & Siracusa, 1977 (3.0 ng/mL); Escobar et al, 
1983 (0.2 ng/mL)). 
The plasma concentrations of fluphenazine found in this study showed 
considerable inter-individual variability, ranging from undetectable to 
27.9 ng/mL. The range was similar to that reported in other studies 
where fluphenazine decanoate was administered (Escobar et al, 1983; 
Furet et al, 1991). Using the proposed therapeutic range for fluphenazine 
of 0.2 to 2.0 ng/mL as a guide, about two thirds of the plasma levels fell 
within the range, with the remainder almost equally split above and 
below this optimal range. Pooling data from many studies, Axelsson 
(1990) found that in general about half of all patients fall within, one-
quarter fall above and one-quarter fall below the optimal range. 
The steady-state plasma concentration of fluphenazine was not 
significantly related to the fluphenazine decanoate dosage. Others have 
reported similar findings, indicating great variability in the 
pharmacokinetics of the drug (Rivera-Calimlim & Hershey, 1984; 
Wistedt et al, 1982). Log transformed plasma concentrations, however, 
were moderately related to dosage. A lack of correlation between sex or 
age and steady-state plasma concentrations of fluphenazine was found, 
confirming the results of others (Dysken et al, 1981; Wistedt et al, 1982; 
Kane et al, 1982; Smith et al, 1979). 
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A significant correlation between fluphenazine dosage or plasma level 
and the presence of tardive dyskinesia was not revealed. Escobar et al 
(1983) reported that even though there was a trend for patients with high 
fluphenazine plasma levels to have higher extrapyramidal symptom 
scores than those with lower levels, no statistically significant 
relationship could be found. Other studies which had similar findings 
were those by Dysken et al (1981) and Wisdedt et al (1982). Levinson et al 
(1990) in a study of 53 patients claimed that severity of acute 
extrapyramidal symptoms was significantly correlated with oral 
fluphenazine dosage per kilogram. Van Putten et al (1991) studied 72 
patients and found a significant correlation between plasma level of 
fluphenazine and the incidence of disabling side effects, defined as "side 
effects that outweigh therapeutic effects". 
The steady-state plasma concentrations of fluphenazine in patients 
taking anti-Parkinsonian medication were significantly higher than in 
patients not taking such medication. It has been proposed that 
anticholinergic agents may decrease the amount of fluphenazine 
absorbed from the gastro.intestinal tract by decreasing gastric motility 
(Dysken et al, 1981). This would allow more fluphenazine to pass 
through the gut wall and undergo extensive first-pass metabolism before 
reaching the systemic circulation. In addition antipsychotics including 
fluphenazine may be metabolised in the gut wall and as a result 
fluphenazine levels would be expected to decline (Dysken et al, 1981; 
Davis et al, 1994). However, that interaction would be significant only 
with orally administered phenothiazines and recent studies have shown 
that concomitant anticholinergic medication does not affect plasma 
fluphenazine levels (Dahl, 1986; Javaid, 1994). These conflicting results 
have left the effect of anti-Parkinsonian medication on plasma levels of 
antipsychotics unclear (McCreadie et al, 1992). 
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Therefore, higher fluphenazine plasma levels are likely to be related to 
the presence of the adverse extrapyramidal effects rather than as a result 
of subsequent anticholinergic medication. In addition, although the 
difference was not significant, patients receiving an anticholinergic 
medication were generally also receiving higher dosages of 
fluphenazine. Supervening extrapyramidal side effects constitute a cause 
for dosage reduction rather than prescribing anticholinergics, as their 
long-term administration with an antipsychotic agent may worsen 
dyskinetic symptoms (Whiteford et al, 1987) and increase the intensity of 
anticholinergic side effects. 
More manifest schizophrenic symptoms were associated with higher log 
transformed plasma concentrations of fluphenazine, probably because 
poor control also tended to be associated with a higher fluphenazine 
decanoate dosage. That is, patients with more severe clinical symptoms 
were generally receiving higher dosages and consequently had higher 
plasma levels of fluphenazine (see Table 4.1 for a summary of other 
studies). There was also a trend for patients with poor control to be 
taking another antipsychptic drug. In fact, the patient with the highest 
steady-state plasma concentration (27.9 ng/mL) was receiving the highest 
dosage of fluphenazine decanoate (150 mg monthly), along with oral 
thioridazine, and had the most marked global symptoms of 
schizophrenia. It was surprising to note that this patient showed no 
Table 4.1: Summary of studies examining relationships between fluphenazine plasma levels and clinical outcome 
Source No. subjects Route Assay Range of levels Clinical Assessment Relationship (p) 
Van Putten et al, 1991 72 
Dysken et al, 1981 29 
Mavroidis et al, 1984a 19 
Escobar et al, 1983 14 
Fairbairn et al, 1983 12 
Wisdedt et al, 1982 14 
Dudley et al, 1983 5 
Wiles & Gelder, 1979 36 
Marder et al, 1991 35 
Levinson et al, 1990 53 
Javaid et al, 1981 18 
Nasrallah et al, 1978 10 
PO - oral fluphenazine 
IM - depot fluphenazine decanoate 
CGI - Clinical Global Impressions Scale 
BPRS - Brief Psychiatric Rating Scale 
NHSI - New Haven Schizophrenic Index 
GAS - Global Assessment Scale 
NRS - Neurological Rating Scale 
PO 
PO 
PO 
PO,IM 
IM 
IM 
PO,IM 
IM 
PO,IM 
PO 
PO 
IM 
RIA .. CGI, BPRS 
GC 0.1-4.2ng/mL NHS! 
GC 0.13 - 4.8 ng/ mL NHS! 
GC 0.2-8.0 ng/mL CGI, BPRS 
RIA .. .. .. 
RIA 0.4 - 2.4 ng/ mL .... 
GC, RIA 1.0-3.0 ng/mL GAS 
RIA 0.63 -16.4 ng/mL .... 
RIA 0.1- 5.0 ng/mL BPRS 
.... .. .. BPRS, SANS, NRS 
GC 0.2 - 4.4 ng/ mL .... 
GC 3-16 ng/mL peak NIMH 
• - not documented in paper 
•• - not investigated in particular study 
NC - no significant correlations found 
NIMH - National Institute of Mental Health Inpatient Behavioural Rating Scale 
0.015 
0.02 
<0.05 
NC 
NC 
NC 
NC 
.. .. 
0.001 
.... 
.. .. 
NC 
~ 
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signs of suffering from extrapyramidal side effects. This may, in part, be 
explained by the fact that his Positive Symptom score was high (19 out of 
a possible 20), and it has been frequently noted clinically that patients 
with prominent positive symptoms require relatively high doses of 
neuroleptics to diminish their positive symptoms, and that they have 
remarkably few side effects (Andreasen, 1985). These results indicate the 
useful role that plasma level monitoring can fulfil in identifying patients 
who are therapy-resistant despite optimal or high plasma levels 
(Axelsson, 1990). These patients are generally best managed by 
prescribing a different antipsychotic drug, perhaps clozapine, or adding 
lithium (Balant-Gorgia et al, 1993; Farmer & Blewitt, 1993). 
Overall, any lack of correlation in clinical studies involving 
antipsychotic control may be associated with the small sample size, 
considerable variation in pharmacokinetics, the confounding effect of 
haloperidol and other antipsychotics, clinical rating scales of varying 
sensitivity, indistinct and nonspecific clinical endpoints, as well as such 
technical problems as low steady-state levels, poor assay sensitivity, and 
other sources of error. Also, it highlights the enormous difficulties in 
working with human subjects and the additional difficulties associated 
with working with the mentally ill. For example, in this study we were 
dealing with outpatients who had to be relied upon firstly to turn up for 
their clinic appointment, and secondly to consent to a procedure which 
to someone suffering from schizophrenia may present as threatening. 
Conclusions 
To further elucidate the relationship between plasma concentrations of 
fluphenazine and clinical response, more studies with greater numbers 
of patients treated in monotherapy (i,e,. avoidance of other drugs) and 
baseline (pre-therapy) measurements of clinical status are required. 
Ideally, a baseline rating representing pretreatment assessment would be 
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measured and then steady-state clinical scores would be determined after 
stabilisation; the change in schizophrenic symptoms would then indicate 
the true clinical response to the fluphenazine treatment. 
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PART II 
THE EFFECTS OF CARDIOPULMONARY BYPASS ON THE 
PHARMACOKINETICS OF DRUGS USED IN ANAESTHESIA 
CHAPTER 5 : INTRODUCTION 
5.1 The Bypass Procedure 
5.1.1 Technical Aspects 
Operations involving cardiopulmonary bypass are no longer rare with 
an estimated 110,000 being performed in the USA in 1980 (Holley et al, 
1982) increasing dramatically to 480,000 by 1986 (Reves et al, 1987). 
During cardiac surgery, including both coronary bypass graft operations 
and corrective surgery for heart valves, cardiac activity must be stopped, 
usually with the infusion of a concentrated potassium ion solution 
(cardioplegia) (Holley et al, 1982). An artificial device which both pumps 
and oxygenates the blood must therefore temporarily be substituted for 
the cardiac and pulmonary function of the patient; this is termed 
cardiopulmonary bypass (CPB). In addition, a number of changes occur 
in the normal physiological status of the patient, resulting in CPB being 
described as a 'controlled form of shock' (Holley et al, 1982). 
After anaesthetisation has occurred, a median sternotomy is usually 
performed to gain access to the heart. A massive dose of heparin (25,000 
to 35,000 U) is given to prevent blood coagulation. The blood of the 
patient then flows by gravity from the superior and inferior venae cavae 
via silicone or PVC tubing to the membrane oxygenator/heat exchanger 
where it is cooled to below 27°C and exposed to a mixture of oxygen and 
carbon dioxide to maintain Paco2. It is necessary to induce hypothermia 
in order to diminish the metabolic needs and oxygen requirements of 
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the patient; Murkin et al (1987) documented a 30% decrease in cerebral 
blood flow and oxygen consumption at 27°C during CPB. A pump is 
then used to return the blood to the ascending aorta and to perfuse the 
tissues using non-pulsatile flow. The mean arterial pressure is 
approximately 40 mmHg (Buylaert et al, 1989). There are usually filters 
in the pumplines to remove emboli resulting from bubbles or organic or 
inorganic material. Before being attached to the patient's circulation, the 
pump's dead space is primed with 1.5 to 2.5 L of an isotonic or slightly 
hypertonic electrolyte solution with buffered physiological pH (i,e,. 
dextrose 5% in lactated Ringer's solution) which results in 
haemodilution to a haematocrit of about 0.25 and an increase in plasma 
osmolarity. A combination of this haemodilution and the relatively low 
pump flow rate (1.2 to 2.4 L/m2/min), may cause hypotension and 
alterations in perfusion to values considerably less than normal 
(Buylaert et al, 1989). Towards the end of the procedure the patient is 
gradually rewarmed and the effect of heparin is reversed by the 
administration of protamine; the heart is defibrillated if necessary. The 
current use of relatively inert plastics throughout the extracorporeal 
circuit has reduced the denaturation of plasma proteins and aggregation 
of platelets (Holley et al, 1982). 
5.1.2 General Physiological Changes as a Result of Bypass 
Cardiopulmonary bypass causes profound physiological changes in 
addition to those induced by anaesthesia and seen in 'normal surgery', 
because of the massive invasion of the body. These include 
haemodilutiori, hypotension and hypothermia (Buylaert et al, 1989). 
• Haemodilution will decrease blood viscosity and occurs abruptly as 
bypass commences when the patient's blood is mixed with the 
cardiopulmonary bypass priming solution. 
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• Hypotension and altered regional blood flow are due to a combination 
of decreased systemic vascular resistance, low pump flow rate and 
haemodilution. Blood flow to vital organs is preserved at the expense of 
peripheral tissues such as muscle and fat. 
• Hypothermia affects drug metabolism, distribution and effect. It also 
serves to promote anaesthesia. 
Cardiopulmonary bypass also results in a generalised stress response 
which leads to the production or alteration of a large number of 
vasoactive substances, such as hormones, autacoids and cytokines 
(Downing & Edmunds, 1992). A 9 to 15 fold elevation in adrenaline and 
a 2 to 5 fold elevation in noradrenaline have been documented 
(Schwinn et al, 1991). The highest levels of these endogenous 
catecholamines usually occur towards the end of CPB and while 
rewarming and their clearance, which is primarily enzyme dependent, is 
reduced. These substances and some of the others which are released 
during CPB and their effects are outlined in Table 5.1. Very high doses of 
opioids are thought to block the stress response during surgery but are 
more than likely to cause post-operative respiratory depression (Reves et 
al, 1987). Administration of clonidine before CPB will reduce opioid 
requirements in addition to diminishing the catecholamine response by 
inhibiting adrenergic transmitter release (Flacke et al, 1987). 
Table 5.1: Some of the Vasoactive Substances Released During CPB (adapted from 
Downing and Edmunds, 1992) 
Substance Vasoactive Effect 
adrenaline i HR, i CO, inotrope 
noradrenaline i BP, i SV, i SVR 
vasopressin i sodium and water resorption 
bradykinin vasodilator 
calcium inotrope, vasoconstrictor 
potassium negative inotrope 
magnesium arrythmias 
prostaglandin E2 vasodilator 
thromboxane A2 vasoconstrictor 
endothelin-1 vasoconstrictor 
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anaphylatoxins from complement activation i vascular permeability, i HR, hypotension, 
vasoconstrictor 
histamine i capillary permeability 
HR=heart rate; CO=cardiac output; BP=blood pressure; SV=stroke volume; 
SVR=systemic vascular resistance; i =increased. 
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In vitro heparin causes increases in the levels of non-esterified fatty acids 
which have been shown to competitively inhibit drug binding to plasma 
proteins, however, the in vivo effect of heparin dosing is still uncertain 
(Finegan et al, 1992). 
Finally, at the termination of bypass, the blood pressure and cardiac 
output will increase with the perfusion to all tissues improving; most 
noticeably so in peripheral tissues such as muscle and fat (Holley et al, 
1982). 
5.1.3 Drugs Commonly Administered in Bypass 
Pharmacotherapy of cardiac surgery is complex with as many as 20 drugs 
being administered in the perioperative period (Holley et al, 1982). 
Preoperatively, long-term medication may include beta-blockers, 
nitrates, diuretics, digoxin and antihypertensive agents. Premedication, 
given about 90 minutes prior to surgery, usually consists of oral 
hypnosedatives such as diazepam and droperidol. On induction, a high 
dose of narcotic (eg fentanyl, morphine) which also provides analgesia 
postoperatively, a neuromuscular blocking drug to prevent movement 
(eg alcuronium, tubocurarine) and thiopentone to ensure hypnosis are 
given intravenously. Just before bypass, heparin is given to ensure 
anticoagulation and then as required during bypass vasodilators such as 
hydralazine are given to decrease peripheral resistance and increase 
perfusion. Protamine is given post-bypass to reverse the effect of 
heparin and IV cephalosporins or semisynthetic penicillins are given as 
antibiotic prophylaxis. 
Other drugs given postoperatively may include further doses of narcotics 
and hypnosedatives and cardiac drugs to maintain optimum 
haemodynamics. The potential for drug interaction in addition to 
altered pharmacokinetics as a result of CPB is enormous. 
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5.1.4 Changes in Pharmacokinetics During Bypass 
Cardiopulmonary bypass has a profound effect on the pharmacokinetic 
behaviour of many drugs both during and immediately after the surgery 
period with temperature and flow both changing at a great rate (Hall, 
1991). Even in normal surgical patients, drug distribution studies are 
extremely complex due to the multiple effects of premedication, 
anaesthesia and surgery on the cardiovascular system (Mather, 1983). 
Absorption would be expected to be reduced or delayed as a result of 
hypotension and reduced blood flow but as all drugs given during the 
bypass procedure are given intravenously, this is not a problem. 
Distribution is expected to be affected in several ways. Firstly, the 
sequestration of the lungs will decrease volume of distribution with the 
possibility of accumulation of some substances (Buylaert et al, 1989) and 
then redistribution on restoration of pulmonary circulation. 
Hypotension and altered blood flow are likely to decrease the 
distribution to organs, however, an increase in volume of distribution 
may result due to a haemodilution-induced decrease in the 
concentration of plasma protein binding leading to redistribution of 
drugs from the serum to the tissues. 
The elimination of drugs by the kidney will be affected (Holley et al, 
1982). Hypotension and reduced renal blood flow will potentially 
decrease active tubular secretion and glomerular filtration rate. The 
decreased concentration of plasma binding proteins will increase free 
fraction and hence glomerular filtration rate, especially in highly protein 
bound drugs, and changes in pH and filtration volume are likely to alter 
the extent of tubular reabsorption. Hypothermia is expected to affect the 
temperature-dependent renal tubular enzymes which are involved in 
active secretion and reabsorption and will decrease glomerular filtration 
rate. In addition, non-pulsatile flow tends to result in temporary 
impairment of renal function (Holley et al, 1982). 
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Hepatic elimination of most drugs will be reduced mainly due to the 
decreased intrinsic clearance (diminished activity of metabolic enzymes) 
as a result of hypothermia and severely decreased liver blood flow 
(Buylaert et al, 1989). This reduction in blood flow will also decrease the 
clearance of drugs with flow-dependent elimination (i,e,. high extraction 
drugs such as lignocaine) resulting in a prolonged effect (Buylaert et al, 
1989). A decrease in binding protein concentration is likely to increase 
the clearance of low extraction drugs (restrictive elimination) as only free 
drug is able to be cleared (Buylaert et al, 1989). 
In summary, plasma concentrations of most drugs may fall initially after 
connection to the bypass apparatus (attributed to changes in distribution), 
are relatively constant for a period during bypass and then increase at the 
termination of extracorporeal support depending on the regimen by 
which the drug is given. There is also a prolonged terminal half-life for 
most drugs during the recovery period after surgery because of reduced 
clearance (Mather, 1983). 
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5.2 Drugs of Interest 
5.2.1 Fentanyl Characteristics 
Fentanyl (N-(l-phenylethyl-4-piperidyl)propionanilide) is a short-acting, 
highly lipophilic, synthetic narcotic analgesic with a potency 50 to 100 
times that of morphine and much greater access to the brain (Mather, 
1983). The structure of fentanyl contains a large hydrocarbon mass 
which gives it the lipophilic properties and an amide functional group 
and a piperidine ring tertiary amine functional group. It is made water 
soluble through salt formation with citric acid and does not contain a 
chiral centre so studies are not complicated by the presence of 
enantiomers (Mather & Gourlay, 1991). It was developed in 1960 after a 
need arose for a more potent yet less toxic opioid than morphine to be 
used as a primary anaesthetic agent (Clotz and Nahata, 1991). Morphine 
was being employed but it produced incomplete amnesia and 
undesirable haemodynamic responses to surgery, such as histamine 
release, myocardial depression, and vasodilatation (Clotz and Nahata, 
1991; Holley et al, 1982; Robbins et al, 1990). 
Fentanyl and its derivatives (alfentanil, sufentanil) afford excellent 
cardiovascular stability and have reduced or eliminated most of the 
disadvantages of other opioid anaesthetics (Koska et al, 1981). These 
narcotic analgesics are currently the most commonly used drugs for 
maintenance of anaesthesia during cardiopulmonary bypass (Kumar et 
al, 1988). Fentanyl is given intravenously and is rapid-acting, in fact 
because of this short duration of action after a single dose was originally 
thought to have a short elimination half-life (Mather & Gourlay, 1991). 
However, fentanyl has a long elimination half-life due to the slow 
return of the unchanged drug from the peripheral to the central 
compartment where elimination occurs (McClain & Hug, 1980). The 
rate-limiting step for its elimination is therefore redistribution from the 
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peripheral compartment. Estimates of the apparent volume of 
distribution of fentanyl range from 60 to 300 L, and the terminal half-life 
has been found to be 1.5 to 6 hours (Mather, 1983). Less than 10% of a 
dose of fentanyl is excreted renally as unchanged drug (Clotz & Nahata, 
1991) with the remainder eliminated predominantly hepatically, by 
metabolism (hydrolysis of the amide) to norfentanyl. 
H O 
II 
N -C -CH2-CH3 Fentanyl 
N-dealkylation 
CH -CH -N 2 2 
H 
N-H Norfentany! 
Total body clearance ranges from 0.4 L/min to greater than 1.5 L/min 
and approximates liver blood flow in healthy subjects (Mather, 1983) 
with its hepatic extraction ratio approaching unity (Bower & Hull, 1982). 
Higher concentrations of fentanyl have been noted in the elderly and 
could be attributed to an age-related reduction in cardiac output and an 
age-related reduction in fat-lean body distribution (Mather & Gourlay, 
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1991). The maximum concentration of fentanyl occurs in fat about 30 
min after intravenous injection (Mather, 1983), reflecting the drug's high 
affinity for lipid and the low perfusion of adipose tissue. 
Protein binding of fentanyl to plasma proteins is about 80% at pH 7.4 and 
was found to be constant over a range of fentanyl concentrations from 
0.076 to 76 ng/mL (McClain & Hug, 1980). Binding is dependent on the 
plasma concentration of protein and is favoured with increasing pH 
(Mather, 1983). The most avid binding of fentanyl occurs with ai-acid 
glycoprotein and there is also some de~ree of binding to albumin 
(Mather & Gourlay, 1991). 
Plasma concentrations of fentanyl are likely to reflect receptor 
concentrations and hence pharmacological effect, since fentanyl is highly 
lipophilic and rapid receptor association and dissociation has been 
measured in vitro (Mather & Gourlay, 1991). 
5.2.2 Fentanyl and the Effects of Cardiopulmonary Bypass 
The pharmacokinetic parameters (clearance, volume of distribution and 
half-life) in patients undergoing regular surgery (non-cardiac) have been 
found to be comparable with values in normal volunteers (Holley et al, 
1982) suggesting changes during CPB are due to the bypass procedure 
itself rather than the effects of surgery or anaesthesia. 
Fentanyl is given intravenously in CPB and its high lipid solubility 
results in high concentrations of drug in the well-perfused tissues such 
as the lungs, kidneys, heart and the brain (Mather, 1983). Skacel et al 
(1986) noted that plasma concentrations of fentanyl greater than 20 to 30 
ng/mL are required to initially depress the cardiovascular response to 
surgery; the concentration required decreases during surgery and will 
also depend on other medication administered (e.g., nitrous oxide). The 
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redistribution of fentanyl is rapid, with 90% of an IV dose cleared from 
the plasma within 5 to 10 min due to uptake of the drug by well perfused 
tissues (Bovill & Sebel, 1980). On commencement of extracorporeal 
circulation, the concentration of fentanyl falls rapidly and during the 
bypass procedure the expected pharmacokinetics of the drug can be 
severely disrupted and normal methods of analysis are not suitable. 
Apparent volume of distribution (V d) may increase as a result of 
haemodilution which is due to the abrupt decrease in plasma drug 
concentration: 
V d = amount of drug in the body /plasma drug concentration 
The total plasma drug concentration is reduced because, as fentanyl is a 
highly bound drug, the decreased concentration of binding proteins due 
to haemodilution will lead to an increase in the fraction of unbound 
drug which will favour distribution of fentanyl from plasma to tissues. 
The V d may also be reduced by hypotension and the subsequent decline 
in peripheral perfusion which reduces blood flow to some organs; the 
overall change will depend on the predominance of these opposing 
influences. It is sometimes practice to give an additional dose of fentanyl 
to prevent suboptimal concentrations at the start of CPB but it is not 
usually necessary and can cause postoperative ventilatory depression 
(Hall, 1993). 
Hepatic clearance of fentanyl will decrease during CPB due to an 
estimated reduction in liver blood flow to 70% of normal (Hall, 1991; 
Koska et al, 1981). In addition fentanyl, being a weak base, is metabolised 
by microsomal enzymes whose activity is reduced by hypothermia (Hall, 
1991). Creatinine clearance is typically reduced by 50% during the bypass 
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procedure (Robbins et al, 1990) although this is not directly relevant for 
fentanyl as only negligible amounts are excreted unchanged in the urine. 
The terminal half-life may be prolonged to over seven hours due to a 
combination of increased apparent volume of distribution and decreased 
clearance (Cl) (Bovill and Sebel, 1980): 
ti/2 = 0.693Vd/Cl 
After bypass, it should be possible to determine an elimination half-life 
as plasma fentanyl concentration/time curves would be expected to 
regain an apparent log-linear decay (Koska et al, 1981). However, 
statistically significant fluctuations with peaks of 1 to 2 ng/mL on top of 
the washout curve have been noted about 45 minutes after the 
completion of bypass preventing exponential curve fitting (Mather, 
1983). The mobilisation of the patient on admission to the recovery 
room with subsequent release of fentanyl from tissue depots (eg skeletal 
muscle, stomach) by increased perfusion could cause these fluctuations 
during the elimination phase. This redistribution is important for basic 
drugs such as fentanyl that tend to have extensive initial distribution 
and even more so with the sudden increase in tissue perfusion after CPB 
due to spontaneous and voluntary movements as consciousness returns 
(McClain & Hug, 1980; Bovill & Sebel, 1980). 
Repeated doses of fentanyl are given during surgery and this prolonged 
exposure may lead to accumulation in plasma and the CNS and an 
increased possibility of recurrent ventilatory depressant effects (McClain 
& Hug, 1980). These effects may be antagonised by noxious stimulation 
during surgery and on transfer of the patient to recovery, and thus may 
only become evident when the patient is unstimulated in the post-
operative period. This respiratory depression is thought to become 
insignificant at plasma levels below about 0.7 ng/mL (McClain & Hug, 
1980). 
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The haemodilution caused by the priming solution of the CPB apparatus 
alters the plasma protein concentrations and may produce changes in 
drug-protein binding. Kumar et al (1988) reported the concentration of 
both a.1 - acid glycoprotein and albumin decreased by 50% during 
cardiopulmonary bypass. McClain & Hug (1980) found that a 57% 
reduction in protein content of pl_asma led to an 18% decrease in binding 
of fentanyl, thus increasing the free fraction. It is this free fraction which 
is able to equilibrate with the tissues and to initiate the pharmacological 
response so changes in binding may have clinical significance (Bower, 
1981). For this reason, it may be necessary to monitor unbound as well as 
total concentrations in pharmacokinetic studies. 
It is also known that plasma a.1-acid glycoprotein concentration may 
increase during conditions of stress as it is an acute phase reactant but 
this may not occur until a couple of days following surgery (Hall, 1991) so 
is probably unlikely to affect the pharmacokinetics of fentanyl given 
during CPB. 
It has also been reported that under hypothermic conditions there is a 
reduced binding affinity of opiate receptors for certain opioids, thus 
conceivably reducing their potency (Hall, 1991). 
5.2.3 Alcuronium Characteristics 
Alcuronium (diallylnortoxiferine) is a semisynthetic, water-soluble 
quaternary amine with a large organic structure (MW=2408) which has 
been in use since 1961 (Walker et al, 1980). It acts as a nondepolarising 
neuromuscular blocker and when administered as a single IV bolus dose 
of approximately 0.25 mg/kg at the start of cardiac surgery produces 
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skeletal muscle relaxation while avoiding hypertension, histamine 
release and tachycardia (Kiinzer et al, 1994). This absence of side effects is 
its main advantage over tubocurarine. 
There is no evidence of any appreciable metabolism of the drug and it is 
eliminated almost entirely (80 to 85%) unchanged by the kidneys, 
predominantly due to glomerular filtration (Walker and Brown, 1983). 
Because it is permanently charged, alcuronium is not likely to undergo 
tubular reabsorption (Walker et al, 1983). Approximately 15 to 20% is 
secreted unchanged into the bile and eliminated with the faeces. The 
pharmacokinetic parameters for alcuronium in general surgical patients 
(described using a two compartment model) have been reported as 3.3 
hours for elimination half-life and 90 mL/min for mean plasma 
clearance (Walker et al, 1980). 
Alcuronium is not highly protein bound; only 40 % is bound to alpha-1 
globulins (Hunter, 1994). 
Alcuronium 
II 
CH 
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5.2.4 Alcuronium and the Effects of Cardiopulmonary Bypass 
Alterations in renal function as a result of cardiopulmonary bypass may 
alter the pharmacokinetics of alcuronium because of its high renal 
clearance. 
It has been reported that the renal elimination of the neuromuscular 
blocking agents pancuronium, d-tubocurarine and alcuronium decreases 
during hypothermia of cardiopulmonary bypass (Wierda et al, 1990) with 
creatinine clearance typically reduced by 50% (Robbins et al, 1990). In a 
study involving alcuronium given as a bolus dose followed by an 
infusion, the concentration actually increased on CPB (Walker et al, 
1983). However, studies involving single bolus doses of pipecuronium 
and metocurine concluded that the overall effect of hypothermia and 
bypass did not appear to influence the terminal half-lives of the drugs 
(Wierda et al, 1990; Avram et al, 1987). This could be explained by the 
fact that the patients were relatively hypovolaemic preoperatively and 
thus already had diminished renal perfusion. Thus, the effect of CPB on 
alcuronium concentrations following a single bolus dose is not well 
documented. 
5.2.5 Drug Sequestration 
The irreversible sequestration of fentanyl (through hydrophobic binding) 
to constituent parts of the bypass apparatus or to the lungs is 
documented and is expected to further complicate the pharmacokinetics 
of fentanyl during cardiopulmonary bypass. The membrane oxygenator 
has been reported as the major site of binding, whereas PVC tubing and 
the plastic reservoir had no binding effect on fentanyl (Koren et al, 1984). 
Hall (1991) claimed that sequestration is unlikely to have a major impact 
on plasma concentrations in vivo due to the large tissue reservoir of the 
drug. Studies indicate that the binding of fentanyl to the system appears 
to be a saturable process (Hynynen, 1987). This was shown when low 
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levels of fentanyl (20 ng/mL) used for priming totally disappeared from 
the system, whereas priming of the cardiopulmonary bypass solution 
with high levels of fentanyl (140 to 280 ng/mL) prevented the marked 
decrease immediately after the start of bypass and sufficient drug 
remained to maintain a constant low concentration (Koren et al, 1984). 
Hynynen (1987) calculated that the cardiopulmonary bypass devices were 
capable of adsorbing a total of 30 to 240 µg of fentanyl which represents 
only about 0.4 to 3% and 0.7 to 5% of the total fentanyl dose used in 
studies by Bentley et al (1983) and Bovill and Sebel (1980), respectively. 
Addition of plasma proteins to the priming solution did not prevent the 
binding of fentanyl to the bypass system (Hynynen, 1987). 
( 
High potency opioids such as fentanyl may also be sequestered in the 
lungs which can serve as a reservoir for drug which cannot be rapidly 
eliminated or distributed when the pulmonary circulation is bypassed 
(Bentley et al, 1983). Taeger et al (1988) reported that about 71 % of an IV 
fentanyl dose can be extracted by the lungs over one minute. Upon 
termination of the extracorporeal support and resumption of blood flow 
to the lungs, there is a washout of a significant amount of drug back into 
the systemic circulation with an elevation of plasma levels. The clinical 
importance of this phenomenon is unknown, but as the body 
temperature rises back to normal, the regional blood flow, enzymatic 
activity, blood pressure and cardiac output will all increase, altering once 
again the pharmacokinetics and pharmacodynamics of fentanyl (Holley 
et al, 1982). 
Sequestration of alcuronium to any parts of the extracorporeal circuit has 
not been documented in any studies. 
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5.3 Objectives of this Study 
Previous studies have involved measuring total fentanyl levels after a 
single intravenous bolus dose (Koska et al, 1981; Bovill & Sebel, 1980) or 
after a bolus dose followed by an infusion which was discontinued on 
initiation of bypass (Koren et al, 1984) (Table 5.2). 
Table 5.2: Previous studies measuring fentanyl levels 
Study No. subjects Dose Assay 
Koska et al (1981) 6 0.5 mg/70 kg bolus RIA 
Bovill & Sebel (1980) 5 60 µg/kg bolus RIA 
Koren et al (1984) 19; children SO µg/kg bolus+ GC 
0.3 µg/kg/min infusion 
RIA=radioimmunoassay; GC=gas chromatography 
At the Royal Hobart Hospital, fentanyl is given in up to six bolus doses 
before bypass and often another dose is given on warming to maintain 
adequate anaesthesia resulting in pharmacokinetics which are difficult to 
interpret. Also, because fentanyl exists in plasma as either a protein 
bound or unbound (pharmacologically active) moeity it was considered 
important to examine unbound concentrations as well as total 
concentrations which have been more generally reported. This is 
particularly significant in cardiac surgery patients as several factors may 
affect the extent of plasma protein binding of fentanyl. 
This study aimed to describe the plasma levels of fentanyl with this 
dosage regimen and plasma levels of alcuronium after a single bolus 
dosage in patients undergoing cardiopulmonary bypass surgery, 
including an investigation of the change in plasma protein binding of 
fentanyl throughout the procedure. An.important factor is whether any 
of these changes that occur as a result of CPB will affect the ability of 
appropriate plasma concentrations of fentanyl and alcuronium to be 
maintained throughout the procedure. 
In addition, an in vitro study was performed to investigate the possible 
adsorption of fentanyl and alcuronium to extracorporeal circuits. 
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CHAPTER 6: MATERIALS AND METHODS 
6.1 Materials and Equipment 
6.1.1 Fentanyl 
Fentanyl citrate and imipramine hydrochloride were donated by Janssen-
Cilag Pty Ltd (Lane Cove, NSW, Australia) and Ciba Geigy (Pendle Hill, 
NSW, Australia), respectively. Standard solutions were prepared in 
methanol (Waters; Lane Cove, NSW, Australia). All other chemicals 
and solvents were of analytical reagent grade quality; hexane (Waters; 
Lane Cove, NSW, Australia), isopropanol (Ajax Chemicals; Auburn, 
NSW, Australia), hydrochloric acid (May and Baker Ltd; West Footscray, 
Victoria, Australia), and sodium hydroxide (BDH Chemicals Australia 
Pty Ltd; Kilsyth, Victoria, Australia). Glassware was washed in Decon® 
(Selby Anax, Australia) and rinsed in distilled water. 
A Varian (Varian Pty Ltd; Melbourne, Australia) 3300 gas chromatograph 
equipped with a nitrogen phosphorus detector (NPD) was used for the 
analysis. The column used was an 11 m x 0.32 mm internal diameter 
Hewlett-Packard (Melbourne, Australia) crosslinked fused-silica 
ultraperformance capillary column coated with silicone gum (0.52 µm 
film thickness; HP-1) which was fitted to a Varian model 1093 septum-
equipped programmable injector (SPI) containing a glass wool packed 
insert (0.8 mm internal diameter). The glass wool provided efficient 
transfer of the liquid sample from the syringe and trapped any 
contaminants present in the sample. The insert was cleaned frequently 
to avoid loss in sensitivity and carryover effects from adsorption. The 
injection-port septum (11 mm TCS, Scientific Glass Engineering Pty Ltd 
(SGE), Melbourne, Australia) was also changed weekly to minimise 
sample leakage. Chromatographic responses were recorded and 
integrated using a Milton-Roy CI-lOB integrator (Clare, Ireland). 
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6.1.2 Alcuronium 
The following chemicals were used for the analytical procedure: 
acetonitrile HPLC grade (Waters; Lane Cove, NSW, Australia), deionised 
water, AR grade sulphuric acid (Ajax Chemicals; Auburn, NSW, 
Australia), pure alcuronium dichloride (Lot 912006 Hoffman - La Roche; 
Basle, Switzerland), disodium sulphate (BDH Chemicals; Kilsyth, 
Australia), and physostigmine sulphate (BDH Chemicals; Poole, 
England). 
The method was developed using an isocratic Waters Associates, Inc. 
(Milford, Massachusetts, USA) HPLC system consisting of a Solvent 
Delivery System model M-45, an Injector model U6K, and an Absorbance 
Detector model 441. Separations were performed using a 250 mm x 4.6 
mm CN - 8/5 column (Scientific Glass Engineering Pty Ltd (SGE), 
Melbourne, Australia) with a CN guard column (SGE) attached. 
Chromatographic responses were recorded and integrated using a 
Milton-Roy CI-lOB integrator (Clare, Ireland). 
6.2 Development of the Assay for Fentanyl in Plasma 
6.2.1 Previous Methods 
In anaesthesia and palliative care, only relatively low doses of fentanyl 
are administered and the plasma concentration tends to fall rapidly to 
low levels in the ng/mL and pg/mL range. Bentley et al (1983) found a 
mean plasma concentration of fentanyl during CPB of 9.1 ± 0.8 ng/mL 
whereas van Lersberghe et al (1994) reported a minimum effective 
plasma concentration of fentanyl for analgesia of 0.3 to 0.7 ng/mL. 
Radioimmunoassay (RIA) methods, with a lower detection limit of 2 
pg/mL have been used in a number of clinical studies (Koska et al, 1981; 
Bovill & Sebel, 1980; Bower & Hull, 1982). 
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A gas-chromatographic assay with nitrogen phosphous detection 
developed by Laganiere et al (1993) used n-butyl chloride to extract 
fentanyl from plasma, and sufentanyl citrate as the internal standard. 
Recovery was 71±10% for 0.4 ng/mL and 75 ± 6% for 3.5 ng/mL and a 
sensitivity of 0.25 ng/mL was obtained from 2 mL plasma. Intraday 
coefficient of variation was found to be 5.1 % and between day coefficient 
of variation was 6.8%; both at a fentanyl concentration of 3.5 ng/mL. 
Van Rooy et al (1981) also used gas chromatography but with a flame 
ionisation detector. Fentanyl was extracted using benzene with 
papaverine as the internal standard. The detection limit was 3.3 ng/mL 
with a recovery of 76 ± 6% (11 ng/mL) from 1 mL plasma. Phipps et al 
(1983) followed a similar initial extraction procedure to Van Rooy et al 
(1981) but used gas chromatography with nitrogen phosphorus detection 
for quantification and achieved a significantly greater sensitivity of 20 
pg/mL from 1 mL plasma; recovery was 69 ± 5% at 20 pg/mL and 
alfentanil was used as the internal standard. Kumar et al (1987) used 
HPLC with UV detection and achieved a recovery of 90 ± 1 % and a 
detection limit of 1.0 ng/mL. 
Table 6.1: Summary of studies for detection of fentanyl 
Author Method Recovery 
Koska et al, RIA 
(1981) 
Bovill & RIA 
Sebel (1980) 
Laganiere et GC (NPD) 71±10% 
al, (1993} 
Bower & RIA 
Hull (1982) 
Koren et al, GC 81% 
(1984) 
Skacel et al, GC 93±4% 
(1986) 
Van Rooy et GC (FID) 76±6% 
al, (1981) 
Kowalski et GC (NPD) 54±12% 
al, (1987) (blood) 
Kumar & HPLC 90±1% 
Morgan 
(1987) 
Phipps et al, GC (NPD) 69±5% 
(1983} 
* Information not provided 
6.2.2 Assay Development 
Internal 
Standard 
sufentanil 
alfentanil 
papaverine 
dextromoram 
ide 
* 
alfentanil 
Detection 
Limit 
0.25ng/mL 
2pg/mL 
* 
* 
3.3ng/mL 
0.25ng/mL 
l.Ong/mL 
20pg/mL 
Extraction 
Solvent 
n-butyl 
chloride 
* 
benzene 
heptane 
heptane 
benzene 
A sensitive and reproducible assay is necessary to study the 
pharmacokinetics and pharmacodynamics as fentanyl levels frequently 
fall below 10 ng/mL following intravenous injection. The method was 
developed based on published assays and using GC with nitrogen 
phoshorus detection. 
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The first objective was to optimise the extraction of fentanyl from the 
plasma so that there was maximum recovery of fentanyl and minimum 
interference from endogenous substances. Different solvents were tried 
including heptane, toluene, benzene and hexane. Hexane was found to 
be the most suitable solvent as it gave the best recovery and least 
interfering peaks. Isopropanol (0.2 mL) was added to help break up 
emulsions which formed on agitation of plasma/ solvent mixtures. 
54 
Next, the chromatographic conditions were considered. A TSD test 
mixture (Varian; Australia, containing 2.00 ng/µL azobenzene, 4.00 
ng/µL malathion, 4.00 µg/µL C17 in iso-octane, and methyl parathion in 
an unspecified concentration) was utilised according to the 
manufacturer's directions so as to achieve suitable gas flow rates through 
the system. These were: carrier+ make up 30 mL/min, hydrogen 4.5 
mL/min and air 175 mL/min. Instrumental operating conditions with 
regard to temperature (given later) were initially based on previous 
studies, and altered in order to separate peaks, improve peak shapes, or 
alter retention times when required. 
Ultimately, the method for drug extraction from plasma was very 
similar to Kowalski et al, (1987) with imipramine, rather than 
dextromoramide, as the internal standard and the use of hexane, rather 
than heptane as the extracting solvent. 
6.3 Analytical Methods-Fentanyl 
6.3.1 Extraction from plasma 
When blood samples were received (see Chapter 6.6), the plasma and red 
blood cells were separated after centrifugation at 2,000 rpm for 15 
minutes Gouan CT 1000 centrifuge). The plasma (-3.5 mL) was kept in 
glass miniature vials (Packard, USA) at -l8°C until analysis and thawed 
by gently shaking in a water bath at 37°C. For preparing standard curves, 
outdated plasma from The Red Cross Society (Melville Street, Hobart) 
was used. 
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Plasma standards were spiked to give fentanyl concentrations of 0.25, 0.5, 
0.75, 1.0, 2.0, 2.5, 4.0, 5.0, 7.5, 10.0, 12.5 and 15.0 ng/mL from methanol 
solutions; 0.1 ng/µL and 1.0 ng/µL. Aliquots (2 mL) of plasma (patient 
samples, drug-free plasma, and plasma standards as above) were pipetted 
into 10 mL glass, conical-tipped, stoppered, centrifuge tubes. To this was 
added 25 µL internal standard solution (containing 1 ng/µL imipramine 
in methanol), 0.4 mL 5 N sodium hydroxide, 4.5 mL hexane and 0.2 mL 
isopropanol. The tube was stoppered, agitated for 1 min on a vortex 
mixer, then centrifuged for 10 min at 2500 rpm. The organic layer was 
transferred via a disposable pasteur pipette to another glass centrifuge 
tube. Hydrochloric acid (2 mL, 0.1 N) was added to the tube, which was 
capped, mixed for 1 min, and centrifuged as above. The organic layer 
was pipetted off and discarded. To the aqueous layer was added 0.2 mL 
sodium hydroxide 5 N and 0.6 mL hexane. The tube was again mixed for 
1 min and centrifuged at 2500 rpm for 10 min. The organic phase was 
then transferred to a 1.0 mL Reacti-Vial™ (Pierce Chemical Company; 
Rockford, USA) and evaporated, in a heating block at 60°C, to 
approximately 10 µL under a gentle flow of nitrogen (high purity grade; 
Commonwealth Industrial Gases Ltd; Hobart, Australia), which had 
passed through oxygen and hydrocarbon trap filters (Scientific Glass 
Engineering Pty Ltd, Melbourne, Australia) to remove oxygen and 
organic contaminants. 
6.3.2 Quantification by Gas Chromatography 
GC operating conditions were as follows. 
Ultra high-purity helium was used as the carrier gas to produce a head 
pressure of 8 psi (2.5 mL/min), high-purity nitrogen (25 mL/min) as the 
makeup gas, and air (175 mL/min) and hydrogen (4.5 mL/min) as the 
detector gases. All gases were supplied by CIG (Commonwealth 
Industrial Gases Ltd; Hobart, Australia). The injector temperature began 
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at 60°C and was increased at 200°C per minute to 300°C. The column 
temperature was initially held at 80°C for 1 min and then increased at 
30°C per min to 300°C. The detector was maintained at 300°C. The NPD 
was optimized for maximum sensitivity according to the manufacturer's 
directions, the current applied to the rubidium bead of the NPD being 
approximately 3.0 A. About 1 µL of the organic phase was injected into 
the gas chromatograph. A standard curve was constructed using the 
peak area ratios of fentanyl/ imipramine. 
The precision of the assay was assessed both within and between days. 
For the within-day testing, five 2 mL aliquots of a spiked plasma sample 
(2.5 ng/mL) were processed on the same day, while 2 mL aliquots of a 
single spiked plasma sample (2.5 ng/mL) were processed on five 
consecutive days for the between-day assessment. 
The specificity of the assay was examined by analysing plasma from 
patients not treated with fentanyl to ensure typical drugs taken by the 
patients did not interfere with the assay (see Appendix 5 for a list of 
drugs). Plasma from six cardiac patients was obtained as single 5 mL 
blood samples taken immediately prior to administration of fentanyl. 
Plasma from ten palliative care patients was obtained from a previous 
study in the department (Bleasel et al, 1994) and had been stored frozen 
at -18°C until determination of the fentanyl concentration. 
l 
6.3.3 Ultrafiltration 
Tritiated fentanyl (372 GBq/mmol) with a reported radiochemical purity 
of 99.6% was obtained from Janssen Research Foundation (Beerse, 
Belgium) which enabled recovery and plasma protein binding studies to 
be undertaken. 
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For the determination of recovery of fentanyl, plasma (2 mL) was spiked 
with both fentanyl (2.5 ng/mL) and tritiated fentanyl (approximately 
10,000 dpm; 120 pg in 50 µL ethanol). A 0.1 mL aliquot was withdrawn 
and assayed for radioactivity by liquid scintillation spectrometry (LKB 
Wallac 1215 Rackbeta 11, Finland) after the addition of 5 mL of liquid 
scintillation fluid (Insta-Gel®, Packard Instrument Company Inc., 
Illinois, USA). A further 2 mL of the spiked plasma was then subjected 
to the extraction procedure for fentanyl as outlined in section 6.3.1. In 
the final step rather than evaporating the hexane (0.6 mL) under 
nitrogen, it was placed in a glass liquid scintillation (LSC) vial, 5 mL of 
Insta-Gel® was added and the radioactivity counted. Recovery was then 
determined by calculating the amount of radioactivity which would 
have been in 2 mL of plasma (i,e,. standard x 20) and dividing the actual 
count from the plasma extraction by this number. 
Fentanyl binding to plasma proteins was measured by ultrafiltration 
using the Amicon MPS-1 micropartition system and YMT membranes 
(Amicon Division, W.R. Grace & Co.; Danvers, Ma, USA). An aliquot of 
each patient plasma sample (approximately 1.0 mL) was spiked with 
tritiated fentanyl (120 pg; approximately 10,000 dpm) and pipetted into 
the upper chamber of the unit. A 0.1 mL plasma sample was taken for 
counting (standard) after the addition of 5 mL of liquid scintillation 
fluid. The ultrafiltration unit was placed in a fixed angle rotor centrifuge 
Gouan CT 1000) prewarmed to 37°C. Centrifugation was performed at 
3,000 rpm for 10 min to produce approximately 0.2 mL ultrafiltrate, of 
which 0.1 mL was taken for counting. 
The unbound fraction was then calculated: 
counts per minute (ultrafiltrate)/counts per minute (standard) x 100% 
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The unbound fentanyl concentration was calculated as the product of the 
total fentanyl concentration and the unbound fraction. Counts per 
minute were used for calculations rather than absolute activity as 
preliminary tests confirmed that the counting efficiency was essentially 
constant. 
Additional preliminary experiments in which fentanyl (2.5 ng/mL) in 
plasma was ultrafiltered showed that only minimal adsorption (3.2 ± 
2.8%, n = 5) to the membrane or to the ultrafiltration device occurred. 
Spiked plasma samples (n = 5) were counted for radioactivity (0.1 mL), 
before 1 mL was pipetted into the ultrafiltration unit and centrifuged as 
above. Samples were taken from both the supernatant and the 
ultrafiltrate as well as measuring the volume in both compartments. 
This allowed the calculation of total radioactivity in the unit which was 
compared to the total expected radioactivity (calculated from the 
standard before ultrafiltration) and the percentage fentanyl adsorbed was 
calculated. 
Also, experiments were performed in order to determine whether 
freezing and subsequent thawing of plasma samples affected the extent of 
protein binding of fentanyl. Human blood was taken by venous 
puncture with a hypodermic syringe from six healthy volunteers. 
Plasma was obtained by centrifugation, one half of which was frozen. 
The remainder was spiked with 2.5 ng/mL of fentanyl and tritiated 
fentanyl to measure unbound fraction. After two weeks the samples 
were thawed in a water bath at 37°C and the above steps repeated. Before 
freezing, fentanyl was 30.0 ± 3.4% free, whereas after freezing it was 29.7 ± 
3.1 % free. Paired t-tests suggested the change in fentanyl binding before 
and after freezing was not considered significant (t = 0.4524, p = 0.67). 
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6.3.4 Loss of Fentanyl and the CPB Apparatus 
A one litre solution of 10 ng/mL fentanyl spiked with tritiated fentanyl 
(0.01 ng/mL; approximately 106 dpm) in lactated Ringer's soh.1:tion was 
flushed through a circuit consisting of only silicone tubing (9 .5 mm and 3 
mm ID; Imamura Co Ltd, Tokyo, Japan). The solution was pumped 
(Manostat Varistaltic Pump, NY, USA) through at 200 mL/min for 120 
min at 25 to 26°C (representing body temperature during bypass). 
Samples (SOO µL) were drawn from the reservoir (1.5 L conical flask) at 0, 
1, 2, 5, 10, 20, 30, 60, 90 and 120 min. The samples were assayed for 
radioactivity by liquid scintillation spectrometry after the addition of 5 
mL of liquid scintillation fluid (see section 6.3.3). The fentanyl 
concentration remained unchanged over 120 min indicating that no 
fentanyl was lost to the silicone tubing (Figure 6.1). There was no loss in 
volume from the system due to evaporation. 
The silicone tubing was flushed with distilled water to remove any traces 
of fentanyl before connection to the CPB apparatus which consisted of 
silicone tubing (9 .5 mm and 3 mm ID) and either a CMS 30™ membrane 
oxygenator (Cobe Cardiovascular, Inc., Arvada, USA), or an Optima™-
HVRF membrane oxygenator with open filtered reservoir (Cobe 
Cardiovascular, Inc., Arvarda, USA). The oxygenators used can be seen 
in Figure 6.2. The pump (Manostat Varistaltic Pump, NY, USA) 
circulated the solution of 10 ng/mL fentanyl (and tritiated fentanyl) in 
lactated Ringer's solution through the CPB apparatus at a rate of 200 
mL/min at 25 to 26°C. Samples were drawn and analysed as above. 
In a preliminary stability study, one litre of lactated Ringer's solution 
containing 10 ng/mL fentanyl was left in a 1.5 L conical flask for the same 
length of time at room temperature and analysed in a similar manner. 
The concentration remained unchanged over 120 min. 
Figure 6.1: The concentration of fentanyl during a 120-m.in 
circulation in silicone tubing 
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Figure 6.la: The concentration of alcuronium during a 120-m.in 
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Figure 6.2: Cobe CMS 30™ membrane oxygenator 
0 10 20 cm 
Figure 6.2a: Co be Optima TM - HVRF membrane oxygenator 
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6.4 Development of the Assay for Alcuronium in Plasma 
6.4.1 Previous Methods 
Quaternary amine neuromuscular blocking agents such as alcuronium 
are often considered difficult to chromatograph because of their large 
organic structures which contain one or two positively charged groups. 
Walker et al (1983) used a spectrofluorimetric technique to measure 
akuronium in plasma with a detection limit of 0.05 µg/mL. Recently 
HPLC methods with UV detection have been more frequently used, the 
differences being mainly in the preparation of samples. deBros et al 
(1990) used solid-phase extraction foi preparing samples (Bond Elut™ 
columns) and achieved a sensitivity of 0.05 µg/mL. This method 
however was time-consuming and relatively expensive. 
Bjorksten et al (1990) used isopropanol-dichloromethane for extraction 
from plasma and a silica column with a detection limit of 0.015 µg/mL. 
Although inexpensive, .this method still had a number of extraction 
steps. Kiinzer et al (1994) developed an assay which used acetonitrile to 
precipitate proteins from the plasma sample and a Spherisorb 5-CN 
column for better separation yet reduced elution times. The sensitivity 
of the assay was reported as 0.025 µg/mL. 
6.4.2 Assay Development 
Because of its quick and simple pre-HPLC sample processing, the assay 
method of Kiinzer et al (1994) was chosen for plasma alcuronium 
determination in this study. 
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However, the assay could not be used directly as published due to several 
problems. Firstly, the internal standard used, laudanosine, did not 
chromatograph very well on our system so an alternative, 
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physostigmine, was used. Secondly, after injecting only a small number 
of plasma samples, the back pressure of the system increase~ to over 
2,000 psi. This was eventually tracked down to a severely blocked guard 
column which had to be replaced. As it was most likely to have been 
caused by "dirty" samples, it was decided that they should be filtered in 
some way before injection into the system. Filtering the samples would 
remove any particles and insoluble chemical contaminants that were 
accumulating in the guard column and would also make the 
chromatography more reproducible. 
A 0.45 µ cellulose acetate filter was tested initially but proved unsuitable 
as it was not acetonitrile-resistant. A material such as nylon is resistant 
to most solvents, so 0.45 µ, non-sterile, nylon membrane filters were 
used (Alltech Associates Pty Ltd; Baulkham Hills, Australia). After 
injecting over 250 samples, no increase in back pressure was noted 
indicating the value of pre-filtration in avoiding premature column 
rep la cement. 
6.5 Analytical Methods-Alcuronium 
6.5.1 Extraction from Plasma 
When blood samples were received, the plasma and red blood cells were 
separated after centrifugation at 2,000 rpm for 15 min. The plasma (about 
1 mL) was kept frozen in glass LSC vials at -18°C until analysis and was 
thawed by gently shaking in a water bath at 37°C. For preparing standard 
curves, outdated plasma from The Red Cross Society (Melville Street, 
Hobart) was used. 
Plasma standards were spiked to give alcuronium concentrations of 0.1, 
0.25, 0.5, 0.75, 1.0, and 1.5 µg/mL from an aqueous solution of 0.05 µg/µL. 
Aliquots (250 µL) of plasma (patient samples, drug-free plasma, and 
plasma standards as above) were pipetted into cappable plastic vials 
(Eppendorf), and 400 µL of a solution containing 50 µg/mL 
physostigmine sulphate in acetonitrile was added to each vial. The 
addition of acetonitrile was to effect protein precipitation. 
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The vials were then vortex-mixed for 15 s, and centrifuged (Hettich 
Mikroliter; Tuttlingen, Germany) at 15,000 rpm for 10 min. From the 
supernatant liquid, 250 µL were filtered through 4 mm non-sterile 
disposable syringe filters with a 0.45 µnylon membrane (Alltech 
Associates Pty Ltd; Baulkham Hills, Australia) and then centrifuged for 2 
min at 15,000 rpm. 
6.5.2 Quantification by High-Performance Liquid Chromatography 
(HPLC) 
The materials and equipment were described in section 6.1.2 and the 
HPLC operating conditions were as follows. 
The mobile phase consisted of 46% acetonitrile and 54% of an aqueous 
solution of 60 mM disodium sulphate and 5 mM sulphuric acid (Kiinzer 
et al, 1994). The system was operated at room temperature with a flow-
rate of 1 mL/min resulting in a column pressure of 1300 psi. Aliquots (75 
µL) of the supernatant liquid were injected into the HPLC and 
alcuronium was detected at 280 nm. 
A standard curve was constructed using the peak area ratios of 
alcuronium/physostigmine. The recovery of the assay was examined by 
comparing the peak area for plasma extracted alcuronium and 
alcuronium dissolved in water (n = 5). The precision of the assay was 
assessed both within and between days. For the within-day testing, five 
250 µL aliquots of a spiked plasma sample (1 µg/mL) were processed on 
the same day, while 250 µL aliquots of a single spiked plasma sample 
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(1 µg/mL) were processed on five consecutive days for the between-day 
assessment. The specificity of the assay was determined by testing plasma 
from six patient controls immediately prior to bypass surgery (before 
administration of alcuronium) to ensure that drugs typically taken by 
these patients did not interfere with the assay. 
6.5.3 Loss of Alcuronium and the CPB Apparatus 
A one litre solution of 3 µg/mL alcuronium in lactated Ringer's solution 
was flushed through a circuit consisting of only silicone tubing (9 .5 mm 
and 3 mm ID; Imamura Co Ltd, Tokyo, Japan). The solution was pumped 
(Manostat Varistaltic Pump, NY, USA) through at 200 mL/min for 120 
min at 25 to 26°C (representing body temperature during bypass). 
Samples (250 µL) were drawn from the reservoir (1.5 L glass conical flask) 
at 0, 1, 2, 5, 10, 20, 30, 60, 90 and 120 min. Internal standard (5 µg 
physostigmine) was added and an aliquot of about 30 µL was assayed for 
alcuronium concentration determination (see section 6.5.2). An 
additional standard curve was constructed for these higher 
concentrations in Ringer's solution. The alcuronium concentration 
remained unchanged over 120 min indicating that no alcuronium was 
lost to the silicone tubing (Figure 6.la). There was no loss in volume 
from the system due to evaporation. 
The silicone tubing was flushed with distilled water to remove any traces 
of alcuronium before connection to the CPB apparatus which consisted 
of silicone tubing (9.5 mm and 3 mm ID) and either a CMS 30™ 
membrane oxygenator (Cobe Cardiovascular, Inc., Arvada, USA), or an 
Optima™-HVRF membrane oxygenator with open filtered reservoir 
(Cobe Cardiovascular, Inc., Arvarda, USA). The pump (Manostat 
Varistaltic Pump, NY, USA) circulated the solution of 3 µg/mL 
alcuronium in lactated Ringer's solution through the CPB apparatus at a 
rate of 200 mL/min at 25 to 26°C. Samples were drawn and analysed as 
above. 
In a preliminary stability study, one litre of lactated Ringer's solution 
containing 3 µg/mL alcuronium was left in a 1.5 L conical flask for the 
same length of time at room temperature and analysed in a similar 
manner. The concentration remained unchanged over 120 min. 
6.6 Human Procedures 
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The study protocol was approved by the Research and Ethics Committees 
of the Royal Hobart Hospital and was carried out in collaboration with 
the Cardiac Surgery Unit at lhe hospital. 
Subjects (n' = 16) were chosen from a consecutive series of patients who 
were undergoing uncomplicated coronary artery surgery in which a 
cardiopulmonary bypass apparatus (COBE Membrane Lung with Integral 
Filter; COBE Cardiovascular, Inc., USA) containing 2.5 L of crystalloid 
priming solution temporarily assumed cardiac and pulmonary function 
(Figure 6.3). Relevant patient data were extracted from medical records, 
and included age, weight, height, drug therapy and serum creatinine 
concentrations (before surgery) and blood haemoglobin levels (before 
and during surgery). Estimated creatinine clearance was calculated using 
the equation (Cockroft & Gault, 1976): 
estimated creatinine clearance (mL/sec) = (140 - age) x body weight(kg) 
48,869 x serum creatinine (mmol/L) 
Plasma was also collected from six preliminary patients (not included in 
results) in order to develop the blood sampling regimen. Each patient 
gave written, informed consent before entering the study and received a 
Patient Information Sheet (Appendices 6 and 7). 
Figure 6.3: Cardiopulmonary bypass apparatus 
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Premedication typically consisted of 10 to 15 mg of diazepam and 10 mg 
of droperidol given orally approximately 90 min before the induction of 
anaesthesia. Anaesthesia was induced with an intravenous dose of 120 
to 150 mg of thiopentone, 10 mg droperidol and 500 µg fentanyl and 
maintained with a total of a further 1500 to 2500 µg of fentanyl in up to 
five divided bolus doses and ventilation with 50% nitrous oxide. 
Corrected for weight, the total fentanyl dose ranged from 27.1 to 39.7 
µg/kg (mean± SD: 33.5 ± 3.5 µg/kg). Alcuronium was also given at the 
time of induction at an intravenous dosage of either 20 or 30 mg. A 
prophylactic antibiotic, 1 g of either cephalothin or cephamandole, was 
administered intravenously. Before the start of bypass 350 to 450 
units/kg of heparin was given intravenously and each patient received 
20 mg hydralazine. Ten patients who required extra neuromuscular 
blockade received 10 to 20 mg of tubocurarine. All patients were cooled 
to 25 to 26°C and gradually rewarmed towards the end of the procedure. 
After termination of CPB, by which time the patient was back to 37°C, the 
effect of heparin was reversed by the administration of 300 to 500 mg of 
protamine. An additional bolus fentanyl dose was given at this time in 
fifteen of the patients to ensure adequate anaesthesia until the end of 
surgery. Neuromuscular blockade was not reversed and the lungs were 
ventilated for at least six hours postoperatively. The time scale of drugs 
received and intraoperative events for a typical patient are shown in 
Table 6.2. 
Blood samples (7 mL) were drawn from the radial artery at various 
intervals throughout surgery (1 min, 5 min and 10 min after the last 
fentanyl IV dose prior to the start of bypass; 5 min, 30 min and 60 min 
after the start of bypass; just before rewarming; and 1 min before, 1 hour, 
2 hours and 3 hours after the end of bypass; Appendix 8) and placed into 
tubes containing lithium heparin as an anticoagulant. Plasma was 
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Table 6.2: An example of the drugs received and the time course of the operation (Patient 
AD) 
Time 
1130 
1210 
1220 
1230 
1236 
1245 
1305 
1310 
1320 
1325 
1337 
1350 
1425 
1445 
1522 
1540 
Event 
15 mg diazepam 
10 mg droperidol 
10 mg droperidol 
500 µg fentanyl 
125 mg sodium thiopentone 
20 mg alcuronium 
500 µg fentany 1 
30mMMgS04 
20mMKCl 
1 g cephamandole 
surgeryconunenced 
500 µg fentanyl 
250 µg fentanyl 
250 µg fentany 1 
35,000 U heparin 
500 µg fentanyl 
20 mg hydralazine 
start of bypass 
maximum hypothermia 
rewarming conunencement 
10mMMgS04 
20mMKCl 
end of bypass 
400 mg protamine 
500 µg fentanyl 
Body temperature 
36°C 
32°C 
26°C 
26°C 
34°C 
38°C 
separated by centrifugation and frozen at -18°C until determination of 
the total fentanyl, unbound fentanyl and total alcuronium 
concentrations. 
6.7 Pharmacokinetic Analysis 
Blood sampling was timed from the end of the last pre-bypass fentanyl 
bolus injection. Biexponential equations were fitted to the fentanyl 
plasma versus time data (first five or six points) using the software 
package Minim 2.0.2® (RD Purves, Pharmacology Department, 
University of Otago, Dunedin, NZ) on a Macintosh® computer. The 
expected fentanyl concentration at a later time (t) was then estimated 
from the equation. This concentration was compared to the actual 
concentration found on rewarming to determine the size of the change 
in total fentanyl concentration on rewarming (Figure 6.4). 
The elimination half-life of fentanyl was estimated from the 
semilogarithmic concentration-time plot of the last four (post-bypass) 
points in Figure 7.9, using the mean values from all sixteen patients. 
Only post-bypass points were used because of the disruptions to the 
plasma concentrations during CPB and the bolus of fentanyl 
administered after the end of CPB. It was not possible to estimate half-
lives in individuals because of the occurrence of plasma level 
fluctuations about two hours after the end o~ bypass in some -patients. 
The elimination half-life of alcuronium was estimated individually 
from semilogarithmic plots of the plasma alcuronium concentration-
time curve using the last four samples for each patient. 
All data were stored and statistically analysed (Statview SE+Graphics®, 
Abacus Concepts; Palo Alto, Ca, USA) on a Macintosh® computer. 
Relationships were investigated using appropriate non-parametric 
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Figure 6.4. Calculation of the size of the increase in fentanyl plasma 
concentration on rewarming in two patients 
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statistical procedures (Spearman rank correlations and Mann-Whitney 
U-tests), with a p value below 0.05 considered statistically significant. 
Results are expressed as means± SD, unless otherwise stated. The 
patient data file can be seen in Appendix 9. 
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CHAPTER 7: RESULTS 
7.1 Analytical Variables-Fentanyl 
7.1.1 Retention Times of Relevant Peaks 
The approximate retention times for imipramine and fentanyl under the 
described chromatographic conditions were 5.4 and 6.9 min respectively. 
Blank plasma extractions demonstrated that using GC, there were no 
interfering peaks at these retention times. An example of a patient 
plasma sample is shown in Figure 7.1 indicating fentanyl and the 
internal standard, imipramine and a blank plasma trace is shown in 
Figure 7.2. 
7.1.2 Standard Curve 
The relationship between the plasma concentration of fentanyl and the 
peak area ratio (fentanyl/imipramine) was essentially linear (r2 = 0.993) 
over the concentration range 0.25 to 15 ng/mL (Figure 7.3). A full 
standard curve was run each time samples were analysed. 
7.1.3 Recovery and Reproducibility 
The analytical recovery of the assay was examined using tritiated 
fentanyl. The mean overall recovery of the assay for five plasma 
samples (2.5 ng/mL) was 81.5 ± 3.7%. The intra- and inter-day 
coefficients of variation (CV) for the determination of fentanyl at 2.5 
ng/mL were 5.7% (n = 5) and 4.9% (n = 5), respectively. 
A lack of interfering peaks in any of the cardiac or palliative care controls 
was evidence for the specificity of the method. At a fentanyl 
concentration of 2.0 ng/mL, no degradation was observed for plasma 
samples stored at -l8°C over a six month period compared with freshly 
spiked plasma samples. 
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Figure 7.1: GC trace of CPB patient plasma sample (containing fentanyl 
13.7ng/mL) 
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Figure 7.2: GC trace of plasma blank 
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Figure 7.3: Fentanyl standard curve 
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7.1.4 Sensitivity 
The sensitivity limit ?f the described procedure for measuring the 
fentanyl concentration in plasma (based on a signal to noise ratio greater 
than 2) was 0.25 ng/mL when 2 mL of plasma was used. 
7.2 Analytical Variables-Alcuronium 
7.2.1 Retention Times of Relevant Peaks 
The approximate retention times for physostigmine and alcuronium 
under the described chromatographic conditions were 3.6 and 8.9 min 
respectively. Blank plasma extractions demonstrated that, using HPLC, 
there were no interfering peaks eluting at these retention times. An 
example of a patient plasma sample is shown in Figure 7.4 indicating 
alcuronium and the internal standard, physostigmine and a blank 
plasma trace is shown in Figure 7.5. 
7.2.2 Standard Curve 
The relationship between the plasma concentration of alcuronium and 
the peak area ratio (alcuronium/physostigmine) was essentially linear (r2 
= 0.993) over the concentration range 0.1to1.5 µg/mL (Figure 7.6). 
7.2.3 Recovery and Reproducibility 
The mean overall analytical recovery of the assay for five plasma 
samples (250 µL) was 68.9 ± 3.1 %. The intra- and inter-day coefficients of 
variation for the determination of alcuronium at 1.0 µg/mL were 4.6% 
(n = 5) and 5.1 % (n = 5), respectively. A lack of interfering peaks in any of 
the controls was evidence for the specificity of this method. 
7.2.4 Sensitivity 
The sensitivity of the described procedure for measuring the alcuronium 
concentration in plasma (based on a signal to noise ratio greater than 2) 
was 0.1 µg/mL when 250 µL of plasma was used. 
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Figure 7.4: HPLC trace of CPB patient plasma sample (containing alcuronium 0.6 
µg/mL) 
internal standard (3.55 min) 
alcuronium (8.89 min) 
Figure 7.5 HPLC trace of plasma blank 
internal standard (3.55 min) 
alcuronium (8.89 min) 
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7.3 Study Results 
7.3.1 Patient Characteristics 
The sample of 16 patients consisted of 13 males and 3 females, ranging in 
age from 47 to 83 years, with a median age of 65 years. The patients all 
had ischaemic heart disease and between one and four coronary vessel 
grafts (CVG) were performed in addition to a left internal mammary 
artery graft (LIMAG) in each case. 
Serum concentration of creatinine prior to CPB ranged from 62 to 139 
µmol/L (mean 94 µmol/L) and estimated creatinine clearance ranged 
from 44.5 to 116.7 mL/ min (mean 75.2 mL/ min). 
Significant correlations did not exist between sex and either the serum 
creatinine or the estimated creatinine clearance (Mann-Whitney U = 9, z 
= -1.4, p > 0.10 and Mann-Whitney U = 13, z = -0.9, p > 0.30, respectively). 
There were no significant associations between age and the serum 
creatinine or the estimated creatinine clearance (Spearman p = 0.2, p > 
0.30 and Spearman p = -0.50, p > 0.05, respectively). 
The mean elapsed time between induction of anaesthesia and 
commencement of extracorporeal circulation was 87 min (range 72 to 106 
min). The lowest temperature during surgery was 25°C and the duration 
of bypass ranged from 57 to 124 min (mean 92 min) and was significantly 
related to the number of grafts being performed (Spearman p = 0.50, p < 
0.05). 
7.3.2 Fentanyl Concentrations in Plasma 
Plasma concentration-time curves of six initial patients led to the 
development of the blood sampling regimen, in addition to a significant 
alteration in the fentanyl dosing regimen which was used throughout 
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the remainder of the study (Figure 7.7). Rather than the former practice 
of giving multiple fentanyl dosages during the whole procedure, it was 
decided to give all the fentanyl prior to the commencement of bypass to 
enable the effect of CPB to be ascertained more easily. In this preliminary 
study, plasma was collected sequentially from the venous then the 
arterial side of the pump just after connection to determine the degree of 
adsorption of fentanyl to the bypass apparatus. A mean change in 
fentanyl concentration of only 0.2 ± 0.3 ng/mL (n = 6) was seen which 
was not significant, although the instantaneous loss proved quite 
difficult to measure. The collection of these plasma samples was 
subsequently discontinued for the main study group of patients. 
The onset and duration of CPB varied between patients and the timing of 
the blood samples during the surgery was different so it was not possible 
to show mean plasma concentration profiles based on actual times; 
instead intraoperative events were used as points of reference. Mean 
times were calculated with standard error bars for each event. 
The peak total fentanyl level measured 1 min after the last dose showed 
great variation between patients and ranged from 9.2 to 1Q6 ng/mL 
(mean 30.6 ± 26.1 ng/mL). This fell quickly to 10.7 ± 3.2 ng/mL after ten 
min. After initiation of CPB, several minutes later, there was a mean 
drop in the total fentanyl concentration of 58.8 ± 14.1 % to 4.8 ± 1.9 ng/mL 
within five min of the start of extracorporeal circulation. The 
haemoglobin level dropped on average 47.3 ± 6.3% on initiation of CPB 
from 14.2 ± 1.2 to 7.5 ± 1.2 g/100 mL and this was used as an indicator of 
the degree of haemodilution. The percentage fall in plasma 
concentration of fentanyl at the start of CPB was related to the magnitude 
of the decline in haemoglobin level (Figure 7.8, Spearman p = 0.65, p < 
0.01). 
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Figure 7.8: Percent drop in plasma concentration of haemoglobin 
versus % drop in plasma concentration of fentanyl at the start of CPB 
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The percentage dilutional effect produced by the start of CPB was also 
estimated by adding the pump volume (2.5 L) to an assumed initial blood 
volume of 80 mL/kg of body weight (Koska et al, 1984a). The measured 
percentage decrease in the plasma concentration of fentanyl on initiation 
of CPB was also related to this percentage dilution of blood volume 
which averaged 40.6%. (Spearman p = 0.55, p < 0.05). The drop in 
haemoglobin level was related to this estimated dilution at the start of 
CPB (Spearman p = 0.43, p < 0.10). 
The fentanyl concentration remained relatively stable during bypass 
until near the end of CPB when the mean total concentration increased, 
coinciding with rewarming (Figure 7.9). The size of the increase was 
calculated and ranged from -0.4 to 5.4 ng/mL and was related to the body 
mass index (BMI =weight in kilograms/(height in metres)2) of the 
patient (Figure 7.10; Spearman p = 0.85, p < 0.001). BMI was used in 
preference to body mass because it gave a better indication of body fat. 
The percentage fall in plasma concentration of fentanyl at the start of 
CPB was also inversely related to the weight of the individual (Spearman 
p = -0.53, p < 0.05) and the size of the increase in fentanyl concentration 
on rewarming (Spearman p = -0.67, p < 0.05). 
7.3.3 Protein Binding 
The unbound fraction (fu) of fentanyl rose 1.5-fold from a mean of 23.5 ± 
5.5% (n = 13) pre-bypass to a maximum of 34.0 ± 7.7% (n = 13) after the 
onset of CPB (Figure 7.11). The unbound fraction was not measured in 
all patients before bypass because of an insufficient volume of plasma for 
analysis. The unbound fraction remained relatively high throughout 
surgery before falling to close to 27.7 ± 4.1 % which is close to its pre-
bypass value. 
Figure 7.9: Plasma fentanyl concentrations versus time in a group 
of patients having coronary artery bypass grafting (n = 15) 
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Figure 7.11: Percent unbound fentanyl versus time in a group 
of patients having coronary artery bypass grafting 
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The unbound concentration of fentanyl fell by a mean of 43% from its 
original value on initiation of bypass (3.0 ± 1.0 ng/mL to 1.7 ± 0.8 ng/mL 
within 5 min of CPB) and then stayed relatively constant during surgery 
before decreasing slightly after the end of the procedure (Figure 7.12). 
7.3.4 Pharmacokinetics - fentanyl 
From a semilogarithmic concentration-time plot using the grouped data 
(Figure 7.9), an elimination half-life of 4.7 hours was estimated. 
7.3.5 Loss of Fentanyl and the CPB Apparatus 
Following the priming of the pump with 10 ng/mL of fentanyl, the 
concentration fell to 8.8 ng/mL within one min and then remained 
relatively stable over the following 120 min during circulation through 
the CML30™ membrane oxygenator (Figure 7.13). 
In the Optima™ membrane oxygenator, the initial fall was from 10.0 to 
9.2 ng/mL within one min before falling further and stabilising at a level 
of 8.5 ng/mL by 120 min (Figl,lre 7.14). 
These decreases in fentanyl concentration represent total losses of 1.2 µg 
and 1.5 µg of fentanyl, respectively from each system. Translating this 
loss in vivo, it is less than 1 % of the total fentanyl dose given. 
7.3.6 Alcuronium Concentrations in Plasma 
The alcuronium dosage was either 20 mg (n = 14) or 30 mg (n = 2) which 
translated to a range of 0.22 to 0.37 mg/kg. The resulting plasma 
concentrations decreased gradually pre-bypass before a more marked 
decline 5 min after connection of the CPB apparatus. The plasma 
concentrations of alcuronium were plotted using the last pre-bypass 
fentanyl dose as time zero; this was usually about one hour after the 
alcuronium dose was given. The mean decline in alcuronium 
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Figure 7.12: Total and unbound plasma fentanyl concentrations 
in a group of patients having coronary artery bypass grafting 
(n = 15) Mean and SEM are shown 
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Figure 7.13: The concentration of fentanyl during a 120-min 
circulation through a membrane oxygenator (CML30™) 
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Figure 7.14: The concentration of fentanyl during a 120-min 
circulation through a membrane oxygenator (Optima™) 
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concentration on connection to CPB was 29.0 ± 10.9% (n = 16). The 
alcuronium concentrations remained relatively constant during surgery 
until falling due to elimination (Figure 7.15). There was no increase in 
the plasma concentration coinciding with rewarming. 
7.3.7 Pharmacokinetics - alcuronium 
The estimated average elimination half-life of alcuronium for the 
sixteen patients was 194 ± 44 min. Half-life calculated individually for 
each patient was significantly inversely related to estimated creatinine 
clearance (Spearman p = -0.55, p < 0.05). Significant correlations did not 
exist between the half-life and either age or sex of the patient (Spearman 
p = 0.36, p > 0.10 and Mann-Whitney U = 11.0, z = -1.1, p > 0.25, 
respectively). 
7.3.8 Loss of Alcuronium and the CPB Apparatus 
Following the priming of the pump with 3 µg/ mL of alcuronium, 
virtually unchanged concentrations of the drug were measured at all 
times for both the CML30TM and the OptimaTM (Figures 7.16 & 7.17). 
A drop from 3 µg/mL to 2.8 µg/mL in the one litre solution of Ringer's 
lactate represents a loss of only 0.2 mg of alcuronium from the system. 
When translated in vivo, this is 1 % of the 20 mg intravenous dose. 
Using a published Vd of 329 mL/kg in bypass patients (Walker et al, 1983) 
the apparent loss of alcuronium on connection to CPB can be estimated. 
The average fall in plasma concentrations of alcuronium in the study 
patients is from 0.8 to 0.6 µg/mL or: 
from 
0.8 µg/mL x 329 mL/kg x 70kg=18424 µg or 18.4 mg 
to 
0.6 µg/mL x 329 mL/kg x 70kg=13818 µg or 13.8 mg 
This represents an apparent loss of alcuronium of 4.6 mg with only 0.2 
mg of this amount being attributed to adsorption to the membrane · 
Figure 7.15: Plasma alcuronium concentrations versus time in a 
group of patients having coronary artery bypass grafting (n = 16) 
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Figure 7.16: The concentration of alcuronium during a 120-min 
circulation through a membrane oxygenator (CML30™) 
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Figure 7.17: The concentration of alcuronium during a 120-min 
circulation through a membrane oxygenator (Optima™) 
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oxygenator in the in vitro study (4.3%). The decline in plasma 
concentration must therefore be due primarily to sequestration by the 
lungs and of course haemodilution. 
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CHAPTER 8 : DISCUSSION 
This study presents a profile of the fate of intravenous fentanyl and 
alcuronium in patients undergoing cardiopulmonary bypass surgery. All 
major pharmacokinetic processes could be affected by CPB; however, any 
attempt at formal pharmacokinetic modelling assumes that the 
physiological status of the patient remains relatively constant over the 
given period. In this study, the number of factors which may affect 
pharmacokinetics such as other drug therapy, dosage regimen, 
haemodilution, hypothermia, lung isolation, adsorption of drug and 
protein to the CPB apparatus and hormonal and catecholamine release 
made the results difficult to deal with mathematically. For these reasons 
the study became largely an observational one. 
Fentanyl 
Some of the previously reported fentanyl assay methods proved 
unsuitable for plasma level monitoring in this study due to both the 
excessive costs of RIA and the unavailabiHty of the internal standards 
used. The GC procedure described here is specific for the measurement 
of fentanyl and sensitive enough to measure the low levels after 
administration of fentanyl citrate for anaesthesia. The extraction is close 
to that of Kowalski et al (1987) but uses a different solvent and internal 
standard and extracts from plasma rather than blood. The limit of 
detection was found to be about 0.25 ng/mL when 2 mL of plasma was 
extracted for fentanyl determination. This is similar to the sensitivity 
reported in other studies (Laganiere et al, 1993: 0.25 ng/mL; Kowalski et 
al, 1987: 0.10 ng/mL; Phipps et al, 1983: 20 pg/mL, Kumar & Morgan, 
1987: 1.0 ng/mL). The recovery of the described method was 82%. This 
compares favourably with van Rooy et al (1981) and Kumar & Morgan 
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(1987) who claimed their extraction methods gave fentanyl recoveries of 
76% and 89% respectively. 
The total fentanyl dosage for each patient over the whole period ranged 
from 27.1to39.7 µg/kg with a mean dosage of 33.5 µg/kg, and was given 
at varied and unscheduled times. This is significantly lower than the 
dosages of fentanyl used in most of the other studies (Table 8.1) and 
differs also in that each study in Table 8.1 involved the administration of 
only a single bolus dose of fentanyl rather than up to six separate 
injections. Other studies have also looked at the pharmacokinetics of 
fentanyl following bolus and infusion (Hall e_t al, 1993) which would 
allow the establishment of a stable fentanyl concentration prior to CPB 
enabling any resultant effects on plasma concentration and binding to be 
determined more precisely. 
Table 8.1: A summary of fentanyl doses used in cardiopulmonary bypass studies 
Study Total fentanyl dose given Sole anaesthetic 
a ent 
Hug & Moldenhauer, 1982 75µg/kg yes 
Bentley et al, 1983 lOOµg/kg yes 
Koska et al, 1981 500µg/70kg ro 
Bovil & Sebel, 1980 60µg/kg yes 
Hall et al, 1993 75µg/kg yes 
It is important to study these lower dosages because the 
pharmacokinetics may differ to some degree. The lower dosage used in 
this study can be explained by the fact that fentanyl was not given as the 
sole anaesthetic agent unlike other studies, but was supplemented with 
sodium thiopentone, droperidol and nitrous oxide. Even though the 
latter is a short acting drug, it provides supplementation for induction of 
anaesthesia and may decrease the dose of opioid required to block the 
haemodynamic responses to surgical stimuli before bypass. During and 
after CPB, smaller plasma concentrations of fentanyl might be sufficient 
especially considering that hypothermia itself depresses cerebral 
metabolic activity and promotes anaesthesia (Koren et al, 1984). 
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The larger dosages used in previous studies resulted in higher peak 
plasma concentrations of fentanyl than found in this study of 30.6 ± 26.1 
ng/mL (range= 9.2 to 106 ng/mL) even though this will be critically 
dependent on timing of blood sampling. Hall et al (1993) reported a peak 
of 85 ± 11 ng/mL and Bovill and Sebel (1980) a concentration 1 minute 
after injection of 102.4 ± 36.5 ng/mL, with a range of 31.2 to 200 ng/mL. 
The total plasma concentration of fentanyl decreased rapidly in the pre-
bypass period mainly due to distribution (Cartwright et al, 1980) before a 
sudden decline of almost 60% in the concentration of total fentanyl in 
plasma on initiation of extracorporeal circulation. Other studies found a 
similar decline in total fentanyl concentration on CPB (Table 8.2). 
Table 8.2: A summary of the % drop in fentanyl concentration on initiation of CPB found in 
other studies 
Study % drop in fentanyl concentration on CPB 
Hug & Moldenhauer, 1982 42% 
Howie et al, 1981 59% 
Bovill & Sebel, 1980 53% 
Koren et al, 1984a 75% 
Lunn et al, 1979 37% 
Koren et al, l984b 71% 
This study 59% 
The magnitude of the decline was inversely related to the body weight of 
the individual suggesting that dilution has more effect in patients who 
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weigh less due to a smaller extracellular fluid volume for the 2.5 L of 
Ringer's solution to distribute within. It should also be noted that CPB 
initiation occurred on average only 13 minutes after the last injection of 
fentanyl and this may have made it difficult to separate the effects of 
redistribution and haemodilution. 
On connection to the CPB apparatus, there is an extension of the initial 
volume of distribution (central compartment), however the 60% drop in 
concentration of fentanyl exceeded the expected effect of haemodilution 
(47% measured by Hb concentration decline or 41 % estimated blood 
volume increase). This phenomenon may be explained by lung or pump 
sequestration. Bovill & Sebel (1980) reported that 24% of a fentanyl dose 
can be taken up by the lungs in 30 sand Taegar et al (1988) found that 
43% to 87% of a dose can be sequestered by the lungs on the first passage. 
This drug is usually released gradually back into the bloodstream over a 
period of time so when the lungs are cut off from the general circulation 
on initiation of CPB, this loss could be quite significant to the resulting 
plasma concentration. Using the data of Hynynen (1987), the amount of 
fentanyl which is generally adsorbed to the CPB device represents only 1 
to 8% of the total fentanyl dose given in this study. Our data from the in 
vitro study also suggests the amount adsorbed is less than 1 % of the total 
fentanyl dose. Therefore this occurrence is probably not as important as 
the pulmonary isolation when attempting to interpret the sudden drop 
in concentration which is not due to haemodilution. 
The mean drop in haemoglobin was almost 50%. Similarly, Bovill & 
Sebel (1980) reported an average drop in haematocrit of 41 % and Koren 
et al (1984a) found haemodilution to be 51 ± 12%. The effect of 
haemodilution is increased by fasting before the operation and moderate 
under-hydration in the pre-bypass phase of surgery (Bovill & Sebel, 1980). 
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Although physiological monitoring took place throughout the procedure 
(Appendix 10), it was not possible to relate fentanyl concentration at any 
stage to pharmacodynamic response variables because during bypass, 
both cardiac output and blood pressure were essentially determined by 
the pump conditions. ·Electroencephalographic (EEG) quantitation of 
narcotic effect may have been useful to determine any evidence of 
arousal or other loss of narcosis. There were no reports of awareness 
from any of the patients in this study. 
The mean unbound fraction of fentanyl before CPB was 23.5% which 
compares to values of 19% and 21 % found by McClain & Hug (1980) and 
Bower & Hull (1982), respectively, in healthy volunteers. The mean 
unbound fraction of fentanyl increased by a factor of 1.5 (from 23.5% to 
34.0%) at the start of CPB which would allow more drug to diffuse across 
capillary membranes and into tissues. It has been suggested that heparin 
activates lipoprotein lipase increasing the concentration of free fatty 
acids, which may displace the drug from its binding site (Finegan et al, 
1992). However, the admini$tration of heparin has been found not to 
alter either the concentration of proteins or their binding capacity to 
alfentanil (Hug et al, 1994). The most likely explanations for this increase 
in unbound fraction are therefore the dilution of binding protein 
concentrations (particularly a.1-acid glycoprotein; Mather, 1983) in 
plasma by the protein-free priming solution of the CPB apparatus and/ or 
adsorption of proteins onto the CPB equipment (Finegan et al, 1992). 
Various studies have documented a significant drop in plasma protein 
levels immediately after CPB connection (Table 8.3). By the end of the 
blood collection period, the unbound fraction of fentanyl had returned to 
close to its pre-bypass value even though the binding protein 
concentration may still be reduced (Kumar et al, 1988). Unbound fraction 
of fentanyl could not be related to either plasma albumin or a.1-acid 
glycoprotein levels because they were not available in these patients. 
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Table 8.3: A summary of the % drop in protein concentration on initiation of CPB found in 
other studies 
Study % drop in protein concentration on CPB 
Kumar et al, 1988 50 % drop in AAG & albumin 
Hynynen et al, 1994 50 % drop in total protein & albumin 
Hug et al, 1994 40 % drop in AAG 
The fentanyl concentrations in plasma would be expected to drop at the 
start of CPB due to haemodilution, but the simultaneous dilution of 
plasma proteins and subsequent decrease in plasma protein binding of 
fentanyl would potentially result in an increase in the unbound 
concentration. The extent to which each of these occurs will determine 
whether the unbound concentration will rise or fall. In addition, 
hypothermia, non-pulsatile flow and hormonal changes can also affect 
the unbound concentration (Holley et al, 1982). In this study, the 
unbound fentanyl concentration dropped by 43% at the start of CPB. This 
is not as great as the decline in the total concentration (59%), attributable 
perhaps to the decreased binding fraction as mentioned above. 
The relatively stable plasma concentrations of fentanyl during bypass 
indicate that there is a decreased clearance compared to the post-bypass 
period, which is most likely due to a combination of decreased liver 
blood flow (Koska et al, 1981) and a reduction in hepatic enzyme activity 
as a result of hypothermia (Bentley et al, 1983). As the patient is 
rewarmed (before the end of CPB) and the tissues (ie muscle and fat) are 
reperfused there is a washout of sequestered drug from the tissues which 
results in a transient rise in the fentanyl concentration. The significant 
relationship between the magnitude of the rise and BMI may indicate 
that those with a higher BMI have a greater proportion of body fat 
leading to more storage of fentanyl which is subsequently released on 
rewarming. The actual amount of fentanyl being released was intended 
to be estimated using a published value of volume of distribution (V d) 
and the measured change in plasma concentration, however it was not 
valid to assign a specific value of V d because of constantly varying 
conditions. 
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The washout of fentanyl from the lungs has been documented by Koska 
et al (1981) who found a rapid 30% rise in the concentration of fentanyl 
with the resumption of pulmonary blood flow. After restoration of 
ventilation and perfusion to the lungs following disconnection from the 
cardiopulmonary bypass apparatus, we would expect a rise in the plasma 
concentration of fentanyl due to drug washout from the lungs, however 
it could not be measured in this study because of an additional fentanyl 
dose given at the same time as CPB termination to ensure adequate 
anaesthesia after rewarming is complete but before the end of surgery. 
For this reason, it would not have been known to what extent any rise in 
fentanyl concentration was due to lung washout alone. 
The gross changes in physiological conditions over the bypass period 
precluded any reliable estimation of clearance or volume of distribution 
and did not allow the individual determination of half-life during the 
procedure in these patiei:its. Also, peaks occurring within 2 hours of the 
end of surgery, probably due to increasing muscle tone and voluntary 
movement causing additional mobilisation of fentanyl from tissue 
depots, made the task even more uncertain. The calculation of apparent 
terminal half-life during the recovery period using the combined patient 
data gave a mean value of 4.7 hours. This is longer than the half-lives of 
3.7 and 3.3 hours for healthy volunteers and non-CPB surgical patients, 
respectively reported by Hug and Moldenhauer (1982) but shorter than 
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values of 7.3 ± 1.4 hours and 5.2 ± 2.7 hours in CPB patients reported by 
Duthie et al (1986) and Koska et al (1981), respectively (Table 8.4). This 
method of calculating elimination half-life requires that samples are 
taken for a period at least equal to three times the half-life. The three 
hour sampling time in this study was less than the half-life, but 
concentrations would have been too small to measure 15 hours after the 
end of bypass especially given the small total fentanyl dosage used, and 
in addition ethical approval only allowed a maximum volume of 55 mL 
plasma to be sampled for each patient. 
Table 8.4: A summary of fentanyl elimination half-life values found in other studies 
Study 
Duthie et al (1986) 
Hug & Moldenhauer (1982) 
Mather (1983) 
Koska et al (1981) 
Bovill & Sebel (1980) 
Patients 
CPB 
CPB 
surgical 
volunteers 
surgical 
volunteers 
CPB 
CPB 
Half-life (hours) 
7.3± 1.4 
11±2 
3.3 
3.7 
2.5- 7 
2-4 
5.2±2.7 
7.0 ± 0.6 
The prolonged half-life in CPB patients is probably ~ue to a combination 
of an increased volume of distribution and a decreased clearance with 
the rate-limiting step being the slow redistribution of fentanyl from the 
peripheral compartment. The main adverse effect of this slow 
elimination is possible persistance of fentanyl and ventilatory depression 
requiring assisted ventilation. McClain & Hug (1980) reported that 
respiratory effects become insignificant below 0.7 ng/mL and patients can 
be extubated at levels below 2.9 ± 0.1 ng/mL (Moldenhauer & Hug, 1982). 
At three hours after the end of bypass, none of the patients in the present 
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study had levels below 0.7 ng/mL but only three were above 2.9 ng/mL 
so it seems that fentanyl in this study sample will have generally 
provided postoperative analgesia without excessive respiratory 
depression. All patients in this study received respiratory support up to 
six hours postoperatively. 
Alcuronium 
The HPLC procedure described in this study was specific for the 
measurement of alcuronium and sensitive enough to measure the low 
levels in plasma after a single injection of alcuronium chloride during 
CPB. The limit of detection was found to be 0.1 µg/mL when 250 µL of 
plasma was extracted for alcuronium determination. This is similar to 
the sensitivity reported in other studies (Walker et al, 1983: 0.05 µg/mL; 
deBros et al, 1990: 0.05 µg/mL and Kiinzer et al, 1994: 0.025 µg/mL). The 
recovery of alcuronium in the described method was 69 ± 3% which 
seems acceptable; the recovery achieved by the extraction method of 
Kiinzer et al, 1994 was not documented. 
The alcuronium dosage ranged from 0.22 to 0.37 mg/kg with a mean 
dosage of 0.27 mg/kg. This is similar to dosages used in other studies 
{Table 8.5). 
Table 8.5: A summary of alcuronium doses used in previous studies 
Study 
Diefenbach et al, 1995 
Walker et al, 1980 
Walker et al, 1983 
Alcuronium dose given 
0.25mg/kg 
0.25 mg/kg (n = 11), 0.375 mg/kg (n = 8) 
0.25 mg/kg + infusion = 0.48 mg/kg total 
The average decline in plasma alcuronium concentration on connection 
to the CPB apparatus was 29 ± 6.6% which was about one-half the drop in 
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total fentanyl concentration (59%). This can probably be explained by the 
fact that alcuronium is hydrophilic and there is less tissue uptake 
initially and it has been shown that it is not expected to be significantly 
bound by the bypass pump in vivo, and so the drop in concentration is 
mainly due to haemodilution and some sequestration by the lungs. Also 
the distribution phase would be complete by this time (t112oc = 13.8 min; 
Walker et al, 1980) as the start of blood sample collection was about one 
hour after the administration of the alcuronium dose in all cases, so 
there would be no decrease in alcuronium concentration due to 
distribution. 
It has been reported that the minimum plasma level required for 
significant neuromuscular blockade is 0.3 µg/mL (deBros et al, 1990). 
This level was exceeded in all patients during the procedure indicating 
expected satisfactory depression of twitch response. 
The elimination half-life for alcuronium was estimated for all patients 
and was found to be 194 ± 44 min which is not significantly different to 
that found in normal surgery. In surgical patients, Walker et al (1980) 
reported a value of 198 minutes and deBros et al (1990) a value of 
approximately 200 minutes, however the elimination half-life was found 
to be prolonged to 532 minutes in CPB patients receiving a combined 
bolus and infusion dosage of alcuronium (Walker et al, 1983; Buylaert et 
al, 1989). 
The half-life of alcuronium when estimated individually was 
significantly related to estimated creatinine clearance which would be 
expected as alcuronium is 85% excreted unchanged by the kidneys so 
renal function is a good indicator of drug clearance in this case. 
The main explanation for the possibility of an increased elimination 
half-life of alcuronium following CPB- is the reduction in glomerular 
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filtration rate (and therefore clearance) due to hypotension, hypothermia 
and other factors related to both CPB and surgery itself. The influence of 
hypothermia on the sensitivity of the patient to the effects of 
neuromuscular blockers may make it difficult to link any of the changes 
in pharmacokinetic parameters found during CPB to the actual 
pharmacodynamic effects of the drug in the same period. 
It has previously been reported that hypothermia may decrease the renal 
elimination of the neuromuscular blockers pancuronium, d-
tubocurarine and alcuronium (Wierda et al, 1990), and Holley et al (1982) 
claimed that non-pulsatile flow during cardiopulmonary bypass may 
temporarily impair renal function. The relatively stable plasma levels of 
alcuronium found in this study during the actual period of hypothermia 
and CPB may be indicative of this reduction. 
However, Wierda et al (1990) reported that the overall effect of 
hypothermia and bypass did not significantly influence the terminal 
half-life of pipercuronium when given as a single bolus dose, as 
alcuronium was in this study. Also Avram et al (1987) found a fall in 
metocurine concentration after initiation of CPB due to haemodilution 
followed by no important changes in terminal drug clearance. In a 
previous report pertaining to alcuronium kinetics and CPB, Walker et al, 
(1983) used a combined bolus and infusion dosage regimen and noted an 
increase in the plasma concentration upon institution of CPB and 
subsequently a prolonged elimination half-life. The increase in plasma 
concentration can be explained by a sudden decrease in the volume of 
distribution with the lungs being cut off while there is a continuing 
input of drug into the body. 
This study showed that although the clearance of alcuronium during 
CPB was reduced, once extracorporeal circulation was terminated and 
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rewarming had taken place, the terminal half-life of alcuronium was 
virtually unaffected when compared to that found after normal surgery. 
The in vitro experiment with alcuronium examined the possibility that a 
similar adsorption mechanism to that of fentanyl may be responsible for 
the decline in plasma concentrations of alcuronium at the onset of CPB. 
The results showed that alcuronium does not appear to be bound by the 
components of the extracorporeal circuit to any significant extent. 
Conclusions 
This study has shown that there is a marked drop in both total and 
unbound fentanyl concentrations and total alcuronium concentrations 
on initiation of bypass. However, suitable plasma concentrations of both 
drugs were maintained even given the extreme physiological changes 
occurring over the bypass period. The findings are consistent with 
haemodilution, alterations in plasma binding and reduced hepatic and 
renal perfusion during and after CPB. 
It also showed that adsorption of drugs to the extracorporeal circuit in 
vitro does not necessarily translate to a significant effect in vivo due to 
the large drug reservoir that exists. 
PART III 
PLASMA CONCENTRATIONS OF FENTANYL WITH 
SUBCUTANEOUS INFUSION IN PALLIATIVE CARE 
PATIENTS 
CHAPTER 9 : INTRODUCTION 
9.1 Use of Fentanyl in Palliative Care 
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Long-term opioid administration is widespread in the treatment of 
cancer pain, with 60 to 90% of patients with advanced disease requiring 
an opioid analgesic to control their pain (Moulin et al, 1992; Schug et al, 
1992; Knowles, 1993). Best pain relief is achieved by regular oral opioid 
administration (Walsh and West, 1988) and this route is preferred for 
convenience and cost-effectiveness (Schug et al, 1992; Agency for Health 
Care Policy and Research, 1994). Oral morphine can control the pain 
sufficiently in most patients (Storey et al, 1990), and is the drug of choice 
because of its wide availability, efficacy and flexibility in dosing (Walsh, 
1994). 
It has been reported that 70% of patients can take oral drugs to within 72 
hours of death (Walsh and West, 1988), but because of intractable 
vomiting, nausea, dysphagia, inadequate absorption and other GI 
symptoms, a substantial proportion of patients require an alternative 
(non .. oral) route (Storey et al, 1990; Dover, 1987; O' Neill, 1994; Zech et al, 
1994). These may include continuous subcutaneous infusion, IV 
infusion and rectal administration. It has been documented that one-
half of dying patients will require parenterally .administered analgesics 
during the last days and hours of life (Zech et al, 1994). 
The rectal route is the traditional alternative and is safe and inexpensive, 
but suppositories are not very useful for long-term opioid 
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administration, especially where surgical resection has occurred or rectal 
discharge and incontinence are present (Maddocks, 1992). 
Intravenous lines are difficult to maintain and are not very suitable for 
patients wishing to be treated at home, whereas bolus IV doses can result 
in pain and distress due to multiple injections (Storey et al, 1990) and 
should not be used for routine analgesia because of poor control and a 
relatively high risk of adverse effects (Walsh and West, 1988). 
Continuous subcutaneous infusions using syringe drivers are a safe, 
simple and effective alternative, and greatly benefit patients unable to 
take oral medication and their carers. The portable, low volume pumps 
are easy to manage, particularly when the patient is at home and they 
avoid the need for four hourly injections (Reid, 1989). They also allow 
flexibility of dosing and the simultaneous administration of opioids with 
anti-emetics, neuroleptics, sedatives and anti-spasmodics (O'Neill, 1994; 
Maddocks, 1992). 
Other advantages of subcutaneous infusions include the production of 
stable blood concentrations which can be easily titrated for each 
individual and that the peak-concentration sedation and trough-
concentration breakthrough pain associated with intermittent dosage 
regimens can be avoided. Continuous subcutaneous therapy has also 
been associated with a lower incidence of nausea, sedation and 
constipation (Moulin et al, 1992). 
Some disadvantages of continuous subcutaneous therapy include the 
possibility of local irritation, discomfort or infection at the indwelling 
needle site and the fact that the portable pumps are relatively expensive 
and often require skilled attention (Westerling et al, 1994). 
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Morphine is the preferred opioid for continuous subcutaneous infusion 
in Australia with the daily requirement by this route being only about 
one-third the total daily oral dosage due to the subcutaneous 
bioavailability approaching 100% (Maddocks, 1992; Dover, 1987). The 
therapeutic dosage range is enormous with a reported range of 40 - 4,024 
mg morphine per day (Storey et al, 1990). In the UK, diamorphine 
(heroin) is available and is considered the narcotic of choice because of its 
superior water solubility (Storey et al, 1990; Beswick, 1987) which is 
important when bearing in mind that 67% of advanced cancer patients 
are anorexic and have reduced muscle mass and subcutaneous tissue for 
the volume to be injected into (Regnard & Tempest, 1992). Heroin is not 
available for medical use in Australia. 
For patients with inadequate pain control or dose-limiting adverse effects 
from one opioid, other opioids, such as fentanyl, should be tried (Agency 
for Health Care Policy and Research, 1994). 
Fentanyl is a potent opiate analgesic which, because of its relatively short 
duration of action, is commonly used intravenously as an anaesthetic 
agent for major and minor surgery (see section 5.2.1). Although more 
expensive than morphine, the use of fentanyl has also now extended to 
palliative care units, to provide analgesia if morphine causes persistent 
distressing side effects such as hallucinations, nightmares, nausea and 
sedation (Maddocks, 1992; Agency for Health Care Policy and Research, 
1994). It has been reported that subcutaneous fentanyl is being used 
commonly or occasionally by 12% of respondents in a survey of ninety-
six teaching hospitals and palliative care services throughout Australia 
(Drummond et al, 1995). There is also speculation that fentanyl might 
cause less constipation than other opioids but this is yet to be confirmed 
(Zech et al, 1994). Because of significant first-pass metabolism in the liver 
after gastrointestinal tract absorption, fentanyl is ineffective when given 
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orally (Mather & Gourlay, 1991). Apart from the subcutaneous route, the 
recent development of a transdermal therapeutic system for fentanyl has 
also allowed it to be delivered continuously through the skin for up to 72 
hours (Portenoy et al, 1993). This analgesic option is not suitable for 
rapid dose titration and is best for patients with stable pain and only low 
to medium opioid requirements. Thus, although it represents a more 
invasive route of administration than transdermal delivery, 
subcutaneous administration of fentanyl is probably a safe, practical and 
very effective treament for both moderate and severe cancer pain in a 
number of palliative care patients. 
Minimum effective analgesic plasma concentrations of fentanyl in 
opioid-naive patients have reportedly ranged from 0.2 to 2 ng/mL 
(Duragesic® product information). Lehmann et al (1988) found a mean 
minimum effective plasma concentration of 1.2 ng/mL (range 0.2 to 8.0 
ng/mL) when fentanyl was used for postoperative analgesia. It has been 
documented that the risk of adverse effects including hypoventilation 
increases with plasma concentrations greater than 2 ng/mL in non-
opioid tolerant patients, especially those with a concurrent underlying 
pulmonary condition (van Lersberghe et al, 1994), and CNS effects have 
been reported to increase at serum concentrations greater than 3 ng/mL 
(Duthie et al, 1988). Plasma concentrations, however, do not always 
reflect patient sensitivity to fentanyl and so should probably not be used 
as the only indicator of efficacy or toxicity. In addition, pain can act as a 
physiologic antagonist to the central depressant effects and so when 
fentanyl is used for the relief of cancer pain, the documented respiratory 
depression is not always a problem. Opioid tolerance occurs in many 
patients to a variable extent and both the,minimum effective 
concentration and the concentration at which toxicity occurs will rise 
with this increasing tolerance. 
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In a study by Portenoy et al (1993) of the pharmacokinetics of fentanyl 
following transdermal administration for cancer pain, the steady-state 
plasma fentanyl concentrations were characterised by a large 
interindividual variability (range 0.6-3.1 ng/mL). Similarly, Varvel et al 
(1989) found an average plasma fentanyl concentration of 1.8 ng/mL 
with a range of 0.5 to 3.1 ng/mL after transdermal administration. 
Since fentanyl is known to undergo extensive hepatic metabolism, a 
decrease in intrinsic clearance due to underlying disease or an alteration 
in liver function may explain some of the variation in analgesic dosage 
required. 
Renal disease may also affect (increase) the plasma fentanyl 
concentration due to an altered volume of distribution (Data on file, 
Janssen Pharmaceutica). 
9.2 Objectives of this Study 
While the pharmacokinetics of fentanyl following intravenous 
administration have been well characterised (Bower, 1982), there are no 
published data on plasma concentrations of fentanyl with continuous 
subcutaneous therapy. 
The objectives of this study were to gather data on steady-state total and 
unbound plasma concen~rations of fentanyl in patients receiving chronic 
subcutaneous therapy and to examine the inter-patient variability in 
these concentrations. Another aim was to compare these plasma 
concentrations with those reported in the literature following 
transdermal administration of fentanyl. In addition, relationships 
between plasma concentrations and dosage, and the age, sex, liver 
function and pain control of each patient were assessed. 
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CHAPTER 10 : MATERIALS AND METHODS 
10.1 Materials 
As described in Chapter 6.1. 
10.2 Analytical Methods 
As described in Chapter 6.3. 
10.3 Human Procedures 
The study protocol was approved by the Research and Ethics Committee 
at Repatriation General Hospital, Daw Park, Adelaide. A consecutive 
sample of in-patients within the Palliative Care Unit at the hospital 
receiving continuous treatment with fentanyl administered as a 
subcutaneous infusion, generally through a needle inserted into the 
chest wall (via a Graseby® portable syringe pump) were studied. 
Proprietary ampoules (David Bull, Mulgrave, Australia) of fentanyl 50 
µg/mL in Water for Injection were used and patients in the unit were 
routinely assessed for pain at least four times daily using visual analogue 
scales, and changes to the infusion rate and/ or the administration of 
bolus dosages occurred, if necessary. All patients gave informed consent 
and received a patient information sheet (Appendices 11 & 12). 
In order to achieve steady-state plasma concentrations of fentanyl, a 
venous blood sample (5 to 10 mL) was drawn after at least 24 hours of 
therapy at a constant rate of infusion with no bolus doses. Plasma was 
separated by centrifugation and frozen at -18°C, and freighted in batch to 
the University of Tasmania where total plasma concentrations of 
fentanyl were determined using the gas chromatographic assay described 
in section 6.3.2. Unbound fractions of fentanyl in plasma were measured 
by ultrafiltration (See section 6.3.3). 
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Clinical and demographic variables were extracted from the medical 
record of each patient. Biochemical tests of liver and renal function were 
performed by the Clinical Chemistry Department of the Repatriation 
General Hospital, Daw Park, Adelaide, using standard methods on 
automatic analysers. Hepatic impairment was defined as the presence of 
hypoalbuminaemia (serum albumin below 35 g/L) with abnormal serum 
concentrations of at least two of bilirubin, alanine aminotransferase, 
alkaline phosphatase, or gamma glutamyl transpeptidase. Abnormal 
renal function was defined as a serum creatinine above 120 µmol/L. 
Estimated creatinine clearance was calculated using the equation 
(Cockroft & Gault, 1976): 
estimated creatinine clearance (mL/sec) = (140 - age) x body weight(kg) 
48,869 x serum creatinine (mmol/L) 
Pain control at the time of blood sampling was assessed using a visual 
analogue scale (a 10 cm line with extremes marked 'no pain' and 'worst 
possible pain'). A copy of the data sheet is attached (Appendix 13). 
Since more than half of the sample of patients were pain free, the total 
sample of patients was also divided into those with any pain and those 
who were free of pain. 
10.4 Statistical Analysis 
Plasma concentrations of fentanyl were compared to literature values 
reported with intravenous and transdermal administration. 
Relationships between the plasma concentrations of fentanyl and 
subcutaneous dosage, and factors such as age, sex, the presence of hepatic 
dysfunction and pain control were investigated using appropriate non-
parametric statistical procedures including the Spearman rank 
correlation and Mann-Whitney U-tests, using Statview® SE + Graphics 
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(Abacus Concepts, Palo Alto, California, USA) on a Macintosh® 
computer. A p-value below 0.05 was considered statistically significant. 
The patient data file can be seen in Appendix 14. 
CHAPTERll:RESULTS 
11.1 Analytical variables 
11.1.1 Retention Times of Relevant Peaks 
An example of a patient plasma sample is shown in Figure 11.1. A blank 
plasma trace is shown in Figure 7.3. 
11.1.2 Standard Curve 
The calibration curve showed linearity (r2 = 0.993) over the range 0.1 to 
15 ng/mL fentanyl added to blank plasma (Figure 7.1). 
11.1.3 Recovery, Reproducibility and Sensitivity 
All as described in Chapter 7.1. 
11.2 Study results 
11.2.1 Patient Characteristics 
The sample of 20 patients consisted of 12 males and 8 females, ranging in 
age from 54 to 86 years, with a median age of 75 years. The patients had 
various forms of cancer: genitourinary (7 patients), lung (6), 
gastrointestinal (4), breast (2) and skin (1). The patients were receiving 
other drugs in addition to fentanyl (median 8 drugs; range 3 to 15), 
including antiemetics (18 patients), laxatives (18), corticosteroids (13), 
benzodiazepines (14), antifungals (6), tricyclic antidepressants (5) and 
nonsteroidal anti-inflammatory agents (5). Nine patients had 
biochemical evidence of hepatic disease while three patients had 
abnormal renal function. Serum concentration of creatinine ranged 
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Figure 11.1: GC trace of palliative care patient plasma sample (containing 
fentanyl 0.5 ng/mL) 
... 
......... 
7 10 
I ...... 
t"'lllT7 ,,...,. , .. 
internal standard (5.38 min) 
fentanyl (6.91 min) 
from 46 to 179 µmol/L (mean 91.8 µmol/L) and estimated creatinine 
clearance ranged from 19.2 to 83.3 mL/min (mean 50.8 mL/min). 
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The total duration of subcutaneous fentanyl therapy at the time of blood 
sampling ranged from 1 to 157 days with a median value of 7 days (n = 
. J..9~dian dosage of fentanyl by continuous subcutaneous 
infusion was 120.0~j.tg/day, with a range of 100 to 5000 µg/ day. There were 
, -----....__-~ 
no significant associations between either the sex or age of the patient 
and the fentanyl dosage (Mann-Whitney U = 41.5, z::::: -0.50, p > 0.20 and 
Spearman p = 0.22, p > 0.20, respectively). The dosage of fentanyl was ·· 
significantly related to the duration of subcutaneous fentanyl therapy 
(Spearman p = 0.56, p < 0.05). 
The patients with bioc~emical evidence of liver disease (n = 9) tended to 
be receiving lower dosages of fentanyl than the other (n = 11) patients 
(respective medians 800 and 1600 µg/ day; Mann-Whitney U = 24.5, z = 
-1.67, p < 0.10). 
11.2.2 Fentanyl Concentrations in Plasma 
The steady-state plasma concentrations of fentanyl displayed a marked 
inter-patient variability. The median total concentration was 1.0 ng/mL, 
with a range of 0.1 to 9.0 ng/mL (Figure 11.2). 
The unbound fraction of fentanyl in the plasma ranged from 17.8% to 
44.4%, with a median value of 33.6% (n = 14). The unbound fraction was 
not measured in all patients because some plasma volumes were 
insufficient. The unbound fraction and the plasma albumin 
concentration were moderately inversely related (Spearman p = -0.5, p = 
0.07: Figure 11.3). The unbound fentanyl concentration ranged from 0.1 
ng/mL to 1.9 ng/mL, with a median value of 0.35 ng/mL (n = 14). The 
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Figure 11.2: Frequency distribution of plasma concentrations of fentanyl 
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total and unbound plasma concentrations of fentanyl were strongly 
correlated (Spearman p = 0.98, p < 0.001). 
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There was also considerable variation in the ratio of total and unbound 
plasma concentrations of fentanyl divided by the daily dosage; the ratio 
varied 8-fold for the total plasma concentrations and 3.5-fold for the 
unbound plasma concentrations. A significant correlation existed 
between fentanyl dosage and both the steady-state total plasma 
concentration and unbound plasma concentration (Spearman p = 0.92, p 
< 0.05 in each case; Figure 11.4). 
Significant correlations did not exist between age and either the total 
plasma concentration of fentanyl, the unbound plasma concentration, 
the unbound fraction, the total plasma concentration to dosage ratio or 
the unbound plasma concentration to dosage ratio (Spearman p = 0.18, p 
> 0.20; Spearman p = 0.43, p > 0.10; Spearman p = -0.19, p > 0.40, Spearman 
p = 0.04, p > 0.20, Spearman p = 0.11, p > 0.60, respectively). 
There were no significant associations between the presence of liver 
disease and either the total plasma concentration of fentanyl, the 
unbound plasma concentration, the unbound fraction, the total plasma 
concentration to dose ratio or the unbound plasma concentration to 
dosage ratio (Mann-Whitney U = 24, z = -1.72, p = 0.09; Mann-Whitney U 
= 20.5, z = -0.45, p > 0.50; Mann-Whitney U = 14.5, z = -1.23, p > 0.20, 
Mann-Whitney U = 35.5, z =- -0.78, p > 0.20 and Mann-Whitney U = 16.5, z 
= -0.97, p > 0.30, respectively). 
There was a significant inverse relationship between the fentanyl plasma 
concentration and estimated creatinine clearance (Spearman p = - 0.68, p 
< 0.01). 
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There were no significant associations between the sex of the patient and 
the total plasma concentration of fentanyl, the unbound plasma 
concentration, the unbound fraction or the total plasma concentration to 
dose ratio (Mann-Whitney U = 35.5, z = -0.96, p > 0.20; Mann-Whitney U 
= 13, z = -1.27, p > 0.20; Mann-Whitney U = 20, z = -0.33, p > 0.50 and 
Mann-Whitney U = 35, z = -1.00, p > 0.20, respectively). The unbound 
plasma concentration to dose ratio, however, was significantly lower in 
the female patients (Mann-Whitney U = 6.0, z = -2.20, p < 0.03). 
The duration of fentanyl therapy was significantly related to the total 
fentanyl plasma concentration and modest correlations existed between 
the duration of fentanyl therapy and the unbound fentanyl plasma 
concentration (Spearman p = 0.67, p < 0.01, n = 19 and Spearman p = 0.55, 
p = 0.06, n = 13, respectively). 
Assuming a systemic bioavailability of 100% for fentanyl from 
continuous subcutaneous infusion (fentanyl losses in portable pumps 
and patient-controlled delivery systems have been found to be 
insignificant; Kowalski & Gourlay, 1990; Tu et al, 1990), values of 
estimated fentanyl clearances were calculated using the equation: 
Css=FxD/Clx't 
where Css is steady state plasma fentanyl concentration, F is availability of the drug 
(assumed to be 1), Dis dosage of fentanyl, Cl is estimated fentanyl clearance and 't is 
dosing interval (1 day) 
The values ranged from 273.2 to 2,222.2 mL/min with a mean value of 
915.3 mL/min. This is similar to clearance values reported in other 
studies (Table 11.1). 
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Table 11.1 Summary of other studies examining fentanyl clearance 
Study 
Mather, 1983 
Koska et al, 1981 
Varvel et al, 1989 
Bower & Hull, 1982 
McClain & Hug, 1980 
Janssen Pharmaceutica, 1993 
Patient type 
surgical 
surgical 
surgical 
healthy subjects 
healthy subjects 
surgical 
hepatically impaired 
renally impaired 
*Results expressed as mean (range) **Estimated 
Clearance 
400 - > 1500 mL/min 
11.2 mL/min/kg 
770mL/min 
1530 (1470 - 2022) mL/min* 
956 (575 - 1179) mL/min* 
450 -1250 mL/min 
50-1333 mL/min** 
500-1300 mL/min** 
11.2.3 Plasma Fentanyl Concentrations in Relation to Pain Control 
Visual analogue pain scores ranged from zero to 5.8, with a median score 
of zero indicating good pain control in the study patients. Significant 
correlations did not exist between pain control and either the fentanyl 
dosage, the total plasma concentration or the unbound plasma 
concentration of fentanyl (Spearrnan's = 0.08, p > 0.50; Spearman p = 0.02, 
p > 0.50 and Spearman p = -0.24, p > 0.30, respectively). 
Total and unbound steady-state plasma concentrations of fentanyl in 
patients experiencing some degree of pain (n = 9) were not significantly 
different from those in patients (n = 11) free from pain (Mann-Whitney 
U = 47, z = -0.19, p > 0.80 and Mann-Whitney U = 18.5, z = -0.71, p > 0.40, 
respectively). 
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CHAPTER 12: DISCUSSION 
There was considerable interpatient variability in subcutaneous dosage 
requirements and resulting steady-state plasma concentrations of 
fentanyl in this sample of patients. The subcutaneous dosages of 
fentanyl varied SO-fold between 100 to 5000 µg/ day, with a median of 
1200 µg/day. The dosages are similar to those studied elsewhere for 
transdermal administration (see Table 12.1). It has been reported that 
92% of the transdermal dosage is delivered to the systemic circulation 
(Varvel et al, 1989), implying that fentanyl is not susceptible to any 
significant cutaneous metabolism and so comparisons with 
subcutaneous dosages are valid. 
Table 12.1: Summary of studies examining steady-state fentanyl concentrations in plasma 
following transdermal administration 
Study 
Varvel et al, 1989 
Portenoy et al, 1993 
Miser et al, 1989 
Zech et al, 1994 
Data on file, Janssen 
Pharmaceutica, 1993 
*Information not provided 
o - receiving other opioids 
No. Patients 
8 
(surgical) 
10 
(palliative care)o 
s 
(palliative care) 
* 
* 
Dosage (µg/ day) Concentrations 
(n /mL) 
2400 1.8 ± 0.8 
2400 1.6± 0.8 
1800-8400 2.5 - 3.5 for 3000 
µg/day 
600 0.3 - 0.6 
1200 0.5 - 2.0 
1800 0.8 - 3.0 
2400 1.0 - 4.0 
600 0.3 - 1.2 
1200 0.6 -1.8 
1800 1.1 - 2.6 
2400 1.9 - 3.8 
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The great variation in dosage of fentanyl required to control pain may be 
' partly explained by the interpatient variability in elimination half-life 
and clearance. Miser et al (1989) noted that the clearance of fentanyl in 
cancer patients appears to be significantly lower than in normal 
volunteers which may be as a result of decreased hepatic microsomal 
enzyme activity. Also of importance in explaining the dosage variability 
' 
are the differing degrees of severity of the pain and the tolerance to the 
narcotic effect (pharmacodynamic sensitivity to fentanyl). 
The fact that the duration of subcutaneous fentanyl therapy in this study 
was significantly related to the current fentanyl dosage suggests that 
tolerance to its narcotic effect may be occurring or, perhaps more likely, 
that the need for these increased dosages may be reflecting worsening 
pain with the progress of the disease. 
The steady-state total fentanyl plasma concentrations in this study also 
varied greatly (90-fold) ranging from 0.1 to 9.0 ng/mL with a median 
concentration of 1.0 ng/mL. This is similar to concentrations reported in 
other studies (Table 12.1). There was a significant correlation between 
the subcutaneous fentanyl dosage and the resulting plasma 
concentrations. Miser et al (1989) also found an excellent correlation (r2 = 
0.8) between fentanyl steady-state plasma concentrations and the 
transdermal delivery rate. 
This study found no significant associations between the sex or age of the 
patient and either the fentanyl dosage or steady-state plasma 
concentration. The unbound plasma concentration to dose ratio was 
significantly lower in the female patients, suggesting that the clearance of 
unbound fentanyl may have been higher in these patients. Holdsworth 
et al (1994) reported that previous pharmacokinetic studies following 
both intravenous and transdermal administration of fentanyl have not 
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demonstrated any important gender differences. Also, it has been noted 
that there is no correlation between fentanyl clearance and weight or age, 
following both intravenous and transdermal delivery (Holley and Van 
Steennis, 1988). 
Values for unbound fractions of fentanyl in plasma in control patients 
have been reported as 13 to 21 % (Mather, 1983). The unbound fraction of 
fentanyl in the plasma in this study was higher, ranging from 18 to 44%. 
This difference may be explained by the high incidence of 
hypoalbuminaemia among these palliative care patients (18 of the 20 
patients). Fentanyl also binds to glycoproteins to a high extent in 
addition to albumin in the plasma; in a 4.0% albumin solution only 46% 
of fentanyl was bound compared with 79 - 87% in plasma (Meuldermans 
et al,1982). This probably explains the relatively poor relationship 
between the unbound fraction and the plasma albumin concentration. 
There were no significant correlations between the steady-state plasma 
concentrations or dosage of fentanyl and the analgesic effect. 
Examination of possible relationships was limited by the finding that 
pain control was generally excellent, with more than half the patients 
being pain free and the highest visual analogue pain score recorded being 
only 5.8/10. By waiting for at least 24 hours of therapy at a constant 
infusion rate with no bolus doses in order to achieve a steady-state, it is 
not surprising that good pain relief had been attained. Patients still in 
pain would most likely be having infusion rate changes and/ or bolus 
doses thus excluding them from the study. A larger sample size of 
patients with varying degrees of pain control would be required to 
perform meaningful statistical analyses. 
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Conclusion 
This study has demonstrated the large interpatient differences in both 
the dosage of subcutaneous fentanyl (50-fold) and the resulting steady-
state total (90-fold) and unbound (19-fold) plasma concentrations of 
fentanyl required to produce pain control in the palliative care setting. 
Even with standardisation for dosage, there was still an eight-fold 
variation in total plasma concentrations and 3.5-fold variation in 
unbound plasma concentrations. This may contribute to the variability 
in therapeutic response to subcutaneous fentanyl between patients and 
highlights the need for careful dosage individualisation and titration 
based on clinical response. 
124 
PART IV 
CONTROLLED STUDY OF NEBULISED MORPHINE FOR 
TERMINAL DYSPNOEA IN PALLIATIVE CARE PATIENTS 
CHAPTER 13 : INTRODUCTION 
13.1 Terminal Dyspnoea 
13.1.1 Aetiology and Clinical Features 
Dyspnoea, or "uncomfortable awareness of breathing" (Bruera et al, 
1993a), occurs in up to 70% of patients with terminal cancer at some 
point during the course of their illness and is a very difficult symptom to 
manage (Reuben and Mor, 1986; Willcock et al, 1994). It can range in 
severity from simple shortness of breath to a feeling of imminent death 
and suffocation. The incidence of dyspnoea increases as death 
approaches and is usually associated with the additional symptoms of 
tachypnoea and anxiety. Lung, breast, and to a lesser extent, colorectal 
cancers are the most common tumours associated with dyspnoea 
(Reuben & Mor, 1986), which may be caused by the tumour itself (e.g., 
compression of the airways, pleural effusion), medical complications 
(e.g., respiratory infection), treatment of the tumour (e.g., radiation 
therapy induced fibrosis), or underlying chronic obstructive lung disease 
(Figure 13.1). 
13.1.2 Treatment 
Initially, the treatment should be aimed" at the cause of the dyspnoea if 
possible such as treating of infections and draining of fluid. The main 
aim of further treatment is to relieve the perception of breathlessness 
and suffocation but it is rarely possible to control completely. deConno 
et al (1991) reported a previous finding that as few as 18% of sufferers are 
successfully controlled. A cool draft of air on the face is often effective 
Mechanical factors 
(e.g., tumour mass, 
bronchospasm, pleural 
effusion, chest wall 
rigidity, compression) 
Impaired gas exchange 
(e.g., lymphangitis, 
carcinomatosa, anaemia) 
Cerebral 
cortex 
DYSPNOEA 
Psychogenic factors 
(e.g., fear, pain) 
Drugs 
(e.g., opioids) 
"uncomfortable awareness of breathing" 
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Figure 13.1: Mechanisms of Dyspnoea(from Sodha & Frampton, 1995) 
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and can be achieved by an open window or a fan. Oxygen is often used 
in the treatment of dyspnoea, although its use is not always indicated as 
few patients with advanced cancer suffer dyspnoea due to hypoxia 
(deConno et al, 1991; Bruera et al, 1993b). If oxygen is used, it should be 
humidified because a dry mouth is also a common symptom in 
advanced cancer. Nebulised saline by itself will moisten the airways and 
assist with the expectoration of thick secretions (Sodha & Frampton, 
1995). An anxiolytic such as diazepam can be helpful in treating shallow 
breathing especially if it is associated with anxiety. Chlorpromazine is 
also used in intractable cases and can aid in drying bronchial secretions 
(Sodha & Frampton, 1995). 
Oral morphine (5 - 10 mg every four hours; Twycross, 1993) is effective in 
reducing the rate of breathing to a comfortable level (e.g., 15 - 20 
inspirations/min at rest), but patients are often already taking some oral 
morphine for control of pain so side effects such as nausea, sedation, and 
constipation may be poorly tolerated during repeat administration. 
Previous studies have shown that morphine administered 
subcutaneously (30 - 40 mg) can be of assistance in treating dyspnoea 
(Bruera et al, 1993a; Bruera et al, 1993b). Additionally, there is evidence 
that low doses of nebulised morphine (5 mg in 5 mL saline) can lead to 
improvement in the exercise capacity of patients with chronic lung 
disease (Young et al, 1989), and there are case reports of the successful use 
of nebulised morphine (5 mg) in dyspnoea in patients with end-stage 
chronic lung and cardiac disease (Famcombe and Chater, 1993) and 
terminal cancer (Tooms et al, 1993). The relief of dyspnoea occurred 
within 15 minutes and lasted over four hours in more than 50% of 
patients (Farncombe et al, 1994). 
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The mode of action of nebulised morphine in dyspnoea is not yet fully 
understood, but it may be through a direct effect on lung afferent nerves 
or by acting centrally on opioid receptors and relieving dyspnoea by 
altering the central perception of breathlessness, pain and anxiety. It has 
also been shown to diminish ventilatory responses to hypoxia and 
hypercapnia at chemoreceptor levels (deConno et al, 1991). The central 
action is presumably due to small amounts of drug being absorbed from 
the buccal and airway mucosa during the nebulisation process and 
subsequently bypassing liver metabolism (Young et al, 1989). This may 
suggest that lower doses are required in nebulisation to yield the same 
benefits thus avoiding some of the central side effects. Relative to an IV 
dose, the bioavailability of a lOmg dose is less than 5% (Davis & Hardy, 
1994). 
Although its benefit has not clearly been proven, or indeed studied in 
any clinical trials, nebulised morphine is now commonly used in 
palliative care units to manage dypsnoea (Regnard & Tempest, 1992; 
Davis & Hardy, 1994; Tooms et al, 1993) as it often appears to be rapidly 
effective and involves a non-invasive route of administration. One 
theoretical risk of nebulised morphine worth considering is 
bronchospasm induced by histamine whose release may be triggered 
either by morphine itself or its preservative. 
11.2 Objectives of this Study 
The present controlled trial was designed to determine the effect of low 
dose nebulised morphine on the intensity of dyspnoea and respiratory 
function in terminally ill patients. 
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CHAPTER 14 : METHODS 
14.1 Human Procedures 
The study protocol was approved by the Research and Ethics Committees 
of the Royal Hobart Hospital. 
Between March 1994 and November 1995, all inpatients at the Palliative 
Care Unit (Repatriation General Hospital) with dyspnoea due to 
terminal illnesses were asked to participate in the study. All patients (or 
their relatives) who agreed to participate were required to fill out a 
consent form (Appendix 15). 
A baseline assessment of the intensity of dyspnoea was made using a 
visual analogue scoring system (a lOcm line with extremes marked 'no 
shortness of breath' and 'worst possible shortness of breath') (Bruera et 
al, 1993b). The patient was instructed to mark the line at any point they 
wished to rate the severity of dyspnoea. A baseline measurement of 
forced expiratory volume in one second (FEV1) and forced vital capacity 
(FVC) was taken using a bedside spirometer (Vitalograph® Compact 
Spirometer, England). Daily calibration of the spirometer was performed 
using a 9 L syringe. Initially measurements of respiratory function were 
taken on three consecutive days in a healthy subject to determine the 
between-day variability of the spirometer (FEV1-3.0%; FVC-1.5%). In 
addition, each time respiratory function was measured, at least three 
tests were performed until the CV between readings was less than 5% (as 
calculated instantaneously by the spirometer) and the highest obtained 
values of FEV1 and FVC were recorded. 
After daily baseline assessment, patients received 3 mL of isotonic (0.9%) 
saline, morphine 2.5 mg in 3 mL saline and morphine 5 mg in 3 mL 
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saline on three consecutive days delivered by a nebuliser 4 times a day 
over 15 minutes. Dyspnoea was again assessed at 1 hour after each dose. 
Also at 1 hour after the second dose, another reading of respiratory 
function was taken. A nurses information sheet and timing schedule 
can be found in Appendix 16. 
It should be noted that, initially the study was designed and approved as 
a randomised double-blind crossover trial. Unfortunately, this element 
of deception with placebo usage discouraged some patients from 
consenting to participate and the order of administration of the three test 
treatments had to be made consistent as outlined above. 
14.2 Statistical Analysis 
All data was stored and statistically analysed (Statview rv®) on a 
Macintosh® computer. Changes in intensity of breathlessness and 
respiratory function after morphine or saline nebulisation from control 
values on the same day were compared using the Analysis of Variance 
statistical test. 
CHAPTER15:RESULTS 
15.1 Patient characteristics 
The sample of eleven patients consisted of 5 males and 6 females, 
ranging in age from 49 to 79 years, with a median age of 69 years. The 
patients had various forms of terminal illness: lung cancer (5 patients), 
breast cancer (1), colon cancer (1), cancer of the pharynx (1), thymoma (1), 
motor neurone disease (1), and congestive cardiac failure (1). The 
patients were regularly receiving other drugs in addition to nebulised 
morphine (median 9 drugs; range 3 to 12), including oral or 
subcutaneous morphine (10 patients), benzodiazepines (9), laxatives (7), 
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antiemetics (6), corticosteroids (6), tricyclic antidepressants (4), 
nonsteroidal anti-inflammatory agents (4), and antifungals (3). At least 
four other patients were forced to withdraw from the study (in addition 
to those listed below) due to worsening condition, increasing drowsiness 
and inability to perform respiratory function tests. 
Individual case studies are outlined below. 
Casel 
A 53 year old man with a 14 month history of motor neurone disease 
was admitted with episodes of acute shortness of breath, tiredness and a 
lack of sleep. He agreed to take part in the morphine trial and after the 
second nebulised morphine dose (2.5 mg) he reported some 
improvement. Some dizziness (attributed to waxy build up in his ears) 
precluded measurement of respiratory function on Day 2, but he slept 
well and seemed to gain relief from the morphine. On Day 3, a 
noticeable improvement in breathing made him decide to continue with 
the nebulised morphine (Smg in 3mL of normal saline) four times a day 
after the end of the trial. Measured respiratory function and subjective 
assessment of dyspnoea improved over the three day trial. He was 
discharged on nebulised morphine and continued this therapy at a 
nursing home until his death 2 months later. 
Case2 
A 69 year old nonsmoking woman with no previous illnesses until four 
weeks previously when she presented with increasing shortness of 
breath on exertion, cough, tiredness, malaise, anorexia, night sweats, and 
yellow I green sputum. She was then diagnosed with metastatic 
adenocarcinoma of the lung with persistent pleural effusion and 
lymphangitis in the lungs. Chemotherapy or radiotherapy had little to 
offer due to the widespread disease and her frail mental and physical 
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state. Breathlessness on minimal exertion progressively became 
dyspnoea at rest by 3 weeks after admission with an increasing 
respiratory rate evident. The nebuliser study was commenced and by 
Day 2 she was subjectively feeling better and sleeping better. On Day 3 
she was more settled and relaxed and found the morphine nebules had 
helped quite a lot and was happy to continue them regularly four times a 
day. She was now experiencing nil shortness of breath at rest which was 
indicated by a decrease in her subjective dyspnoea score. There was no 
significant improvement in her measured respiratory function over the 
study period. Nebulised morphine (5 mg in 3 mL) continued for two 
weeks until her condition deteriorated, her chest began to rattle, she 
refused the nebuliser as it overly distressed her and she died the next 
morning. 
Case3 
A 72 year old man who was a chronic smoker with bronchitis and 
emphysema. He was diagnosed with squamous cell carcinoma of the left 
lung in 1991 and a carcinoma of the rectum in 1991 which had recently 
recurred. He had received both chemotherapy and radiotherapy with 
multiple hospital admissions over the past three years. He was admitted 
in November 1994 with increasing shortness of breath and lower back 
pain and commenced the study two days later. By Day 2 he was 
experiencing only shortness of breath on exertion rather than at rest and 
by Day 3 he showed marked improvement and decided to continue the 
nebulised morphine (5 mg in 3 mL) four times a day. Despite this 
subjective feeling of improvement, there was no significant changes in 
respiratory function or dyspnoea scores. One week later he thought that 
four times daily was too often (in addition to nebulised salbutamol) so he 
asked to be cut back to three times a day and when required. A further 
two weeks later he became sick of receiving morphine nebules after 
claiming they took too long to give and were of no benefit to him any 
more. He was discharged soon after. 
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In May 1995 he was readmitted because of a large bowel obstruction and 
had an operation for the formation of a colostomy. After the operation, 
he became very anxious and died one week later. 
Case4 
A 49 year old man with a history of chronic alcohol abuse and alcohol 
related seizures had been diagnosed 10 months previously with a 
squamous cell carcinoma in the left pharyngeal wall. He developed 
metastases to the cervical lymph node and experienced pain in his neck 
and jaw, controlled by morphine in a syringe driver. Other symptoms 
on admission included left sided weakness, dysphagia and a choking 
sensation in the throat. He agreed to participate but due to worsening 
cyanosis and shallow breathing, the use of the nebuliser was 
inappropriate, he was unable to even commence the study became 
semiconscious later that same day and died early the next morning. 
Cases 
A 72 year old man with an inoperable squamous cell carcinoma of the 
right lung diagnosed twelve months ago. He had received no 
radiotherapy or chemotherapy. He was admitted with a one week 
history of lethargy, shortness of breath, constipation, decreased appetite 
and malignant hypercalcaemia. Three weeks after admission he began 
the trial, but after the first two nebulised doses (saline only), the patient 
felt too drowsy to continue, the study was stopped and he died two days 
later. 
Case6 
A 74 year old woman with a history of chronic obstructive pulmonary 
disease, smoking, ischaemic heart disease and hypothyroidism presented 
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with increasing dyspnoea over the past six to nine months, weight loss 
and recent pneumonia. About ten days ago a large malignant mass was 
found in her left lung and her peak flows were very poor. She was 
experiencing severe shortness of breath on exertion and atrovent nebules 
were given with good effect. Within one week her shortness of breath 
was worsening at rest and on transfer to the Whittle Ward was 
commenced on the nebulised morphine trial. There was no significant 
improvement in either respiratory function or subjective assessment of 
dyspnoea over the three day trial. However, she claimed the morphine 
nebules were effective and she continued to receive them (morphine 5 
mg) regularly four times a day after the trial for the next week until she 
died. Two days before her death she had an extreme episode of shortness 
of breath which was not well controlled with nebulised morphine. 
Case7 
A 59 year old woman with a two year history of metastatic breast cancer, 
with multiple bone and liver involvement. She had a recent episode of 
pneumonia and a three day history of nausea, vomiting and abdominal 
pain on admission. Over the next month, her dyspnoea increased and so 
the amount of morphine in her driver was increased and saline nebules 
were given with some effect. The morphine trial was commenced and 
despite documented relief from acute episodes of dyspnoea, there was no 
significant improvement in respiratory function or assessment of 
dyspnoea. After the trial she continued to receive morphine nebules 
when required for dyspnoea. 
Case8 
A 58 year old woman with congestive cardiac failure and chronic 
obstructive airways disease was admitted due to increasing dyspnoea, 
pain and tightness in the legs, epistaxis, malaena, ascites, and oxygen 
dependence. Two weeks after admission she began receiving nebulised 
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morphine. Her respiratory function improved and her assessment of 
dyspnoea was reduced significantly after the first day of nebulised 
morphine. Because of weekend leave, the third day of the trial was not 
fully completed although she continued the nebules at home and on 
return to the ward. Two days before her death she ceased both morphine 
and oxygen therapy as they were no longer able to be tolerated. 
Case9 
A 79 year old woman with an eighteen month history of colon cancer 
(colostomy) with metastases to the liver, lungs and kidneys was admitted 
with symptoms of moist cough, incontinence, anorexia, nausea, mild 
constipation and dull but not unbearable pain. She complained of 
episodic shortness of breath at rest and whilst washing herself but said it 
was relieved by taking a deep breath. It was thought that the nebulised 
morphine trial would be beneficial to her dyspnoea but after the first two 
doses she withdrew because of intolerance to the nebulisation process. 
She died one week later. 
Case 10 
A 63 year old man who was diagnosed four months ago with a squamous 
cell carcinoma of the lung with widespread bony metastases after a three 
month history of backache, cough, 8-10 kg weight loss, hoarse voice and 
increased sputum. He had been a heavy smoker for many years and was 
admitted due to increasii:i-g weakness and debility and hip pain which 
was relieved by subcutaneous ketorolac. Increasing shortness of breath 
and difficulties in getting around led to the morphine trial being 
commenced. Initially, he was not keen to receive the nebules but after 
the second morphine dose he said they were helping his breathing and 
he continued to receive regular morphine nebules for another five days 
until he died. 
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Case 11 
A 72 year old lady with a history of unstable angina and myocardial 
infarctions who had open heart surgery six months ago. During the lead 
up to surgery, a thymoma with widespread mediastinal invovement was 
found. She was admitted two days ago with sudden shortness of breath, 
a choking sensation, nausea, dry mouth, palpitations and pain in the 
chest and back. The morphine nebule trial was commenced. She· gained 
some relief from the nebulised morphine and continued receiving the 
nebules (morphine 5 mg) for two weeks after the end of the trial until 
she became semi-conscious and her deteriorating condition made the use 
of the nebuliser inappropriate. 
15.2 Statistical Analysis 
The small sample size and the intersubject variability did not facilitate an 
extensive statistical analysis. Figure 15.1 clearly shows that there is some 
benefit of nebulised morphine over saline for particular patients (for 
example, case 8) without the need for a statistical test and the individual 
case studies reflect this also. Table 15.1 gives the mean values of 
dyspnoea and respiratory function over the course of the study for the 
eight patients who completed the trial. 
Table 15.1: Values of dyspnoea and respiratory function obtained over three days (n = 8) 
Dyspnoea (cm) 
FVC (L) 
FEV1 (L) 
mean±SD 
3.34 ± 2.60 
1.24 ± 0.34 
0.66± 0.21 
minimum 
0 
0.73 
0.37 
maximum 
9.7 
2.12 
0.91 
Figure 15.1: Visual analogue scores for dyspnoea (patients who completed trial) 136 
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15.2.1 Effect of Morphine on Subjective Symptoms of Dyspnoea 
Not surprisingly, analysis of variance tests indicated that there was a 
statistically significant difference in subjective symptoms of dyspnoea 
between individuals (F = 22.4, p < 0.001; Table 15.2). For analysing the 
value of a treatment (whether it be morphine or saline), scores of 
dyspnoea were allocated into one of two groups - either a baseline 
measurement (one per day) or a measurement one hour after receiving a 
nebule (four per day). Analysis of variance tests suggested that treatment 
(over the three days) resulted in significantly lower scores of dyspnoea 
compared with baseline values measured on each of the three days (F = 
8.0, p < 0.01). However, saline treatment could not be differentiated from 
either morphine 2.5 mg or morphine 5 mg in its efficacy. That is, there 
was no difference in symptom scores between days (F = 1.7, p > 0.2). Table 
15.2 shows the results of the statistical analysis. 
Table 15.2: Analysis of variance - nebulised morphine trial dyspnoea symptom scores 
degrees of sum of mean 
Source of variation freedom squares square F-value P-value 
between individuals 7 297.3 49.5 22.4 <0.001 
between treatments 2 7.4 3.7 1.7 0.20 
between times (ie, 1 17.6 17.6 8.0 <0.01 
either baseline or after 
treatment) 
15.2.2 Effect of Morphine on Respiratory Function 
Again, there was significant variation in IIJ.easured respiratory function 
between individuals (F = 6.3, p < 0.01; Table 15.3). 
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Table 15.3: Analysis of variance - nebulised morphine trial respiratory function (FVC) 
degrees of sum of mean 
Source of variation freedom squares square F-value P-value 
between individuals 7 1.387 0.28 6.3 0.001 
between treatments 2 2.SE-3 1.2E-3 0.02 0.90 
between times (ie, 1 0.25 0.25 5.8 0.02 
either baseline or after 
treatment) 
PVC was found to be significantly better during treatment than at 
baseline over the three day study period (F = 5.8, p <0.05) but there was 
no difference in values of FEV1. The effect of nebulised morphine (2.5 
mg and 5 mg) was found to be no better than that of nebulised saline for 
improving respiratory function (F = 0.02, p > 0.8). 
CHAPTER 16: DISCUSSION 
There are many difficulties involved in performing blinded and 
randomised trials of drugs or drug therapies in palliative care patients, 
and so relatively few treatment strategies have been subjected to 
controlled clinical trials. N-of-1 trials have been used successfully to 
evaluate the efficacy of various treatments in individual patients in 
settings other than palliative care (Guyatt et al, 1994). However, 
randomisation of treatments within the patient is important for the 
success of such trials and both a stable medical condition and a 
previously well investigated treatment are other prerequisites, making 
the current study unsuitable for this method of approach. 
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This study highlighted some of the problems with clinical trials in 
palliative care. Problems were encountered with both patient 
recruitment and attrition, and the initial randomised double-blind 
crossover design of the study had to be altered in the hope of increasing 
the patient numbers by presenting a study where patients were in no 
doubt about receiving therapy. It would clearly be easier to obtain 
recruits by presenting a study with no uncertainties about whether a 
patient is receiving the best available or new treatment, than making it 
randomised or double-blind. Thus, the ultimate design used here did 
not control for variation in the natural history of the illness which is 
likely to have progressed from day 1 to day 3 in many cases. 
There are only small numbers of patients in the Whittle Ward and few 
may suffer from dyspnoea. The 'breathless at rest' criteria for subject 
selection in this study further limited the number of available patients 
since these patients we-re often recruited in the final stages of their 
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disease and were thus too unwell or insufficiently stable to participate in 
the study either at all or for the total three days. 
Often the question of unethical use of the placebo in clinical trials is 
raised. One problem is that even though in many cases witholding an 
acceptable treatment may not in fact lead to any serious harm, it is still 
unethical if patients do not receive the most effective known therapy to 
treat their condition (Rothman & Michels, 1994). Especially in palliative 
care patients, who are suffering in what is likely to be the last few days of 
their lives, there is really no justification in using a treatment which 
may not offer optimum relief from symptoms. In this study, the use of 
saline as a control should not be considered a placebo because nebulised 
saline has been used as an effective treatment for dyspnoea (Sodha & 
Frampton, 1995; Farncombe & Chater, 1994) (and it controls for the 
psychological effect of receiving some treatment) and so the test is not 
whether nebulise4 morphine is better than nothing but whether it is 
better than a potentially effective treatment. 
This study found some evidence of the benefit of nebulised morphine 
for dyspnoea in palliative care as documented in individual cases but 
this was not supported by statistical tests. Seven out of the eight patients 
who completed the trial continued to receive regular nebulised 
morphine after the end of the study period claiming it was beneficial to 
their condition. This represents 87% of patients, which is similar to the 
81 % of patients treated with nebulised opioids who reported good results 
in a chart review of 42 patients at a palliative care facility by Farncombe et 
al (1994). Similarly, in a study by Young et al (1989), 82% (9 out of 11) of 
the patients with chronic lung disease receiving nebulised morphine 
showed an increase in exercise endurance time which was significantly 
greater than with nebulised saline (p < 0.01). Other previous studies 
describing the use of nebulised morphine in palliative care have 
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involved only individual cases or reports without statistical tests or 
controlled trials (Tooms et al, 1993; Farncombe & Chater, 1994). They 
found, however, that nebulised morphine did provide effective relief of 
dyspnoea and there was no evidence that it was unsafe. Other reported 
benefits in individual cases in these studies included an increased 
exercise tolerance, improved mood, better sleep quality and a more 
relaxed state. 
However, some problems were also encountered in the current study. 
Dyspnoeic patients frequently found the use of the nebuliser 
claustrophobic, distressing and restrictive, and subsequently were unable 
to tolerate the regular administration of nebules. This effect was only 
seen in a small number of patients (10%) in the review by Farncombe et 
al (1994) and was even less prevalent in studies involving patients with 
chronic lung disease who are likely to be accustomed to receiving 
nebulised medications (Farncombe & Chater, 1993; Young et al, 1989). 
Also there may have been some tolerance to the effect of nebulised 
morphine illustrated by Case 3 who received it for three weeks and then 
claimed that the treatment was no longer of any benefit. Clearly, many 
palliative care patients would not be receiving nebulised morphine for 
any length of time, but the effect must be considered. 
Conclusion 
With such small number~ in this study, no definite conclusions can be 
made as to the benefit of nebulised morphine for dyspnoea despite 
anecdotal evidence in some individuals. There was a statistical 
indication that nebulisation of saline (with or without morphine) had 
favourable effects on the subjective symptoms of dyspnoea with no data 
to support any additional benefit of morphine. More subjects are needed 
to generate useful results, perhaps incorporating palliative care wards in 
other hospitals or patients in the community. 
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GENERAL CONCLUSION 
The research presented here has confirmed that there are a number of 
clinical situations where there exists large inter-individual variations in 
drug plasma concentrations and clinical response creating a potential for 
difficulties in optimum management. In the following cases, the 
clinicians seemed to have overcome this by close clinical monitoring and 
subsequent adjustments where necessary. 
Fluphenazine study 
Inter-individual differences in the pharmacokinetics of antipsychotic 
drugs has led to great variability in the steady-state plasma levels of 
patients receiving the same dosage. Over the last ten years there has 
been an increased interest in research examining the relationships 
between the antipsychotic drug plasma level and both clinical efficacy 
and adverse effects. Being able to recognise patients who are seemingly 
therapy-resistant despite high or optimal plasma levels may help reduce 
the overall duration of exposure to antipsychotics.(which has been 
associated with tardive dyskinesias) and reduce the incidence of adverse 
effects (given the possible association between extrapyramidal symptoms 
and plasma level). 
This study investigated the steady-state plasma concentrations of 
fluphenazine in 24 subjects suffering from chronic schizophrenia. 
Considerable inter-patient variability was found with plasma 
concentrations ranging from less than 0.1 ng/mL to 27.9 ng/mL. We 
used the Andreasen Scale for positive and negative symptoms as a 
measure of clinical response which was found to be inversely related to 
both log transformed plasma fluphenazine concentrations and 
fluphenazine decanoate dosage. Another finding was that patients 
receiving an anticholinergic agent (for the treatment of extrapyramidal 
symptoms) had significantly higher plasma concentrations of 
fluphenazine than those not receiving such drugs. 
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These results indicate that plasma level monitoring of antipsychotics 
may fulfil a role in improving the treatment outcome in some patients 
with chronic psychotic disorders but observing for clinical responses and 
adverse effects are also important. 
Cardiopulmonary bypass study 
With the number of operations involving cardiopulmonary bypass 
steadily increasing it is important to determine the effect that such a 
massive perturbation of normal body function has on the 
pharmacokinetics of the many drugs administered in the perioperative 
period. 
The research presented in this study investigated two drugs commonly 
used as part of the anaesthetic regime in such operations - fentanyl and 
alcuronium. Plasma concentrations of both drugs were characterised by a 
marked decline on initiation of CPB, however, during CPB it was 
difficult to estimate pharmacokinetic parameters because of the gross 
changes in physiological conditions. In vitro studies also showed that 
the amount of drug generally adsorbed to the bypass apparatus was only a 
small proportion of the total dose and large in vivo drug reservoirs 
prevented this from being a significant occurrence. 
The clinical implications of the present study are that even given the 
drug adsorption to the bypass apparatus and the extreme physiological 
changes occurring over the bypass period, suitable plasma concentrations 
of both drugs and adequate clinical responses were maintained. 
Additional bolus dosages were administered as required based on 
intraoperative clinical monitoring such as evidence of arousal. 
Subcutaneous fentanyl study 
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Given that responses to the opioid analgesic, fentanyl, are variable 
between individuals and within individuals over time, it is important to 
continually individualise and titrate dosage based on clinical response. 
The study presented in this section of the thesis highlighted the 
variability in subcutaneous fentanyl dosage required for pain control and 
the resulting steady-state plasma concentrations of fentanyl in palliative 
care patients. It also demonstrated some degree of tolerance to the 
analgesic effect of fentanyl over time. 
Such variability in the palliative care setting was explained by differences 
in the clearance of fentanyl (pharmacokinetic), severity of pain and 
pharmacodynamic sensitivity to fentanyl, all of which are likely to be 
changing constantly in these patients. The pain control in this setting 
was adequate indicating that despite the variability displayed, the 
clinicians were managing by carefully adjusting dosage. 
Nebulised morphine study 
Dyspnoea is a very common and distressing symptom in patients with 
advanced cancer and one which has proved difficult to manage 
successfully. Nebulised morphine use for dyspnoea in palliative care 
patients is a relatively recent development and the present study was 
designed to ascertain its benefits over and above nebulised saline. 
Problems with a small and heterogenous sample precluded the ability to 
make reliable conclusions despite individual patients claiming a 
perceived subjective benefit. Further studies in a larger group of patients 
are required to confirm the results obtained. The decision to continue 
treatment with nebulised morphine in any one individual should be 
based on initial symptom improvement and the patient's desire to 
receive the therapy. 
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Thus, even though large clinical trials can predict the outcome of drug 
treatments in populations and can propose suitable dosages, responses to 
drugs are never totally foreseeable or consistent. Any individual may 
behave differently to the population group as a result of variability in 
pharmacokinetics and pharmacodynamics. This emphasises the need for 
individualisation of therapy based either on plasma level monitoring or 
on clinical response depending on the drug regimen in question and 
these above-mentioned studies have indicated that in many clinical 
situations this is very achievable. 
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CONSENT FORM 
FLUPHENAZINE STUDY 
Fluphenazine (Modecate) is a drug often used alone or with other drugs 
to treat emotional disturbances. This joint study between the 
Rehabilitation and Long Term Support Service and the School of 
Pharmacy at the University of Tasmania is involved with measuring the 
levels of fluphenazine in the bloodstream of patients who have been on 
this drug for at least several months. Hopefully, from this study 
information will be gathered which can improve the use of this drug and 
reduce the possibility of side effects. 
As a patient receiving fluphenazine you are being asked to take part in 
this study. This would involve having one blood sample taken (five to 
ten mL) to measure the level of fluphenazine. If the dosage of your 
medication is changed, it may be appropriate to take another blood 
sample for comparison. Also, we will record some data (age, sex, weight, 
and possibly biochemical test results) from your medical record. This 
information will be kept completely confidential. Your personal 
identification will be known only to those staff from the Rehabilitation 
and Long Term Support Service (Elizabeth House I Club 422) who are 
directly involved in the study. Staff from the School of Pharmacy will 
know you only by a given reference number. 
Prior to participating in this research, we have to ask if you would please 
sign this form indicating your consent, on the understanding that:-
1. The research study will be carried out in a manner conforming with 
the principles set out by the National Health and Medical Research 
Council. 
2. I comprehend the general purposes, methods, demands and possible 
risks, inconvenience or discomforts of the study which have been 
explained to me. 
3. In giving my consent I acknowledge that my ·participation in this 
study is voluntary and that I may withdraw at any time. 
Your continued attendance at Elizabeth House and I or Club 422 and any 
ongoing support given by the staff of the Rehabilitation and Long Term 
Support Service will in no way be affected by your participation or non-
participation in the study. 
Thank you. 
Signature: Date: 
Witnessed by: Date: 
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FLUPHENAZINE STUDY 
CRN: Study number: 
Weight (kg): 
Diagnosis: Approximate duration 
of condition (year of diagnosis) 
Relevant medical history: 
Current drug therapy (drugs and dosages): 
Approximate duration of fluphenazine therapy: 
Last fluphenazine dose (date): 
Total amount of fluphenazine received over past 12 months (if 
determinable): 
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CLINICAL ASSESSMENT 
Andreasen scale 
Positive symptoms: Negative s.ymptoms: 
Biddisch Behavioural Assessment Scale (and date of assessment): 
Case manager: 
Extrapyramidal movement disorders: 
Present mild 
moderate 
severe 
Parkinsonism Y /N 
Tardive dyskinesia Y/N 
Absent 
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CLINICAL CHEMISTRY DATA 
Serum creatinine: 
Liver function: 
Bilirubin: 
ALT: 
GGT: 
AP: 
Albumin: 
Evidence of liver disease YIN 
Fluphenazine plasma level: 
Other comments: 
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SCAl.E FOR ASSESSMENT or POSITIVE SYHPTOHS (SAPS) 
ID NOr NAHE:~~~~~----,..--~~~-CARD NO: 12343678910 
DATE: ACE: SEX: DIACNOSISr MEDICATION: 
11 lb TI le i9 
0-None I-Questionable 2-Hlld 3-Hoderate 4-Harked )-Severe 
HALLUCINATIONS 
Auditory Hallucinations 
The patient reports voices, noises, or other 
sounds that no one else hears 
2 Voices Commenting 
The patient reports a voice which makes a running 
commentary on his behaviour or thoughts 
3 Voices Conversing 
The patient reports hearing two or more voices 
conversing 
4 Somatic or Tactile Hallucinations 
The patient reports experiencing peculiar physical 
sensations in the body 
5 Olfactory Hallucinations 
The patLent reports experiencing unusual smells 
which no one else notices 
6 Visual Hallucinations 
The pat1ent sees shapes or peo~le thac are not 
actua 1 ly present 
7 Global Rating of Hallucinac!ons 
This rating should be based on the duration and 
severity of the hallucinacions and their effects 
on the patient's life 
Df:LUS IONS 
B Persecutory Delusions 
The patient believes he Is being conspired against 
or persecuted 
9 Delusions of Jealousy 
The patient be! ieves his spouse Is having an affair 
with someone 
10 Delusions of Guilt or Sin 
The patient believes that he has committed some 
terrible sin or done something unforgiveable 
11 Grandiose Delusions 
The patient belLeves he has special powers or 
abilities 
12 Religious Delusions 
The patient Is preoccupied with false beliefs of 
a religious nature 
13 Somatic Delusions 
The patient be! !eves that somehow his body Is 
d! seased, abnorma t, or changed 
20 TI 
0 1 2 3 4 5 
(17) 
0 I 2 3 4 S 
TI a> 
0 1 2 3 4 5 
(29) 
0 I 2 J 4 5 
oo> 
0 1 2 J 4 5 
( J 1) 
0 1 2 3 4 5 
(52) 
0 1 2 3 4 5 
03) 
0 1 2 3 4 5 
04) 
0 1 2 3 4 5 
05) 
0 1 2 J 4 5 
06) 
0 1 2 J 4 5 
07) 
0 1 2 3 4 5 
08) 
012345 
TI9> 
174 
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14 Delusions 0£ Rer,r,nce 
The patient belleve1 that Insignificant rrmark1 or 
event~ refer to him or hav' 1peclal meaning 
15 Delusions of Being Controlled 
The patient feels that hl1 !eel Inga or actlon1 are 
controlled by some out1lde force 
16 Delusions of Mind R'adlng 
The patient feels that people can read his mind or 
know his thoughts 
17 Thought Broadcasting 
The patient believes that his thoughts are broadcast 
so that he himself or others can hear them 
18 Thought Insertion 
The patient believes that thoughts that are not his 
own have been Inserted Into his mind 
19 Thought 
The patient believes that thoughts have been taken 
away from his mind 
20 Global Rating of Delusions 
This rating should be based on the duration and 
persistence of the delusions and their effect on the 
patient's life 
BIZARRE BEHAVIOUR 
0 I 2 J 4 .5 
01234.5 
0 I 2 J 4 5 
0 1 2 J 4 5 
0 1 2 3 4 5 
0 I 2 3 4 5 
0 I 2 3 4 5 
21 Clothing and Appearance O 1 2 3 4 5 
(40) 
T41> 
{42) 
{43) 
(44) 
(45) 
(46) 
The patient dresses in an unusual manner or does other {47) 
strange things to alter his appearance 
22 Social and Sexual Behaviour O 1 2 ) 4 5 
The patient may do things considered inappropriate, {4a) 
according co usual social norms, (eg. masturbating 
1n public) 
23 Aggressive and Agitated Behaviour 
The patient may behave in an aggressive, agitated 
manner, often unpredictably 
24 Repetitive or Stereotyped Behaviour 
The patient delvelops a set of repetitive actions or 
rituals that he must perform over and over 
25 Global Rating of Bizarre Behaviour 
This rating should reflect the type of behaviour and 
the extent to which it deviates from social norms 
POSITIVE FORMAL THOUGHT DISORDER 
0 1 2 3 4 5 
0 1 2 3 4 5 
0 1 2 3 4 5 
26 Derailment 0 1 2 J 4 5 
(49) 
50) 
TI1> 
A pattern of speech In which Ideas slip off track onto CS2) 
Ideas obliquely related or unrelated 
27 Tangeatlallty 
Replying to a question In an oblique or Irrelevant 
manner 
0 I 2 J 4 S 
DJ> 
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2tl lncoherl!nce 
A pacc~rn of sp~~th which Is ~ssenCl•lly 
lncompr~hensl~le at tlm~s 
29 Illogicality 
A pett~rn of speech In w~lch conclusions ar~ reach~d 
which do not follow logically 
JO Clrcumstantlallcy 
A paccern of speech which ls very lndlrecc and 
delayed In reaching lcs goal Idea 
JI Pressure of Speech 
The patient's speech ls rapid and difficult co 
!nrerrupt: the amount of speech produced Is greater 
than that considered nor~al 
J2 Dlstraccible Speech 
The patient ls distracted by nearby stimuli which 
interrupt his flo~ of 1peech 
JJ Clanging 
A pattern of speech in which sounds rather than 
meaningful relationships govern word choice 
J4 Global Rating of Positive Formal Thought Disorder 
This rating should reflect che frequency of 
abnormality and degree to which le affects the 
patient's ability to communicate 
01234.5 
TI4> 
0 1 2 3 4 .5 
TI.5> 
012345 
TI6> 
0\2J45 
Tin 
0 I 2 J 4 5 
08) 
0 I 2 J 4 5 
(59) 
012345 
(60) 
SOURCES: In-:erview Scaff Family Friends Other 
T5 
RELIABILITY: 1 2 J 4 5 FORM NO: 
COPYRIGHT: Nancy C Andreason, H.D. Dept. of Psychiatry Unlv. of Iow~ Io~a City IA(!: 
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SCALE roR ASSESSHENT or NEGA!lVE SYHPTOHS (SANS) 
Name: C.rd No I ID No: 
I 2 J 4 r 6789 lo 
Date: :hx: Hec!lc11t Ion Age: i:la~no1l1 
TI 11 l)-li;""" TI T6 TI T8 B 2o :! 1 
Q .. Nune; 2 • Questlonable; 2 • Hlld; J •Moderate; 4 •Harked: 5 •Severe 
Af'FECTI'/E FLATTENING OR BLUNTING 
1 Unchanging Faclal Expression 
The patlent's face appears wooden, changes less than 
expected as emotlonal content ~f dlscourse changes 
2 Decreased Spontaneous Movements 
<he parlenr shows few or no spontaneous movements, 
does nor shlfr poslrlon, move extremitles, ere 
0 1 2 J 4 5 
Tin 
012J45 
TI a> 
J Pa"clty of Expresslve Gestures 0 1 2 3 4 5 
Th~ parlenr dlles nor use hand gestures, body posltlon (29') 
etc. a! an ald ln e~pressing hl5 ldeas 
4 Foor E1e Contact 
The pa~ient avoids eye contact or 'stares through' 
intervlew~r even ~hen speaking 
5 Affecri•fl! N•:nresponsiviry 
Th~ patient fails ro smile or laugh when prompt~d 
6 Inappropriate Affect 
The parl~nr's affect I~ lndppropriate or lncongruous 
not slmply flat or blunted 
7 Lack of Vocal Inflections 
Tha parien~ fails ro show normal vocal emphasis 
patterns, Is often monotonic 
8 Global Raring of Affective flattening 
Tnis ratLng should focus on overall severity of 
"symptoms, especially unresponsiveness, eye contact, 
facial expression, and vocal inflectlons 
A LOGIA 
9 Poverty of Speech 
The pdtient's replles to questlons are restricr.ed in 
~· rend to be brief, concr~re, an~ unelaborared 
012345 
00) 
012345 
Tiil 
0 1 2 3 4 5 
02) 
012345 
TIJ> 
012345 
(14) 
012345 
lTI> 
10 Poverr.y of Content of Speech 0 1 2 J 4 5 
The patient's repli~s are a.lequar~ ln amount but tend TI6> 
rob~ vague, overconcrer~. or overgenerallsed, and 
convey little ln lntormarlon 
11 Blockln\; 
The pJt~~nt Indicates, either spontanenusly or with 
prom~rl~g, that his train of thought w~s lnterrupted 
12 Increased Latency of Response 
The pari~nr rakes a long rime to reply ro questlons; 
promprlng Indicates the parlenr. ls aware of the 
quesc l<ln 
01:345 
en> 
0 1 2 3 4 5 
08) 
Appendix 3: SAPS & SANS questionnaires 178 
IJ Global Racl~g of Alcgld 
The cor~ ieature or alogla are poverty or 1peech 
and poverty of content 
AVOLITION - APATHY 
012J4.5 
14 Grooming and H~gl•ne O 1 2 J 4 .5 
(39) 
The patient's cloches may be sloppy or 1olled, and he (40) 
may have greasy holr, body odor, etc. 
15 Imperslscen~e of Work or School 0 1 2 J 4 5 
The patient has difficulty seeking or malncalnlng (41) 
employment, completing school work, k!!eplng house, 
etc. If an Inpatient, cannot persist at ward 
actlvlcles such as OT, playing cards, etc. 
16 Physical Anergla 
The patient tends to be physically inert. He may sit 
for hours or not initiate spontaneous activity 
17 Global Racing of Avolitlon-Apathy 
Strong weight may be given to nne or twn prominent 
symptoms if particularly striking 
ANNEDONIA - ASOCIALITV 
18 Recreational Interests and Acclvlcles 
The patient may have few or no Interests. Boch the 
quality and quantity of interests should be taken 
into account 
19 Sexual Activity 
The patient may show a decrease in sexual Interest 
and activity, or enjoyment when active 
0 I 2 J 4 5 
012345 
012345 
O I 2 3 4 5 
20 Ability co Feel Intimacy and closeness 0 I 2 3 4 5 
(42) 
(4J) 
(44) 
(45) 
ihe patient may display an inability co form close or "'f46) 
intimate relationships, especially with opposite 
sex and famt ly 
21 Relationships with Friends and Peers 0 l 2 J 4 5 
The patient may have few or no friends and may "'(41) 
prefer co spend all his time Isolated 
22 Global Racing of Anhedonia - Asocial Icy 
This racing should reflect overall severity, taking 
into account the patient's age, family status, ecc 
ATTENTION 
2J Social Inattentiveness 
The patient appears uninvolved or unengaged, he 
may seem 'spacy' 
0 l 2 3 4 5 
(48) 
0 l 2 J 4 5 
(49) 
24 Inattentiveness During Meneal Status Testing 0 l 2 3 4 5 
Tes<:s of 'serial 75' (at ll!ast five subtractions) and (So) 
spelling 'world' backwards: 
Score 2 = I error, scorl! J = 2 l!rrors, score 4 = J errors 
25 Global Racing of Accenclon 
This racing should assess the patient's overall 
conC'entraclon cllnlcally ancl on tests 
012345 
Tit) 
Appendix 3: SAPS & SANS questionnaires 179 
Sources: Interview Scaff: Family: Friends Other: 
TI Ti: TI 76 TI 
Reliability: 2 J 4 5 For:n No: 
78 79 80 
REPR!llTS: Nancy c Andr'!asen M.D., De pt Of Psychuny Unvie:-si.cy of Iowa 
500 Newton Rd Iowa City Iowa .52242 
Study number ID Age (years) Weight (kg) Sex 
1 1101 50 95 Male 
2 1093 44 113 Male 
3 1620 47 84 Female 
4 1716 54 • Female 
5 1199 56 76 Male 
6 1019 58 66 Male 
7 1020 55 89 Male 
8 1062 32 • Male 
9 1044 34 • Male 
10 1052 37 80 Male 
11 1087 34 50 Male 
12 1033 26 86 Male 
13 23275 39 80 Male 
14 30089 67 63 Female 
15 21701 60 77 Male 
16 24288 55 91 Female 
17 29870 48 66 Female 
18 24535 35 68 Male 
19 32676 50 57 Male 
20 23673 67 100 Male 
21 21571 66 89 Male 
22 20450 33 83 Male 
23 21456 46 56 Female 
24 27086 66 95 Male 
Renal Duration of 
dysfunction condition (years) 
No 30 
No 20 
No 25 
No 30 
No 15 
No 30 
No 18 
No 14 
No 13 
No • 
No 16 
No 10 
No 18 
No 14 
No • 
No 31 
No 30 
No 17 
No 27 
Yes 33 
Yes 3 
No 15 
No 12 
Yes 40 
Duration of FPZ 
therapy (years) 
• 
10 
3 
2 
15 
15 
5 
14 
13 
7 
• 
4 
9 
17 
3 
3 
17 
5 
6 
21 
3 
3 
3 
7 
::i:.. 
~ 
"" ~
l:l.. 
>(• 
~ 
::n 
::: 
~ 
~ 
~ 
;:, 
N 
;i• 
"" 
-g 
~-
..... 
l:l.. ;:, 
j;3" 
';::ri 
~ 
..... 
00 
0 
Study number Current FPZ dose Cumulative FPZ Positive 
(mg/month) dose (12 months) symptom score 
1 33.3 • 6 
2 12.5 224.0 7 
3 100.0 2000.0 9 
4 50.0 675.0 4 
5 100.0 1200.0 3 
6 25.0 350.0 5 
7 18.8 275.0 1 
8 33.3 350.0 8 
9 37.5 450.0 7 
10 150.0 2175.0 19 
11 100.0 1300.0 • 
12 50.0 5500 0 
13 37.5 450.0 6 
14 75.0 975.0 6 
15 25.0 325.0 11 
16 50.0 650.0 2 
17 50.0 600.0 8 
18 100.0 1300.0 6 
19 25.0 425.0 2 
20 66.7 460.0 11 
21 25.0 300.0 4 
22 66.7 850.0 9 
23 37.5 444.0 1 
24 16.7 213.0 5 
Negative Total 
symptom score svmptom score 
8 14 
14 21 
17 26 
14 18 
9 12 
13 18 
13 14 
12 20 
12 19 
9 28 
• • 
8 8 
4 10 
15 21 
5 16 
12 14 
5 13 
20 26 
7 9 
12 23 
9 13 
13 22 
7 8 
11 16 
Parkinsonism Tardive 
dyskinesia 
No No 
No No 
No No 
No No 
No Yes 
No No 
No No 
No No 
No No 
No No 
No No 
No No 
No No 
No No 
No No 
No No 
No No 
No No 
No No 
Yes No 
No No 
No No 
No No 
No No 
~ 
~ 
~ 
~ 
~ 
$:)... 
><· 
~ 
::!:! 
-§ 
::::.-
~ 
~ 
!:l 
N 
;i" 
~ 
~ 
!:l 
.... 
~· 
~ 
.... 
$:)... 
!:l 
~ 
'::ri 
~ 
....... 
00 
....... 
Study number FPZ plasma Liver An ~icholinergic Current FPZ dose 
level (ng/mL) dysfunction (mg/kg/month) 
1 0.60 No Yes 0.35 
2 1.00 No Yes 0.11 
3 <0.10 No Yes 1.19 
4 0.30 No No • 
5 1.10 No Yes 1.32 
6 0.40 No No 0.38 
7 4.30 No Yes 0.21 
8 2.80 No No • 
9 0.50 No No • 
10 27.90 No No 1.88 
11 1.20 No Yes 2.00 
12 0.60 No No 0.58 
13 0.20 No No 0.47 
14 13.70 No Yes 1.19 
15 0.10 No No 0.32 
16 <0.10 No No 0.55 
17 0.50 No No 0.76 
18 0.40 Yes Yes 1.47 
19 0.30 No No 0.44 
20 0.90 No Yes 0.67 
21 0.20 No No 0.28 
22 0.70 No No 0.80 
23 0.20 No No 0.67 
24 0.20 No No 0.17 
all SAPS all SANS 
• • 
• • 
• • 
• • 
5 35 
• • 
• • 
26 38 
22 36 
118 35 
• • 
• • 
42 12 
17 45 
66 16 
11 47 
34 14 
25 79 
8 14 
51 48 
9 24 
35 47 
6 22 
5 36 
Anti psychotic Within 
therap. range 
Yes Yes 
No Yes 
Yes No 
Yes Yes 
No Yes 
No Yes 
Yes No 
No No 
No Yes 
Yes No 
Yes Yes 
No Yes 
No Yes 
Yes No 
Yes No 
Yes No 
No Yes 
Yes Yes· 
No Yes 
No Yes 
No Yes 
Yes Yes 
No Yes 
No Yes 
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Drugs tested in specificity 
aspirin 
atenolol 
bisacodyl 
budesonide 
bumetanide 
carbamazepine 
cephalexin 
cimetidine 
clonazepam 
cyclizine 
dexamethasone 
diazepam 
diclofenac 
digoxin 
diltiazem 
docusate sodium 
enalapril 
glibenclamide 
glyceryl trinitrate 
haloperidol 
isosorbide mononitrate 
ketoconazole 
ketorolac 
lactulose 
metformin 
metoclopramide 
metoprolol 
morphine 
naproxen 
nifedipine 
nystatin 
paracetamol 
phenytoin sodium 
potassium chloride 
prednisolone 
ranitidine 
senna 
simvastatin 
sodium valproate 
temazepam 
tiaprofenic acid 
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ROYAL HOBART HOSPITAL 
CONSENT TO PARTICIPATE IN A RESEARCH PROJECT 
I, ................................................................................................................................... . 
of ...................................................................................... : ........................................... . 
have been invited to participate in a research project entitled: 
Pharmacokinetics of Drugs used in Coronary Surgery. 
The aim of this project is to study drug use in cardiopulmonary bypass. 
In relation to this project I have been informed of the following points: 
1) Approval has been given by the Ethics Committee of the Royal 
Hobart Hospital. 
2) The results which will be obtained may not be of any direct benefit to 
my medical management. 
3) The procedure will involve some blood samples being taken for 
analysis. 
4) The results of any test or information regarding my medical history 
will not be published in any way that could reveal my identity. 
5) I have been given adequate opportunity to ask questions about this 
project and my involvement, and I know that if I have other 
questions in the future I may contact Rachel Miller on (002) 202202 
between the hours of 9am and Spm. 
6) I will be given a copy of this form to keep. 
7) I understand that I can refuse to take part in this study, or withdraw 
from it at any time without affecting my medical care or my 
relationship with the hospital and my doctors. 
After considering all of these points, I accept the invitation to participate 
in this project. 
SIGNATURE .............................................................................. . 
Witness's signature .................................................................. . 
Witness's name (print) ........................................................... . 
Address ....................................................................................... . 
Date ............................................................................................. . 
STATEMENT BY RESEARCHER 
I have explained this trial and the implications of participation in it to 
this patient, and believe that he/she understands it, and that this consent 
is based on adequate information. 
SIGNATURE...................................... NAME ..................................................... . 
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Patient Information Sheet 
Pharmacokinetics of Drugs used in Coronary Surgery 
• A number of drugs are used in Cardiopulmonary Bypass. 
• The physiological status of patients is altered by Cardiopulmonary 
Bypass and this may affect the way the body handles the drugs. 
• We are conducting a study to examine this and would like you to 
participate in the study as a subject. 
• All this will involve is taking some blood samples for analysis. 
• It won't involve any alterations to your therapy or management; it is 
essentially an observational study. 
• The results could benefit patients undergoing Cardiopulmonary 
Bypass in the future. 
• If you have any questions, don't hesitate to ask. 
Rachel Miller 
c/- Sister in charge 
Cardiac ward 
Pharmacokinetics of Drugs used in Coronary Surgery 
Patient ID .•.................................. Date ..................... . 
Blood Samples (7 ml into heparinised tubes) 
No. Event Intended Time Intended Time (clock) 
1. Last fentanyl 1 min after 
IV dose 
2. 5 min after 
10 min after 
3. 
4. Start of 5 min after bypass 
30 min after 
5. 
6. 60 min after 
Just before 
7. rewarming 
8. The end of 1- min before bypass 
9. 1 hour after 
10. 2 hours after 
11. 3 hours after 
Rachel Miller 
School of Pharmacy ph 202202 
Actual Time (clock) Actual Time 
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....... 
00 
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Study number Age (years) Sex Weight (kg) 
1 63 Male 86.5 
2 68 Male 78.0 
3 70 Male 72.0 
4 48 Male 86.8 
5 60 Male 81.2 
6 65 Female 71.4 
7 68 Male 85.0 
8 65 Male 70.6 
9 67 Male 66.6 
10 68 Male 98.5 
11 47 Male 68.8 
12 62 Male 67.6 
13 83 Male 92.1 
14 60 Female 63.0 
15 75 Female 76.0 
16 48 Male 83.8 
Serum creatinine Est creatinine 
(µmol/L) CL(mL/min) 
116 70.5 
81 85.1 
139 44.5 
84 116.7 
84 94.9 
103 54.2 
136 55.2 
113 57.5 
108 55.3 
112 77.7 
85 92.4 
84 77.1 
88 73.2 
77 68.3 
62 83.2 
97 97.6 
Ale. elimin. 
half-life (min) 
222 
233 
235 
68 
180 
225 
166 
220 
219 
222 
159 
177 
193 
247 
173 
167 
Total fentanyl 
dosage (µg) 
3000 
2500 
2500 
3000 
2500 
2000 
3000 
2500 
2500 
3000 
2500 
2500 
2500 
2500 
2500 
2500 
t 
i:::... 
~-
~ 
n 
"'O 
ttl 
~ [ 
..... 
§-
i3" 
';::n 
~ 
...... 
00 
00 
Study nwnber Alcuronium dose Haemoblobin Alcuronium Duration of 
(mg) (g/L) dose/kg bypass (min) 
1 20 14.2 0.23 105 
2 20 15.4 0.26 109 
3 20 14.9 0.28 93 
4 20 15.2 0.23 94 
5 30 14.8 0.37 85 
6 20 13.4 0.28 96 
7 20 13.6 0.23 124 
8 20 14.3 0.28 114 
9 20 15.2 0.30 94 
10 30 14.7 0.30 81 
11 20 14.6 0.29 67 
12 20 15.2 0.30 69 
13 20 12.5 0.22 121 
14 20 11.5 0.32 62 
15 20 12.6 0.26 102 
16 20 14.9 0.24 57 
Number of Time induction 
grafts to bypass (min) 
3 87 
4 84 
2 87 
2 91 
3 86 
3 72 
3 82 
2 95 
2 87 
3 85 
1 79 
3 98 
4 79 
2 106 
4 93 
2 78 
Fentanyl 
dose/kg 
34.70 
32.05 
34.70 
34.60 
30.80 
28.00 
35.30 
35.40 
37.50 
30.45 
36.30 
37.00 
27.10 
39.70 
32.90 
29.80 
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::t· 
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tt1 
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00 
'° 
Study number BMI Size of fent % drop in Hb on 
incr. (ng/mL bypass 
1 28.2 5.4 38.0 
2 24.6 -0.3 52.6 
3 24.0 -0.4 50.3 
4 27.1 3.1 48.0 
5 25.6 1.5 48.6 
6 26.9 4.5 57.S 
7 27.4 1.4 47.1 
8 24.7 0.8 52.5 
9 23.0 0.9 44.1 
10 28.5 3.7 40.8 
11 24.4 1.0 43.8 
12 24.8 0.3 44.1 
13 27.8 3.1 45.6 
14 26.2 1.3 64.3 
15 29.3 3.4 49.2 
16 26.7 2.3 40.9 
% drop in fent. % drop in ale. 
cone. on bypass cone. on bypass 
33.7 14.0 
84.3 21.0 
58.8 25.0 
41.5 42.0 
57.4 37.5 
• 18.0 
74.5 25.0 
67.0 36.0 
70.4 32.0 
56.3 29.0 
55.6 16.0 
57.1 41.0 
45.6 39.0 
77.8 41.0 
56.2 21.0 
45.5 14.5 
% decrease in 
binding 
• 
• 
• 
6.6 
5.6 
18.0 
• 
15.1 
5.b 
12.9 
13.5 
8.2 
15.6 
9.1 
15.3 
11.6 
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-
IDAW PARK! 
CONSENT TO RESEARCH STUDIES AND PROCEDURES 
Surname Cbrisuan or given names File No. 
Service No. Sex Age 
(First/or Given names) (Suma.me) 
· Fay Abbott / Professor Ian Maddocks have had explained to me by the investigator---------------------------
(or his/her represenrauve) 
the nature and effects of the Research Study: Fentanyl Pharmacokinetics with Subcutaneous Administrat:. 
(Title of Srudy) in Palliative Care 
I have been provided with a Paaent Information Sheet about the srudy which I have read and understood. Patients. 
I understand [hat the srudy involves the following procedures: 
You will have one blood sample taken (one or two ceaspoonsful) to measure 
the level of fentanyl. Also, we will record some data (age, sex, weight and 
liver function) from your medical record. This information will be 
completely confidential. 
• I have understood and am sausfied w11h [he explanadons that I have been given and hereby consent to the 
paruc1paaon m the above srudy. 
I understand that the results of these srudies may be published. but my idenmy will be kept confidenual. 
I understand that the procedure may not be of any benefit to myself. and that I may withdraw my consent at any 
st.age without affecting my nghts or the responsibiliaes of the invesagator in any respect. 
• I understand tha[ represemauves from the Hospital Research and Ethics Corrunme::, from the sponsonng 
organisation for this srudy and/or from Government Drug Regulatory Authonaes may need to access my medical 
record for mfonnaaon related to the study. I am happy to authonsc access [O my medical record for this purpose. 
• l declare that l am over the age of 18 years. 
Signature 
of Wuness: ------------
Pnmed Name 
of Wimess: ------------
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FENTANYL PHARMACOKINETICS WITH SUBCUTANEOUS 
ADMINISTRATION IN PALLIATIVE CARE PATIENTS 
PATIENT INFORMATION 
Fentanyl is a drug often used with other drugs to help relieve pain. This 
study is involved with measuring the levels of fentanyl in the 
bloodstream of patients who have been on this drug for at least one day. 
Hopefully from this study in the Palliative Care Unit, information will 
be gathered which may improve the use of this drug. 
As a patient in the Palliative Care Unit you are being asked to take part in 
this research. This would involve having one blood sample taken (five 
to ten mL or one to two teaspoonful) to measure the level of fentanyl. 
Also, we will record some data (age, sex, weight, and liver function) from 
your medical record. This information will be completely confidential. 
If you have any questions please feel free to ask. If you agree to 
participate but change your mind during the process, you can withdraw 
at any time. Your decision to take part or not in this study will not affect 
your medical treatment or any therapy you may currently be receiving. 
Should you be interested in the results of the study they will be made 
available to you upon its completion. 
Should you require further details about the study, either before, during 
or after the study, you may contact the investigators, Fay Abbott 
(Pharmacy Department) or Professor Ian Maddocks. This study has been 
reviewed by the Research and Ethics Committee at the Repatriation 
General Hospital. Should you wish to discuss the study with someone 
not directly involved in particular in relation to matters concerning 
policies, information about the conduct of the study or your rights as a 
participant, or should you wish to make a confidential complaint, you 
may contact Ms Debra Rowett (RGH 2769666). 
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UNIVERSITY OF TASMANIA AND REPATRIATION GENERAL 
HOSPITAL, DAW PARK 
FENTANYL STUDY 
Study number 
Age Sex M/F Date 
Weight (kg) 
Diagnosis 
Renal function 
Recent result 
Date Serum creatinine (mmol/L) 
Liver function 
Bilirubin Normal/ Abnormal/Unknown 
ALT Normal/ Abnormal/Unknown 
GGT Normal/Abnormal/Unknown 
AP Normal/ Abnormal/Unknown 
Serum albumin 
History of chronic liver disease? 
Fentanyl details 
Date of commencement of fentanyl therapy 
Current dosage regimen 
Period of time on this dosage 
Time of blood sampling 
Other drug therapy 
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Please rate your current level of pain by marking a cross on the 
line 
No Pain Worst Possible Pain 
Study number Age (years) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
GU - Genitourinary 
GI - Gastrointestinal 
75 
84 
75 
86 
69 
71 
66 
67 
83 
82 
72 
84 
80 
65 
67 
75 
66 
79 
54 
80 
Sex Diagnosis Weight (kg) 
Male GU 60 
Male GU 55 
Female Lung 60 
Male Skin 55 
Female Breast 30 
Female GI 70 
Male GI 55 
Female Lung 50 
Male GU 80 
Male Lung 65 
Male Ltmg 75 
Male GU 50 
Female Ltmg 45 
Female GU • 
Male GU • 
Male GI 75 
Female GU 85 
Male GI 60 
Female Breast • 
Male Lung 75 
Renal ftmction Liver ftmction 
normal abnormal 
abnormal normal 
normal normal 
normal abnormal 
normal normal 
• • 
normal abnormal 
normal abnormal 
normal abnormal 
normal normal 
normal normal 
abnormal normal 
normal normal 
normal abnormal 
normal normal 
abnormal abnormal 
normal abnormal 
normal abnormal 
normal normal 
normal normal 
Fentanyl dosage 
(µg/24 hours) 
5000 
1200 
1700 
2000 
3000 
1000 
800 
800 
600 
1500 
800 
3500 
1000 
300 
3000 
750 
100 
1000 
2000 
300 
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Studynwnber Fentanyl dosage No. of other Fentanyl plasma 
(µg/kg) drugs level (ng/mL) 
1 83.3 10 9.00 
2 21.8 11 0.75 
3 28.3 8 1.50 
4 36.4 10 2.20 
5 100.0 4 2.50 
6 14.3 5 0.50 
7 14.5 8 0.40 
8 16.0 4 0.25 
9 7.5 - 10 0.60 
10 23.1 8 1.20 
11 10.7 13 1.40 
12 70.0 9 4.40 
13 22.2 11 0.60 
14 • 8 0.20 
15 • 7 5.10 
16 10.0 7 0.30 
17 0.9 3 0.10 
18 16.7 15 1.00 
19 • 6 5.10 
20 4.0 13 0.20 
% free Pain score Albumin (g/L) 
21.2 0 21 
33.6 3.0 23 
23.4 1.2 27 
33.6 0 26 
19.7 0 39 
• 0 • 
44.l 3.3 20 
35.1 5.8 24 
• 0 25 
33.7 1.0 24 
24.3 1.2 30 
17.8 4.5 31 
30.1 0 19 
41.7 4.4 24 
• 0 21 
• 0 27 
• 0 28 
32.0 0 32 
• 1.1 20 
44.4 0 22 
Cardiac failure 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
Yes 
No 
No 
Yes 
No 
No 
Yes 
No 
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Study number Chronic liver Level to dose Presence of pain 
disease ratio 
1 No l.80E-3 No 
2 No 6.25E-4 Yes 
3 No 8.80E-4 Yes 
4 No l.lOE-3 No 
5 No 8.30E-4 No 
6 No 5.00E-4 No 
7 No 5.00E-4 Yes 
8 No 3.lOE-4 Yes 
9 No l.lOE-3 No 
10 No 8.00E-4 Yes 
11 No l.75E-3 Yes 
12 No l.30E-3 Yes 
13 No 6.00E-4 No 
14 No 6.70E-4 Yes 
15 No l.70E-3 No 
16 No 4.00E-4 No 
17 No l.OOE-3 No 
18 Yes l.OOE-3 No 
19 No 2.50E-3 Yes 
20 No 6.70E-4 No 
Duration of fentanyl Free level 
therapy (days) (ng/mL} 
157 1.90 
2 0.25 
30 0.35 
11 0.75 
13 0.50 
4 • 
4 0.20 
• 0.10 
4 • 
1 0.40 
13 0.35 
11 0.80 
9 0.20 
3 0.10 
7 • 
4 • 
4 • 
13 0.30 
12 • 
3 0.10 
Free level to 
dose ratio 
3.80E-4 
2.lOE-4 
2.lOE-4 
3.80E-4 
l.70E-4 
• 
2.SOE-4 
l.25E-4 
• 
2.70E-4 
4.40E-4 
2.30E-4 
2.00E-4 
3.30E-4 
• 
• 
• 
3.00E-4 
• 
3.30E-4 
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NEBULISED MORPHINE vs SALINE FOR DYSPNOEA IN PALLIATIVE 
CARE PATIENTS 
CONSENT FORM 
The aim of this study is to investigate the role of nebulised morphine in the 
management of breathlessness in palliative care patients. 
Morphine is a commonly used drug for the relief of pain. It has also been 
used to ease breathing difficulties; however, its effectiveness for this purpose 
has not been proven. Hopefully from this study, information will be 
gathered which may be useful in improving the use of this drug for 
breathing difficulties. 
As a patient in the Palliative Care Unit you are being asked to take part in 
this research. This would involve receiving nebulised saline then 
nebulised morphine and being asked to assess the degree of difficulty of 
breathing. Also respiratory function before and after the dose will be 
measured. In addition, we will record some data from your medical 
record. This information will be completely confidential. 
If you agree to participate in this research, please sign this form, 
indicating your consent, on the following understanding. 
1. This research study has been approved by the Royal Hobart 
Hospital Ethics Committee. 
2. I have read this information and I comprehend the general 
purposes, methods, demands and possible risks, inconvenience or 
discomforts of the study. 
3. If I do not volunteer to participate in the research study, I will still 
receive appropriate treatment for my condition. 
4. In giving my consent I acknowledge that my participation in this 
study is voluntary and that I may withdraw at any time, without 
my treatment being affected. 
5. I agree that research data gathered for the study may be published 
provided that I cannot be identified as a subject. 
Thank you. 
Further information can be obtained from Dr Dunne, or Rachel Miller or, 
Greg Peterson at the University of Tasmania (phone: 202190) 
Signature : Date: 
Statement by the investigator : 
I have explained this project and the implications of participation in it to 
this volunteer and I believe that the consent is informed and that he/she 
understands the implications of participation. 
Signature of investigator : Date: 
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NEBULISED MORPHINE vs SALINE FOR DYSPNOEA IN PALLIATIVE 
CARE PATIENTS 
AGREEMENT FORM FOR RELATIVES 
The aim of this study is to investigate the role of nebulised morphine in the 
management of breathlessness in palliative care patients. 
Morphine is a commonly used drug for the relief of pain. It has also been 
used to ease breathing difficulties; however, its effectiveness for this purpose 
has not been proven. Hopefully from this study, information will be 
gathered which may be useful in improving the use of this drug for 
breathing difficulties. 
As a relative of a patient in the Palliative Care Unit you are being asked 
to allow them to take part in this research. This would involve receiving 
nebulised saline then nebulised morphine and being asked to assess the 
degree of difficulty of breathing. Respiratory function before and after the 
dose will also be measured. In addition, we will record some data from 
your relative's medical record. This information will be completely 
confidential. 
If you agree for them to participate in this research, please sign this form, 
indicating your agreement, on the following understanding. 
1. This research study has been approved by the Royal Hobart 
Hospital Ethics Committee. 
2. I have read this information and I comprehend the general 
purposes, methods, demands and possible risks, inconvenience or 
discomforts of the study. 
3. If I do not volunteer my relative to participate in the research 
study, they will still receive appropriate treatment for their 
condition. 
4. In giving my agreement I acknowledge that my relative's 
participation in this study is voluntary and that I may withdraw 
them at any time, without their treatment being affected. 
5. I agree that research data gathered for the study may be published 
provided that my relative cannot be identified as a subject. 
Thank you. 
Further information can be obtained from Dr Dunne, or Rachel Miller or 
Greg Peterson at the University of Tasmania (phone: 202190) 
Relative's signature : Date: 
Statement by the investigator: 
I have explained this project and the implications of participation in it to 
this volunteer's relative and I believe that the agreement is informed 
and that he/she understands the implications of participation. 
Signature of investigator : Date: 
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Nebulised morphine vs saline for dyspnoea in palliative care patients 
Dyspnoea, or difficulty in breathing, occurs in up to 70% of patients with 
terminal cancer at some point during the course of their illness and is a 
very difficult symptom to manage. 
Nebulised morphine is now commonly used in palliative care units to 
manage dyspnoea although its benefit has not clearly been proven, or 
indeed studied in any clinical trials. 
The present trial is designed to determine the effect of low dose nebulised 
morphine on the intensity of dyspnoea in terminally ill cancer patients. 
All patients at the Whittle Ward with dyspnoea due to advanced cancer 
will be asked to participate in the study. It is hoped that approximately 15-
20 patients will be recruited over the course of the study. All patients (or 
their relatives) who agree to participate will be required to fill out a 
consent form. 
A baseline assessment of the intensity of dyspnoea will be made using a 
visual analogue scoring system. 
No 
Shortness 
of Breath 
Worst Possible 
Shortness of 
Breath 
A baseline measurement of FEV1 and FVC will be taken using a bedside 
spirometer. 
After daily baseline assessment, patients will receive 3 mL 0.9% normal 
saline, morphine 2.5 mg or morphine 5 mg on three consecutive days 
delivered by a nebuliser four times a day. Dyspnoea will again be 
measured at 1 hour after each dose. Also at 1 hour after the second dose, 
another reading of respiratory function will be taken. 
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MORPHINE vs SALINE NEBULISER STUDY: TIME SCHEDULE 
Day 1: Saline (0.9%) 3 mL 
• 8.30 - 9.00am Baseline dyspnoea and respiratory function 
• 9.00am 
• 10.00am 
• l.OOpm 
• 2.00pm 
• 5.00pm 
• 6.00pm 
• 9.00pm 
• 10.00pm 
First dose given via nebuliser 
Dyspnoea measured 
Second dose given via nebuliser 
Dyspnoea and respiratory function measured 
Third dose given via nebuliser 
Dyspnoea measured 
Fourth dose given via nebuliser 
Dyspnoea measured 
Day 2: Morphine 2.5 mg in saline (3 mL) 
• 8.30 - 9.00am Baseline dyspnoea and respiratory function 
• 9.00am 
• 10.00am 
• 1.00pm 
• 2.00pm 
• 5.00pm 
• 6.00pm 
• 9.00pm 
• 10.00pm 
First dose given via nebuliser 
Dyspnoea measured 
Second dose given via nebuliser 
Dyspnoea and respiratory function measured 
Third dose given via nebuliser 
Dyspnoea measured 
Fourth dose given via nebuliser 
Dyspnoea measured 
Day 3: Morphine Smg in saline (3 mL> 
• 8.30 - 9.00am Baseline dyspnoea and respiratory function 
• 9.00am 
• 10.00am 
• 1.00pm 
• 2.00pm 
• 5.00pm 
• 6.00pm 
• 9.00pm 
• 10.00pm 
First dose given via nebuliser 
Dyspnoea measured 
Second dose given via nebuliser 
Dyspnoea and respiratory function measured 
Third dose given via nebuliser 
Dyspnoea measured 
Fourth dose given via nebuliser 
Dyspnoea measured 
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